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Abstract 
Chao Zhang. Population Pharmacokinetic models describing drug-drug interactions 
and variability in HIV infected South Africans on protease inhibitor-based 
antiretroviral regimens with and without tuberculosis. August 2012.  
 
Lopinavir/ritonavir is an important component of the first-line and second-line antiretroviral 
treatment for young children and adults respectively in the current World Health Organization 
guidelines. Rifampicin, a key component of antituberculosis treatment, profoundly reduces 
lopinavir concentrations. Therefore, investigation of the optimal dosage regimens of 
lopinavir/ritonavir when co-administered with rifampicin-based antituberculosis treatment is 
needed urgently. Moreover, treatment adherence is associated with virological and clinical 
responses to antiretroviral treatment, and reduced adherence leads to the development of drug 
resistance. The projects in this thesis were designed to characterize the population 
pharmacokinetic parameters of lopinavir and ritonavir in HIV infected South Africans, to 
account for the drug-drug interactions between lopinavir, ritonavir and rifampicin, to 
investigate optimal dose regimens of lopinavir/ritonavir when administered with rifampicin, 
and to investigate new approach to evaluate adherence.  
 
Population pharmacokinetic models were developed using a nonlinear mixed modeling 
approach. The models provided, in pediatric and adult populations, a thorough description of 
the pharmacokinetics and their variability of antiretroviral agents (lopinavir, ritonavir and 
lamivudine) with and without coadministration of rifampicin-based antituberculosis treatment. 
Antituberculosis treatment reduced bioavailability and increased oral clearance of lopinavir 
and ritonavir respectively. The dynamic influence of ritonavir concentration on lopinavir oral 
clearance was modeled as direct inhibition with an Emax model. Optimal dose regimens of 
lopinavir/ritonavir coadministration with rifampicin-based antituberculosis treatment were 
predicted for adults and young children, respectively. An integrated model was studied to 
investigate the pharmacokinetic differences of lopinavir and ritonavir with rifampicin-based 
antituberculosis treatment between adults and children. Compare to adults, a lower 
bioavailability and stronger induction effect of rifampicin in children was found. Furthermore, 
since lamivudine’s concentrations following an observed dose are predicable and it is not 
prone to drug-drug interactions, in this project lamivudine concentration measurement in 
young children was used to propose the reference cutoff values for evaluation of adherence to 
prior doses. 
 
In summary, the models we developed in this thesis are useful for the optimization of 
antiretroviral therapy regimens for tuberculosis patients with HIV infection in different 
populations, and for adherence evaluation, and therefore could be helpful for improvement of 
clinical outcome.  
 
 
Keywords: Lopinavir; Ritonavir; Lamivudine; Rifampicin; Antiretroviral therapy; Drug-drug 
interaction; NONMEM; Population pharmacokinetics  
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Synopsis of this thesis  
 
A key concern regarding coadministration of antiretroviral and antituberculosis agents 
is drug-drug interactions, which may lead to clinically important alterations in drug 
concentrations. Lopinavir/ritonavir is an important component of the first-line 
antiretroviral treatment for adults in the current World Health Organization guidelines. 
The preferred antiretroviral regimen for young children (< 2 years old) previously 
exposed to nonnucleoside reverse transcriptase inhibitors is lopinavir/ritonavir plus 
two nucleoside reverse transcriptase inhibitors. Children with drug susceptible 
tuberculosis require rifampicin-based antituberculosis treatment. With maturation of 
antiretroviral programmes in many high burden settings, increasing numbers of adults 
require a second-line protease inhibitor-based regimen, and many of these patients 
need cotreatment with first-line antituberculosis treatment. However, rifampicin, a 
key component of antituberculosis treatment, profoundly reduces lopinavir 
concentrations. Although rifabutin is recommended to replace rifampicin in such 
patients, this is not feasible for the majority of adults in high burden countries because 
of prohibitively high cost and it is not available for use in children due to lack of a 
suitable formulation. Therefore, investigation of the optimal dosage regimens of 
lopinavir/ritonavir when co-administered with rifampicin is needed urgently. 
Moreover, treatment adherence is associated with virological and clinical responses to 
antiretroviral treatment, and reduced adherence leads to the development of drug 
resistance. Lamivudine is commonly administered as part of antiretroviral treatment. 
Unlike protease inhibitors and nonnucleoside reverse transcriptase inhibitors, it’s 
concentrations following an observed dose are predictaable and it is not prone to 
drug-drug interactions. Therefore, it can be used as a marker of recent adherence, to 
aid interpretation of protease inhibitor and nonnucleoside reverse transcriptase 
inhibitor concentrations which might be particulary variable during antituberculosis 
treatment. In this thesis, pharmacometric models were developed to describe the 
pharmacokinetics of lopinavir and ritonavir, to account for the drug-drug interactions 
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between lopinavir, ritonavir and rifampicin, and to investigate optimal dose regimens 
of lopinavir/ritonavir when administered with rifampicin. Moreover, we investigated 
the use of lamivudine concentration measurement in young children to propose the 
reference cutoff values for evaluation of adherence to prior doses. 
 
Integrated population pharmacokinetic models of lopinavir and ritonavir were 
developed in young children and adults, respectively. For young children, a 
one-compartment model with first-order absorption and elimination best described the 
pharmacokinetics of lopinavir and a one-compartment model with transit absorption 
compartments described ritonavir pharmacokinetics. The dynamic influence of 
ritonavir concentration on lopinavir oral clearance was modeled as direct inhibition 
with an Emax model. Antituberculosis treatment reduced the oral bioavailability of 
lopinavir by 77% in children receiving twice usual lopinavir/ritonavir doses and 
increased ritonavir clearance by 50%. Simulations predicted that respective 27, 21, 20 
and 18 mg/kg 8 hourly doses of lopinavir (in lopinavir/ritonavir, 4:1) maintains 
lopinavir concentrations >1 mg/L in at least 95% of children weighing 3-5.9, 6-9.9, 
10-13.9 and 14-19.9 kg.  
 
For adults, a one-compartment model with first-order absorption and elimination best 
described the pharmacokinetics of lopinavir and a two-compartment model with 
transit absorption compartments described ritonavir pharmacokinetics. Rifampicin 
reduced the oral bioavailability of lopinavir and ritonavir by 20% and 45% 
respectively, and it increased their clearance by 71% and 36% respectively. Similar to 
young children, with increasing concentrations of ritonavir, clearance of lopinavir 
decreased in an Emax relationship. Simulations predicted that 99.5% of patients 
receiving doubled doses of lopinavir/ritonavir achieve morning trough concentrations 
of lopinavir >1 mg/L during rifampicin co-administration, and 95% of those weighing 
less than 50 kg achieve this target already with 600/150 mg doses of 
lopinavir/ritonavir. 
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Doubling the standard doses of lopinavir/ritonavir can overcome the great reduction 
of lopinavir concentrations due to rifampicin induction to attain the target 
concentration in adults, but this approach failed in 59% of young children in our study. 
A comprehensive population pharmacokinetic model using the combined data from 
children and adults was developed simultaneously, to compare the pharmacokinetic 
differences of lopinavir and ritonavir between young children and adults, with and 
without rifampicin co-administration. The bioavailability of lopinavir was reduced by 
24.7% in adults whereas children on antituberculosis treatment experienced a 58.7% 
reduction in the bioavailability of lopinavir, an effect that was moderated by the dose 
of ritonavir. Conversely, rifampicin increased the oral clearance of both lopinavir and 
ritonavir to a lesser extent in children than in adults. As adult studies cannot reliably 
predict their magnitude in children, drug-drug interactions should be evaluated in 
pediatric patient populations.  
 
A population pharmacokinetic model of lamivudine was developed to describe the 
variability of lamivudine concentrations in young children, and to propose reference 
lamivudine concentrations for adherence investigation. A two-compartment model 
with transit absorption best described the lamivudine pharmacokinetics. Clearance 
was found to mature with age in a sigmoidal relationship: the clearance at full 
maturation is 12.1 L/h in a 10 kg child, and it reaches half of this value by 4 months 
after birth. Oral clearance of lamivudine was found to be 16.7% slower overnight. The 
variability of clearance was small so that simulations could accurately predict 
lamivudine concentrations. Most of the variability in lamivudine pharmacokinetics 
could be explained by body weight and age. Reference cutoff values for lamivudine 
concentrations that can be used to evaluate adherence to recent treatment doses were 
proposed. 
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Introduction and literature review 
Human immunodeficiency virus (HIV) infection is a prevalent and big public health 
issue all over the world. According to estimates from the UNAIDS 2011 AIDS 
Epidemic Update 
1
, around 34 million adults and 3.4 million children were living 
with HIV at the end of 2010. There were 2.7 million new HIV infections in 2010. 
The number of people living with HIV increased dramatically for ten years before 
this trend began to decline in 2007 (Figure 1.1). The overwhelming majority of 
people with HIV live in low- and middle-income countries. Sub-Saharan Africa 
accounts for 68% of all infected people. South and South-East Asia have the second 
highest number of people living with HIV 
2
.  
 
 
Figure 1.1. The trend of global number of people living with HIV during 1990-2010 
(UNAIDS 2011 http://www.who.int/hiv/pub/progress_report2011/en/). 
 
Tuberculosis (TB) is the most common opportunistic infection among people with 
HIV infection and is also associated with substantial morbidity and mortality. An 
estimated 1.1 million HIV-infected persons developed TB globally in 2010, the 
enormous majority in Africa (Figure 1.2) 
3
. Up to 60% of TB patients have HIV 
co-infection in high burden countries, and in some locations more than 30% of 
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patients commencing antiretroviral therapy (ART) have TB 
3
. Not only does HIV 
increase the risk of reactivating latent Mycobacterium tuberculosis (MTB) infection, 
it also increases the risk of rapid TB progression soon after infection and 
re-infection with MTB 
4,5
. Compared with HIV uninfected TB patients, HIV 
infected TB patients experience greater morbidity and mortality, as well as an 
increased risk of rapid disease progression. Therefore, the development of effective 
HIV and TB control strategies, including collaborative antiretroviral and 
antituberculosis interventions, is one of the most important public health challenges 
facing sub-Saharan Africa today. 
 
 
Figure 1.2 Estimate HIV positive TB prevalence, 2010 (WHO 2011 
http://www.who.int/tb/publications/global_report/en/ ) 
 
Despite the complexities of treating two infections requiring multidrug therapy at 
the same time, ART can be life-saving among patients with TB and advanced HIV 
disease
6
. Such patients should commence ART as soon as possible after starting 
antituberculosis treatment (ATT) 
6
. However, concomitant use of treatment for TB 
and ART is often complicated by drug-drug interactions, adherence challenges due 
to polypharmacy, overlapping toxicity, an increasing cost burden and development 
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of the immune reconstitution inflammatory syndrome. Drug interactions between 
ART and ATT may lead to drug resistance and treatment failure or life-threatening 
side effects, which further challenge overburdened heath care systems. Some of 
the drug-drug interactions are extensive 
7–11
. For example, rifampicin reduces the 
trough concentration of PIs>90% 
12
 and reduces exposure to NNRTIs, such as 
nevirapine, efavirenz, and abacavir, about 60-70% 
13
. Subtherapeutic 
concentrations of ART related to these interactions might result in the development 
of resistance. Adherence and tolerability in patients also need to be evaluated as 
the increased pill burden is considerable and the risks of combined toxicity have 
not been adequately described, especially for second-line therapies, across patients 
with different levels of immune suppression, and a variety of other risk factors. 
There is a critical need to investigate optimal regimens and monitoring strategies 
for TB patients co-infected with HIV. The optimization of co-treatment strategies 
is important in the context of limited available ART regimens which need to be 
conserved at the population level and the individual level. Furthermore, 
HIV-infected children in high burden countries have very high rates of TB, often 
with severe, life-threatening manifestations, but there are very limited data about 
co-administration of antituberculosis and antiretroviral drugs among children. The 
pharmacokinetics of drugs behaves differently in adults and pediatric populations, 
the latter being particularly heterogeneous. Therefore there is an even greater need 
to investigate the optimal ART regimens in children co-administered ATT.  
 
In this thesis, population models for antiretroviral drugs during co-administration 
with rifampicin-based ATT in adults and children are presented. The models 
investigated the pharmacokinetics and drug-drug interactions between lopinavir, 
ritonavir and ATT, thus providing a semi-mechanistic basis for the interactions, 
and explored the pharmacokinetic differences between children and adults. 
Moreover, the models could be used to predict optimal doses of antiretrovirals 
during rifampicin-based ATT. Lastly lamivudine concentrations were explored as a 
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potentially useful measure of adherence to recent doses to aid interpretation of 
protease inhibitor or nonnucleoside reverse transcriptase inhibitor concentration 
monitoring results.  
 
1. Treatment of HIV in patients with tuberculosis 
1.1. Antiretroviral therapy  
There are different stages that the virus goes through after it has entered the human 
body and antiretroviral drugs use those different stages as target sites for their 
action. Some drugs interfere with the multiplication and release of the mature virus 
from the host cell while others interfere with the attachment and penetration of the 
host cell by the infecting virus. Figure 1.3 indicates the viral replication process 
and the site of action of antiviral treatment.  
 
  
Figure 1.3 The viral replication process and the site of action of antiviral drugs. (HIV 
virus binds to and enter human immune cells first, then replicates through the 
reverse transcriptase and protease, and then exclude from the human cell to form a 
new HIV.) 
 
Antiretroviral agents are classified under five unique drug classes: protease 
inhibitors (PI), nucleoside reverse transcriptase inhibitors (NRTI), nonnucleoside 
Integrase inhibitors
RNA
Reverse transcriptase
Integrase
inhibitors
P
P
Protein
Protease
RNACD4 cell
New 
HIV
HIV
DNA
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reverse transcriptase inhibitors (NNRTI), integrase inhibitors and entry or fusion 
inhibitors. Each of these groups acts in a different way (summarized in Table 1.1). 
The last two classes are not widely used in clinics due to high prices and not being 
readily available in developing economies.  
 
Table 1.1. Summary of different types of antiretroviral drugs 
Antiretroviral drug 
class 
Action site Represent drugs 
(abbreviation) 
Nucleoside/Nucleoti
de Reverse 
Transcriptase 
Inhibitors (NRTIs) 
NRTIs interfere with the 
action of an HIV protein 
called reverse transcriptase, 
which the virus needs to 
make new copies of itself 
Lamivudine (3TC); 
Abacavir (ABC); 
Zidovudine (AZT); 
Stavudine (d4T); 
Didanosine (ddI); 
zalcitabine (ddC); Tenofovir 
(TDF); Emtricitabine (FTC) 
Non-Nucleoside 
Reverse 
Transcriptase 
Inhibitors (NNRTIs) 
NNRTIs also stop HIV from 
replicating within cells by 
inhibiting the reverse 
transcriptase protein 
Delavirdine (DLV); 
Efavirenz (EFV); Etrairine 
( ETR); Nevirapine (NVP) 
Protease Inhibitors 
(PIs) 
PIs inhibit protease, which is 
another protein involved in 
the HIV replication process 
Amprenavir (APV); 
Atazanavir (ATV); 
Darunavir (DRV); Indinavir 
(IDV); lopinavir (LPV); 
Ritonavir (RTV); Nelfinavir 
(NFV); Saquinavir (SQV); 
Tipranavir (TPV) 
Fusion or Entry 
Inhibitors 
Fusion or entry inhibitors 
prevent HIV from binding to 
or entering human immune 
cells 
Enfuvirtide (T-20); 
Maraviroc (MVC) 
Integrase Inhibitors Integrase inhibitors interfere 
with the integrase enzyme, 
which HIV needs to insert its 
genetic material into human 
cells 
Raltegravir (RAL) 
 
NRTIs are the structural analogues of the nucleotide, which block RNA and DNA. 
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NRTIs competitively block reverse transcriptase’s enzymatic function and prevent 
completion of synthesis of the double-stranded viral DNA, thus effectively inhibit 
viral replication 
14
. NRTIs are generally not metabolized by hepatic cytochrome 
P450 (CYP450) enzymes, instead, intracellular enzymes such as nucleoside 
kinases, 5’-nucleotidases, purine and pyrimidine nucleoside monophosphate 
kinases or similar enzymes are involved 
15
. NRTIs are generally safe and well 
tolerated, but they are associated with important toxicities, for example, 
mitochondrial toxicity and lactic acidosis. 
 
NNRTIs, like NRTIs, also target HIV reverse transcriptase, but the mechanism of 
action is different. NNRTIs block complementary DNA elongation through 
binding directly and noncompetitively to the enzyme, which stimulates irreversible 
alteration in protein at the active site and decreases affinity for nucleoside binding 
14
. NNRTIs are metabolized to some degree by CYP450 enzymes and they can act 
as either inhibitors or inducers, therefore affecting the metabolism of other drugs.  
 
PIs prevent gag-pol polyprotein cleavage through acting on the active site of viral 
protease thus new viral particles cannot mature. PI-based combination regimens 
can result in profound and sustained suppression of viral replication 
16,17
. PIs are 
extensively metabolized by CYP3A4 present in the liver, while the isoenymes 
CYP2C19, CYP2C9 and CYP2D6 may also contribute to the metabolism of some 
PIs 
18–22
. The combination of PIs with low dose of ritonavir is developed and 
widely used in ART regimens in order to minimize the risk of treatment failure and 
maximize the durability of treatment response 
23–25
. This positive drug-drug 
interaction increases the exposure to the PIs, allowing administration of lower 
doses at reduced dosing frequencies with less dietary restrictions. 
 
1.2. Rifampicin-based antituberculosis therapy  
Contemporary treatment of drug-sensitive tuberculosis is divided into two phases: 
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intensive phase and continuation phase. In the intensive phase, covering the first 
two months of drug therapy, the bactericidal effect of the drugs administered is 
most prominent, with rapid bacteriological sputum conversion to culture negativity 
in the majority of adult patients. The continuation phase is usually four months 
and prolonged treatment may be given to some patients with initially poor 
response.  
 
The first-line antituberculosis drugs include isoniazid, rifampicin, ethambutol, and 
pyrazinamide. The WHO guideline 
26
 recommends fixed-dose combinations 
(FDCs) of antituberculosis drugs with the purpose of preventing drug resistance 
due to monotherapy. Rifampicin is the key component of first-line antituberculosis 
treatment regimens. For new patients with TB, guidelines recommend a regimen: 
2HRZE/4HR (rifampicin (R) and isoniazid (H) for 6 months with pyrazinamide (Z) 
and ethambutol (E) for the first 2 months) 
26
.  
 
Among treated TB patients, death rates are higher in HIV-positive than in 
HIV-negative patients. The case-fatality rate is reduced in patients who receive 
concurrent ART 
27
. The first priority for HIV-positive patients presenting with TB 
is to initiate TB treatment, followed by ART. Rifampicin is a potent inducer of 
multiple metabolizing enzymes and drug transporters including CYP3A4 and 
P-glycoprotein (Pgp) 
28
, while isoniazid has been shown to inhibit CYP3A4 
29
 , 
and therefore strong pharmacokinetic interactions with other drugs should be 
anticipated. CYP2C19 and CYP3A were inhibited potently by isoniazid in a 
concentration-dependent way, but isoniazid did not show significant inhibition of 
CYP2C9, CYP1A2, and CYP2D6
29
. No data supports remarkable effects on any 
CYP activity by pyrazinamide and ethionamide. 
 
1.3. Current recommended regimens 
The current WHO guidelines 
6
 indicate that for the adults and adolescents, 
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first-line ART includes an NNRTI in combination with two NRTIs, with the 
preferred regimens comprising AZT or TDF + 3TC or FTC + EFV or NVP. 
Meanwhile, ritonavir-boosted PIs plus two NRTIs are recommended as the 
second-line ART for adults and adolescents and the preferred PIs are 
atazanavir/ritonavir or lopinavir/ritonavir (4:1, LPV/r) 
6
, which have comparable 
antiretroviral effect. As antiretroviral programs mature and patients move onto 
second-line regimens, a sharp increase in the use of PIs is expected. However, 
most PIs have low bioavailability and a relative short half-life 
28
, and the 
pharmacokinetic interactions with food and other medications are common 
30
. 
Accordingly, the treatment regimens are complicated by these factors. 
 
For children < 2 years of age, LPV/r plus two NRTI is recommended as the 
first-line ART regimen by WHO guidelines 
31
. HIV infected infants exposed to 
single dose nevirapine, or maternal NNRTIs-containing ART or prevention 
regimens, PI-based ART should be used 
31,32
. Infants should start ART as soon as 
possible regardless of level of immune suppression. LPV/r is the preferred 
regimen in <2 year-olds with ART exposure (maternal ART or a regimen for 
prevention of mother-to-child transmission). Recently released results of the 
P1060 study suggest that LPV/r might also be preferred to a NVP-based regimen 
in infants not exposed to ART 
33
.  
 
As for the treatment of HIV infected patients presenting with TB, ATT is started 
first, followed by ART as soon as possible afterwards. The ATT regimen is the 
same as for patients who are not HIV-infected. Compared to adults, young children 
(especially those under 2 years) are at particularly high risk of developing TB in 
high burden settings and up to 25% of HIV infected children not on ART develop 
TB each year in South Africa 
31
. All children presenting with TB regardless of age 
or CD4 count should be started on ATT immediately with continuous ART
13
. 
However, considering the potential for combined toxicities and drug-drug 
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interactions, the following ART regimen adjustments are recommended: EFV plus 
2NRTIs is preferred for children > 3 years-old; a triple NRTIs regimen is 
recommended for children < 2 years and NVP plus 2NRTIs for children 2-3 years 
old; super-boosted LPV/r (adding ritonavir in a 1:1 ratio of lopinavir: ritonavir) is 
recommended for children already on a PI when they get TB or in children who 
have failed the first-line therapy. But adding extra ritonavir is technically difficult 
and cumbersome to implement since it is with a high risk of prescription and 
dosing errors. Moreover, ritonavir is poorly tolerated in high doses and ritonavir 
solution should be kept in refrigeration and has a short shelf life to maintenance of 
supply difficult in many settings. Therefore, more studies are needed to evaluate 
pharmacokinetics, safety and efficacy.   
 
2. Drugs of interest in this thesis 
2.1. Lopinavir/ritonavir 
 
 
Figure 1.4 Structure of lopinavir 
 
Lopinavir (Figure 1.4) is one of the most widely used PIs. It exerts a high intrinsic 
antiretroviral potency against viral strains coming from either ART-naive or 
-experienced patients 
30,34
. From in vitro study, lopinavir is highly active against 
HIV-1 cultured in peripheral blood mononuclear cells, with a mean 50% effective 
concentration (EC50) of 6.5 nmol/L 
22
. The clrearance of lopinavir is 0.06-0.18 
L/h.kg, volume is 0.56-2.16 L/kg, and half life is 6.2-8.4 h.
12
 Lopinavir is 98.2% to 
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99.2% protein bound in both healthy volunteers and HIV-infected patients 
35
. 
Protein binding is not concentration-dependent within the therapeutic range. 
Lopinavir is precluded the use as a single PI in ART regimens due to its poor oral 
bioavailability, and its extensive and rapid metabolism by the CYP 3A4 isoenzyme 
in the liver 
22,34,36–38
. Therefore, lopinavir is always co-administered with low dose 
of ritonavir which inhibits intestinal and hepatic CYP3A4 and p-glycoprotein 
(Pgp). Lopinavir and ritonavir are co-formulated in a ratio of 4:1 (LPV/r). The 
antiretroviral activity of LPV/r combination is derived from lopinavir, but adverse 
effects are often due to ritonavir 
39
. Compared with other PIs, this combination has 
demonstrated a favorable resistance profile and shown promising properties in 
suppression of HIV-RNA and recovery of CD4+ T cell counts 
34
.   
 
Figure 1.5 Structure of ritonavir 
 
Ritonavir (Figure 1.5) is metabolized mainly by CYP3A4, and to a lesser but 
clinically relevant extent by CYP2D6 
40
. In vitro, the metabolism of lopinavir is 
inhibited by very low concentrations of ritonavir, with IC50 values of 0.026 mg/L 
and 0.053 mg/L in rat and human liver microsomes, respectively 
28,40
. Ritonavir 
also has been shown to induce its own metabolism 
35
. Ritonavir boosts lopinavir 
concentrations via two possible mechanisms 
30,40–42
. Firstly, it may improve the 
oral bioavailability of lopinavir by inhibiting intestinal CYP3A4 and Pgp. 
Secondly, ritonavir may also decrease the rate of elimination of lopinavir by 
inhibition of CYP3A4 and Pgp in the liver. The mean steady-state lopinavir 
plasma concentrations in HIV infected patients administered LPV/r 400/100 mg 
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twice daily are 15- to 20-fold higher than those of ritonavir. In vitro, compared to 
ritonavir, the antiviral EC50 of lopinavir is approximately 10-fold lower 
22
. LPV/r 
therapy also was found to result in moderate induction of CYP1A2 and CYP2C9 
and potent induction of CYP2C19 activity 
43
. It may be necessary to increase 
doses of concomitant medications metabolized by these enzymes. The median 
trough concentration was reported 5.2 ug/mL with 400/100 mg LPV/r by 
Crommentuyn et al 
44
, which is at least 51-fold above the protein binding-adjusted 
EC50 of lopinavir (0.07 ug/mL ) 
45
. The clrearance of ritonavir is 0.16-1.40 L/h.kg, 
volume is 0.56-1.39 L/kg, and half life is 2.3-3.2 h.
12
 
 
The currently available formulations of LPV/r are tablet (Aluvia
®
, Abbott 
Laboratories), soft gelatin capsule (Kaletra
®
, Abbott) and oral liquid (Kaletra Oral 
Solution
®
, Abbott). Two tablet formulations are available: 200 mg lopinavir + 50 
mg ritonavir or 100 mg lopinavir + 25 mg ritonavir (the latter is for pediatric 
dosing). The liquid formulation contains 80 mg lopinavir + 20 mg ritonavir per 
mL. The liquid formulation is 42% ethanol by volume and is the first and only 
co-formulated ritonavir-boosted PI approved for use in children.  
 
The recommended dosage of LPV/r in ART-naive and -experienced adults and 
adolescents is 400/100 mg twice daily while for children it is dosed according to 
body surface area or body weight according to mg/kg and weight band dosing
31,46
. 
Studies conducted in ART-experienced and –naive patients indicated that the 
pharmacokinetics of lopinavir was similar 
44,47
. The bioavailability of lopinavir is 
increased after administration of the LPV/r co-formulation with food, which effect 
is less prominent with the tablet. The mechanism is not clear, but it may be related 
with food prompting high-protein binding drugs. Compared with fasting, 
administration of a single dose of LPV/r 400/100 mg with a moderate to high 
fat-content meal increased lopinavir maximum plasma concentration (Cmax) and 
area under the plasma concentration-time curve (AUC) by up to 56% and up to 
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130% with the capsule and liquid co-formulations respectively, and by up to 17% 
and up to 27% with the tablet co-formulation 
48,49
. LPV/r is generally clinically 
well tolerated and the most common adverse events are gastrointestinal reactions, 
including diarrhea, nausea and vomiting, and hypertriglyceridaemia and 
hypercholesterolaemia. Hepatic or metabolic dysfunction has been also reported 
50
.  
 
2.2. Lamivudine 
 
 
 
Figure 1.6. Structure of lamivudine 
 
Lamivudine (3TC), the negative enantiomer of 2 -deoxy-3 -thiacytidine (Figure 
1.6), is a dideoxynucleoside analogue widely used in combination with other 
agents in ART regimens and as monotherapy in the treatment of hepatitis B virus 
(HBV) infection
51,52
. As a NRTI, lamivudine is commonly included in first-line 
ART regimens 
31,46
. Lamivudine is rapidly absorbed orally and has a wide 
distribution because of its high lipid solubility as well as tissue binding and low 
plasma protein binding (<36%). Lamivudine is primarily renally eliminated and 
about 5 to 10% is metabolized to the pharmacologically inactive trans-sulfoxide 
metabolite, the majority of which is also excreted in the urine within 12 hour after 
a single oral dose 
53–55
. Since most of an oral dose is eliminated renally as 
unchanged drug, the dose needs to be reduced in patients with renal insufficiency 
56
. Hepatic impairment does not affect the pharmacokinetics of lamivudine. The 
likelihood of metabolic interactions of lamivudine with other medicinal products is 
low due to its small extent of hepatic metabolism (5-10%) and low plasma protein 
binding. Systemic clearance after single intravenous doses averages 20 to 25 L/h 
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(about 0.3 L/h/kg) and the dominant elimination half-life of lamivudine is 
approximately 5 to 7 hours. 
 
Lamivudine exhibits linear pharmacokinetics over the therapeutic dose range. The 
bioavailability of lamivudine in adults and adolescents is between 80 to 85%. The 
mean time to peak serum concentration (Tmax) is approximately one hour 
57–60
. 
Food reduces the peak serum concentration (Cmax) and delays the time to Tmax, 
however, no significant difference in overall bioavailability is observed; therefore, 
no dose adjustment is needed when co-administered with food 
56
. A higher dose is 
recommended for pediatric patients (8 mg/kg/day) because the bioavailability in 
children is reduced to approximately 65% and clearance increased by 0.52 
L/kg/h
58,59,61
.  
 
Lamivudine is well tolerated. Severe adverse effects such as liver and metabolic 
disorders are rare. Pancreatitis has been reported in patients receiving lamivudine, 
particularly in HIV-infected pediatric patients with prior nucleoside exposure 
62–64
.  
 
2.3. Rifampicin 
Rifampicin is the most important agent for the treatment of TB and is lipid soluble 
and readily absorbed from the gastrointestinal tract. Rifampicin is about 80% 
protein bound and widely distributed throughout the body. Rifampicin is rapidly 
eliminated in the bile, and an enterohepatic circulation occurs. Up to 30% of a 
dose is excreted in the urine, with about half of this being unchanged drug 
65
.  
 
Rifampicin activates the pregnane X receptor (PXR), which is a nuclear receptor 
regulating transcription of multiple drug metabolizing enzymes including phase I 
enzymes such as CYP2A6, 2B6, 2C9, 2C19, 2C8, 3A5, 3A4 and 3A7, phase II 
enzymes such as the glutathione-S-transferases, UDP glucuronosyltransferases and 
sulphotransferases and transporters such as Pgp, multidrug resistance protein 2, 
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multidrug resistance-associated protein 2 and the organic anion transporter 
polypeptide 2 
66
. Hence rifampicin reduces the concentrations of many 
concomitantly administered drugs that are metabolized by CYP3A4 and/or are 
transported by Pgp. Rifampicin is regarded to be amongst the most potent inducers 
of CYP3A4 known. The induction by rifampicin at clinical doses of 600 mg is 
near maximal 
67
. 
 
Rifampicin concentrations vary widely between patients and study populations. 
Low concentrations have been observed in children and reductions in the 
bioavailability of rifampicin of 30-50% have been found in HIV infected patients 
68,69
 and might be due to malabsorption because of HIV-associated enteropathy and 
increased susceptibility to enteric infections 
70
. It is unknown how induction of 
enzyme expression associated with rifampicin may be affected with changing 
exposure 
71
 
19
.Therefore, a higher dose of rifampicin should be considered for HIV 
infected patients, but related high incidence of adverse effects may become 
another concern. Significant CYP3A4 induction was detected 8 hours after a 
single rifampicin dose 
72
. The activity of CYP3A4 during rifampicin 
administration reached steady state after one week and returned to baseline about 2 
weeks after termination of rifampicin administration 
73
.  
 
3. Variability in pharmacokinetics of antiretroviral and 
antituberculosis drugs 
3.1. Pharmacokinetic variability  
Large interindividual variability in the pharmacokinetics of the drugs could result 
in a given drug being effective for some patients but ineffective for others. 
Potential sources of pharmacokinetic variability include physiological factors such 
as age, sex, weight, height, hemoglobin, pathological states such as hepatic or 
renal impairment, cardiac failure, severity of HIV, co-administration of ATT 
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regimens, genetic factors, environmental factors and drug-drug interactions 
19
. 
 
It is reported that NNRTIs display less interindividual and intraindividual 
pharmacokinetic variability than PIs 
74
. In total of 457 PI and 172 NNRTI plasma 
concentrations, intraindividual variability was consistently lower than 
interindividual variability 
74
. Genetic diversity could explain variability, for 
example, zidovudine clearance was shown 48% higher in glucuronidation and 33% 
higher in UGT2B7*1c carriers versus non-carriers 
75
; and a wide range of 
efavirenz concentrations can be explained by genetic polymorphism encoding 
CYP2B6 
76–79
. Moreover, ATT tend to increase interindividual variability in 
efavirenz concentrations 
80,81
. 
 
Body weight is an obvious source of pharmacokinetic variability, and bigger doses 
are often prescribed for heavier individuals (e.g. when mg/kg dosing schemes are 
used). Nevertheless, this normalization is not sufficient and it is common 
knowledge for example that many drug doses have to be modified in the elderly 
and children. Moreover, the drug elimination does not have a linear relationship 
with body weight. Therefore doses are increased less rapidly than predicted 
directly from body weight, and in most instances heavier individuals require lower 
dose per kg to achieve the same exposure. Children, especially infants and young 
children have extremely different pharmacokinetics compared to adults in many 
situations.  
 
3.2. Pharmacokinetics in children 
Physiological differences between adults and children can be expected to produce 
significant differences in the way they respond to drugs. For this reason, US Food 
and Drug Administration (FDA) has required trials of new drugs to be done in 
pediatric populations for the use of a product in pediatric patients prior to approval 
for use in adults. Numerous approaches for determining pediatric drug doses have 
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been recommended. Some of these approaches use discrete age points, and others 
use allometric principles that generally assume predictable relationship between 
children and adults 
82
. However, as age-associated changes in body composition 
and organ function are dynamic and tend to be inconsistent especially during the 
first age of life, simplified dosing approaches are not adequate for individualizing 
drug dosages across the span of childhood.  
 
Pharmacokinetics can be expected to differ between children and adults, especially 
for very young children. The oral formulations used for children have to be easy to 
swallow, such as liquid or powder and such formulations may have different 
absorption profile compared to tablets because of diverse solubility, permeability 
and excipients. When paediatric formulations are not available, tablets for adults 
are often crushed, before administration to children, a process which in itself 
might affect absorption. Furthermore, the relative amount of drug available for 
absorption will be influenced by age-dependent changes in luminal pH, which 
affects degree of ionization and drug stability. The solubility and subsequently 
absorb lipophilic drugs can be altered by age-dependent changes in biliary 
function 
83
. There are also varying rates in absorption due to differences in gastric 
emptying and intestinal motility between children and adults. Developmental 
differences in the activity of intestinal drug metabolizing enzyme and efflux 
transporters are also likely to markedly alter drug bioavailability in children and 
adults. 
 
Age-dependent changes in body composition alter the physiologic spaces into 
which a drug may distribute. Large extracellular and total body water in neonates 
and young infants who have higher water/lipid ratios than in adults, result in lower 
plasma concentrations for drugs which distribute into the respective compartments. 
The composition and amount of circulating plasma protein (eg. albumin, α1 
acid-glycoprotein) are changed by age and therefore influence the distribution of 
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highly bound drugs, such as lopinavir and ritonavir 
83,84
. Other differences between 
children and adults, such as regional blood flow, organ perfusion, permeability of 
cell membranes, acid-base balance can also affect drug binding or distribution. 
 
Development of expression of CYP450 enzymes is profoundly affected by age. 
Hattis et al summarized the geometric mean ratios of children/adults elimination 
half-lives from 135 data groups for 41 drugs and found that the metabolism 
enzyme displayed different in the duration from premature neonates to 12-18 years 
old 
84
. Distinct patterns of development of isoform-specific CYP expression have 
been found after birth. CYP3A7 is the predominant CYP isoform enzyme 
expressed in fetal hepatocytes and its expression attains a peak shortly after birth 
and then diminishes rapidly to levels that are undetectable in most adults. The 
clearance of carbamzaepine, which is largely dependent on CYP3A4, is greater in 
children than in adults 
84
. Phenytoin metabolism is not attatining saturation until 
approximately 10 days of postnatal age, demonstrating the developmental 
attainment of CYP2C9 activity. For renal elimination, the maturation of renal 
function is a dynamic process that starts early during fetal organogenesis and is 
complete by early childhood 
83
.  
 
Key considerations for drug exposures in HIV-infected pediatric patients include 
factors such as etiological, physiological, psychological and social differences 
between children and adults. This is further complicated for children during 
co-administration of ART and ATT regimens since the drug induction or inhibition 
may display differently between children and adults. Therefore, given the growing 
number of TB children with HIV-infection who have access to treatment, a better 
understanding and comparison of pharmacokinetics of ART drugs between adult 
and pediatric populations, as well as drug-drug interactions associated with 
antiretroviral and antituberculosis agents, is important.   
 
3.3. Therapeutic drug monitoring of antiretroviral drugs 
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Since high variability is observed during ART, which may be accentuated when 
co-administered antituberculosis agents, therapeutic drug monitoring of 
antiretroviral drugs is quite necessary with the purpose of improvement of efficacy 
and reduction of toxicity. During therapeutic drug monitoring of ART, trough 
concentrations are usually applied for virological efficacy and peak samples for 
toxicity management. Guidelines provide therapeutic concentration ranges for PIs 
and NNRTIs based on current available clinical data 
6,31
. A target lopinavir trough 
concentration greater than 1 mg/L is recommended for PI-naïve patients. For 
PI-experienced patients the minimum recommended trough concentration is based 
on the phenotypic or genotypic viral resistance patterns, therefore related to 
different mutations, ranging from 3.6 to 6.2 mg/L 
85,86
. Although altered lipid 
profiles and elevated liver enzymes have been associated with increased 
concentrations of lopinavir, the available data does not support an upper limit for 
the therapeutic range 
86
. Moreover, the presence of ATT, especially rifampicin, and 
possibly the sequence of treatment introduction with antituberculosis drugs and 
LPV/r, respectively, alters the risk of toxicity.  
 
4. Pharmacokinetic drug-drug interactions 
Drug-drug interactions occur when one therapeutic agent either alters the 
concentration (pharmacokinetic interactions) or the biological effect of another 
agent (pharmacodynamic interactions). Pharmacokinetic drug-drug interactions 
may include alterations in the pharmacokinetics of one drug by other drugs in the 
absorption, distribution, metabolism and excretion (ADME), leading to alterations 
in plasma or blood concentrations of the drug and subsequently at the site of action. 
Pharmacodynamic interactions are a result of the influence of combined treatment 
at a site of biological activity and produce altered pharmacological actions. 
Synergistic or antagonistic pharmacologic effects arise when pharmacodynamic 
drug interactions occur. Either type of drug interaction may lead to adverse effects 
in patients. 
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Pharmacokinetic drug-drug interactions that result in alteration of drug absorption 
can affect the rate or extent of absorption. The mechanisms include an alteration in 
blood flow to the intestine; increased or decreased drug metabolism by the 
intestine; change in intestinal motility; an alteration of pH in stomach or a change 
in the bacteria that reside in the intestine 
87
. For example, magnesium, aluminium 
and iron cations have an affinity for fluoroquinolones, resulting in reduced 
absorption 
88
. Hence, administration of buffered didanosine and antacids should be 
separated by several hours from administration of fluoroquinolones. Protein 
binding changes by drug-drug interaction can also influence the absorption, as 
well as drug distribution. The unbound concentrations of drug at steady state for 
most drugs will not be affected except high extraction drugs or drugs that are 
given in doses achieving near saturation of protein binding. Drug-drug interactions 
affecting the renal excretion of drugs can be caused by alterations in the 
transporters involved in the efflux of drug molecules into the urine by secretion. 
Alteration of pH in urine or flow of urine can also result in drug-drug interactions.  
 
The most clinically vital drug-drug interaction result from alteration of drug 
metabolism. Drug metabolism occurs mainly in the liver, although other sites such 
as the gastrointestinal tract, kidneys, skin and lungs can be involved. The possible 
drug-drug interactions can be predicted by identifying the CYP enzymes that are 
modified through induction or inhibition by a particular drug. In addition to 
enzyme-based interactions, drug transporters play crucial roles in determining the 
pharmacokinetic profiles of drugs and are prone to induction and inhibition 
interactions.  
 
4.1. Drug-drug interactions mediated by CYP enzyme  
Drug metabolism by means of the CYP 450 system has been known as being of 
crucial importance for drug-drug interactions 
24,89,90
. Enzyme induction or 
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inhibition results in enhanced or reduced drug metabolism, which results in higher 
or lower drug concentrations. CYP 3A4 isozyme is the most predominant hepatic 
and intestinal phase I enzyme and is responsible for the biotransformation of about 
50% of all marketed drugs 
91
. The substrates of CYP3A4 to a large extent overlap 
with those of Pgp, and the synergy effect is usually observed on the functions of 
Pgp and CYP3A4 
92
, such as lopinavir and clarithromycin. The inhibition or 
induction of CYP3A4 by drugs often causes unpleasant and long-lasting drug-drug 
interactions, that may even result in fatal toxicity, depending on many factors 
associated with the enzyme, the drugs involved, or the patients 
28,93–95
.  
 
4.1.1. Enzyme kinetics 
The simple conversion of substrate (A) into product (P) catalyzed by the enzyme 
(E) is described Equation 1.1. Substrate binding first and the catalytic step is 
followed. 
 
(1.1)  
where k1 is the synthesis rate, k-1 is the degradation rate of enzyme-substrate 
complex , EA is the enzyme-substrate complex and kcat is the catalytic rate 
constant.  
 
During a very brief initial period, the enzyme–substrate complex is formed and 
reaches a concentration at which its consumption is matched by its formation. The 
[EA] then attains near constant as the steady state, and the Michaelis–Menten 
equation is used to describe (Equation 1.2). Finally, substrate diminishes in which 
the [EA] gradually falls. 
 
Michaelis-Menten kinetics of enzyme metabolism is described as follows: 
   
      
    
 (1.2) 
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where v is the rate of metabolism of enzyme; C is the concentration of substrate. 
Km is the Michaelis–Menten constant; The Vmax is the maximum velocity that an 
enzyme could achieve and Vmax = kcat   [total amount of enzyme]. 
 
Therefore, clearance can be described as: 
    
    
    
 (1.3) 
 
and intrinsic clearance is 
       
    
  
 (1.4) 
 
The Km indicates the binding strength of that enzyme to its substrate. Assuming a 
stable pH, temperature, and redox state, this parameter is constant for a given 
enzyme. Michaelis–Menten kinetics assumes that kcat is very low when compared 
to k1 and k –1. Therefore, a high Km indicates the enzyme binds the substrate 
weakly. Conversely, a low Km indicates a higher affinity for the substrate.  
 
4.1.2. Enzyme induction  
Enzyme induction can enhance synthesis of enzymes through either binding 
inducers to a nuclear receptor or stabilization of enzyme, such as the case of 
CYP2E1 
96
. Enzyme induction is a time-dependent process and may take from a 
few hours to several weeks to occur because it results from gene transcription and 
the following protein synthesis 
97
. The steady-state levels of an enzyme depend on 
the balance between its rate of synthesis and degradation. Therefore, reaching a 
new steady-state level of induction or after withdrawal of the inducer will take 
time, no matter of whether the induction was due to synthesis of new enzymes or 
to enzyme stabilization. The time to reach a new steady state is determined by the 
enzyme half-life. The extent of CYP induction is related to the baseline levels of 
CYP enzymes, genetic polymorphism in the CYP enzymes, and environmental 
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factors such as smoking and alcohol consumption 
98
. 
Enzyme induction enhances drug metabolism, and therefore may decrease its 
plasma concentration, which may be followed by a reduction in drug efficacy, 
depending on its therapeutic index. Induction effect will increase CLint through 
complex binding to DNA and activating RNA polymerase or elevating level of 
protein 
99,91,100
. Enzyme induction may increase plasma concentrations of 
metabolite. If the metabolite is toxic, enzyme induction results in aggravated 
toxicity, but alternatively it results in an enhanced effect for prodrugs.  
4.1.3. Enzyme inhibition  
Drug-drug interaction due to inhibition can be competitive, noncompetitive or 
uncompetitive 
21,101,102
. The typical reactions in complex reality often involve 
mixed mechanisms of these three components. Comp titive inhibition depends on 
the affinities of the substrate and inhibitor to the enzyme, since the inhibitor would 
be removed from the enzyme, and therefore increasing the concentration of the 
substrate can lead to recovery from inhibition. The presence of an inhibitor 
reduces the ability of the enzyme bind to its substrate. The half-life of the inhibitor 
decides on the recovery from competitive inhibition. An increase in the 
concentration of a competitive inhibitor will increase the apparent Km of the 
enzyme, but there is no effect on Vmax 
101,103
. A noncompetitive inhibitor does not 
bind to the catalytic site but binds to a second site on the enzyme and acts by 
reducing the turnover rate of the reaction 
28,104
. The binding of the inhibitor and 
substrate is completely independent, and binding of the inhibitor produces total 
inhibition of the catalytic step. Noncompetitive inhibitors will not alter the Km but 
will reduce the apparent kcat as inhibitor concentration increases. For 
uncompetitive inhibition, the enzyme can no longer metabolize the substrate 
because enzyme is inactivated by the inhibitor 
28,101
. Inactivation of the enzyme 
usually lasts longer with uncompetitive compared to competitive inhibition, and 
recovery from uncompetitive inhibition is dependent on the half-life of the enzyme 
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if the half life of the inhibitor is comparatively negligible 
28,90,105
. 
 
Enzyme inhibition decreases drug metabolism and increases plasma drug 
concentrations, which may lead to elevated pharmacological activity and, if the 
drug has a narrow therapeutic index, to adverse effects. For prodrugs, inhibiting 
drug metabolism would reduce the anticipated pharmacological effect. However, 
the metabolism pathway of a drug may shift to alternative minor pathways when 
the enzyme that is primarily involved in the metabolism has been inhibited.  
 
4.2. Drug-drug interactions mediated by drug transporters 
Uptake and efflux transporters, located in intestine, kidney, liver and other tissues, 
affect the pharmacokinetic profile of a drug substrate 
106–108
. Efflux transporters 
expressed in the intestine and liver include Pgp or ABCB1, bile salt export pump 
(BSEP, ABCB11), multidrug resistance protein (MRP1-6, ABCC1-6), breast 
cancer resistance protein (BCRP, ABCG2), and all members of the ATP-binding 
cassette (ABC) superfamily 
106,109,110
. Absorption transporters control drug transfer 
into the systemic circulation and secretary transporters mediate the excretion of 
substrates from the circulation into bile, urine, or intestinal lumen. Transporters 
also play important roles in oral drug disposition. Therefore, alteration of the 
functions of transporters may potentially change the disposition of drugs, as well 
as influencing drug-drug interactions. 
 
The Pgp is an important efflux transporter which is expressed in many tissues and 
located on the apical side of intestine, liver, and kidney epithelia 
111
. Drug-drug 
interactions can arise from induction or inhibition of Pgp by up-regulating the 
MDR1 gene, which encodes Pgp 
28,112,113
. Induction or inhibition of intestinal Pgp 
results in alterations of the rate and extent of absorption of Pgp substrates. Drug 
metabolism is decreased by Pgp inhibition in the small intestine but enhanced in 
the liver. Moreover, alteration in Pgp activity can affect drug secretion in the urine 
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as well as distribution to different organs, such as the brain and placenta 
111,113
. 
 
Intestinal transporters will exclusively affect bioavailability, thus clearance will 
not change in response to induction or inhibition of intestinal transporters, but the 
rate constant of absorption may be influenced 
66,114–116
. Transporters in the liver 
and kidney can affect the clearance of orally administered drug that escapes the 
first-pass effect. Inhibiting uptake transporters prevents drug from being exposed 
to metabolizing enzymes within hepatocytes, decreasing the clearance of drugs 
that are substrates for these enzymes. For drugs that are not metabolized but are 
eliminated by biliary excretion, clearance may also decrease, since drug is 
prevented from getting into the bile through the hepatocytes 
109
. Moreover, 
transporters may influence volume of distribution by mediating their transport into 
and out of a variety of tissue and organs 
117
. If a tissue’s uptake transporters are 
inhibited, more drug remains in the plasma and less drug is eliminated by the liver, 
which leads to decreased volume of distribution. Induction may increase the 
amount of drug remaining in the liver, decrease the concentration in plasma, and 
increase volume of distribution in action tissues. While the effect of altering 
function of hepatic efflux transporters on volume of distribution may behave in the 
opposite way, this effect is not always predictable. 
 
4.3. Potential drug-drug interactions between lopinavir/ritonavir-based ART 
and ATT  
Concomitant use of ATT and ART is complicated by drug-drug interactions. The 
result of interactions can be either a decrease or increase in drug exposure, which 
in turn can reduce efficacy or increase toxicity. Since PIs are extensively 
metabolized by the CYP450 system, there is considerable potential for 
pharmacokinetic interactions when these drugs are administered concomitantly 
with ATT drugs metabolized via the same pathway.  
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Rifampicin is a substrate of Pgp, and OATP1B1, as well as having a potent PXR- 
mediated action on CYP2B6, 2B9, 2C8, 2C9, 3A4, 3A7, GSTs, UGTs, SULTs, 
Pgp, MDR2, OATP2, MRP2, hence leads to a reduction in the concentrations of 
four classes of ART drugs: NNRTIs, PIs, CCR5-receptor antagonists, and integrase 
inhibitors. Rifampicin induction is mediated by the activation of PXR, which is 
highly expressed in the liver and intestine, and when a PXR ligand binds to PXR, 
it activates transcription of CYP 3A4 and Pgp 
118
. CAR is another receptor is 
involved in CYP3A4 transcriptional regulation and it can trans-activate CYP3A4 
gene expression both in vitro and in vivo 
119
. The CAR response elements are also 
bound by PXR, which interacts in CYP3A4 expression. Rifampicin reduces trough 
concentrations of ritonavir-boosted PIs >90% and reduces exposure to NNRTIs 
(delavirdine > nevirapine > efavirenz), abacavir, zidovudine, maraviroc (60–
70%), raltegravir (40%), linezolid (32%), moxifloxacin (30%) and rifampicin 
itself 
11
. 
 
Though rifabutin is recommended instead of rifampicin to avoid drug-drug 
interaction
13
, it is not a feasible option because rifabutin is currently prohibitively 
expensive and, in high burden countries, there is a tendency to rely on standard 
treatment regimens, often administered in FDCs. The use of rifabutin is further 
complicated by a lack of suitable formulations: a once daily dose that could be 
incorporated in a FDC would be easier to implement in tuberculosis control 
programs, and formulations suitable for children are not available. Moreover, 
ritonavir-boosted PIs significantly increase exposure to rifabutin and cause even 
greater increases in plasma concentrations of the active metabolite. Therefore, a 
reduced rifabutin dose is needed. However, there is not sufficient evidence for 
efficacy and safety of reduced rifabutin doses in HIV infected patients on PIs. It 
was reported that rifabutin three times weekly in combination with LPV/r- based 
ART may be feasible to achieve sufficient rifabutin concentrations 
120
, but it is 
difficult to implement in the clinic where daily administration of other 
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antituberculosis drugs is used. Therefore, rifampicin is still a key component in 
concurrent ATT and ART regimens.  
 
Considering lopinavir being the substrate of both CYP3A4 and Pgp, it was 
reported that the concomitant administration of rifampicin with standard dose of 
LPV/r reduces the bioavailability and minimum concentration of lopinavir by 
approximately 75% and 99% respectively 
12
. Rifampicin 300 mg or 600 mg once 
daily for 10 days decreased the AUC of ritonavir by about 35% 
67
. Ritonavir is a 
potent inhibitor of CYP3A ,CYP2D6 and Pgp, and therefore a high dose of 
ritonavir can counteract the induction effect of rifampicin to be used to maintain 
concentrations of PIs’, such as saquinavir and lopinavir during rifampicin therapy 
121–123
. It has been demonstrated that ritonavir inhibition involves both reversible 
and irreversible mechanisms 
21
. Meanwhile, ritonavir also has induction effects on 
other hepatic enzyme systems. The main drug-drug interactions between lopinavir, 
ritonavir and rifampicin related in this thesis are described in Figure 1.7. Moreover, 
isoniazid is often involved in the ATT regimens co-administered with lopinavir 
and ritonavir. It inhibits CYP1A2, 2C9, 2D6, 2C19, 3A4 and monoamine oxidase 
29,69,96
, and therefore affect the ritonavir metabolism. Co-trimoxazole is frequently 
used in young children on ART and rifampicin could reduce the AUC of 
trimethoprim 
111
. Also, potential pharmacokinetic interactions between lopinavir, 
ritonavir and rifampicin have not been thoroughly evaluated and hence 
unanticipated interactions might arise. But all these effects are of secondary to 
those described in the Figure 1.7. 
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Figure 1.7. Drug-drug interaction between lopinavir, ritonavir and rifampicin. 
 
In order to overcome the great induction effect from rifampicin, there is some 
evidence from a small study in adult volunteers to support the strategies of adding 
extra ritonavir to LPV/r, or increasing the dose of both lopinavir and ritonavir 
components, when rifampicin is given concomitantly 
12
. The first approach is to 
add extra ritonavir to match the lopinavir dose (super-boosted) while on 
rifampicin-based TB treatment. However, in young children using the oral 
solutions, the approach of adding additional ritonavir to LPV/r is technically 
difficult, and cumbersome to implement with a high risk of prescription and 
dosing errors. Moreover, ritonavir oral solution is poorly tolerated in high doses 
and has a short shelf life hence clinics frequently run out of stock. The second 
approach is doubling the standard dose of LPV/r when it is given with rifampicin. 
As shown by la Porte et al. 
12
 and Decloedt et al 
124
, double dose of LPV/r can 
balance the rifampicin induction effect in adults. Another study by Nijland et al. 
125
 
also evaluated the pharmacokinetics of adjusted dose LPV/r with rifampicin. 
However, the study which was conducted in healthy volunteers was discontinued 
prematurely due to very high rates of hepatotoxicity. Side effects such as nausea, 
Ritonavir
(substrate of CYP3A4 
and Pgp)
Lopinavir
(substrate of CYP3A4 and Pgp)
Rifampicin
(substrate Pgp, OATP1B1 
and autoinduction)
Inhibitor of CYP3A and 
transporters (OATP1B1, 
Pgp)
Inducer of CYP3A and Pgp
Inducer of CYP3A and Pgp
Inhibitor of CYP3A ,Pgp, OATP1B1
Inducer of other hepatic enzymes
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vomiting and elevated transaminases occur commonly when adjusted doses of 
LPV/r and rifampicin are co-administered 
126, 12, 124 9
. Although altered lipid 
profiles and elevated liver enzymes have been associated with increased 
concentrations of lopinavir, the available data does not support an upper limit for 
the therapeutic range 
86
, and the presence of rifampicin, and possibly the sequence 
of treatment introduction with rifampicin and LPV/r, respectively, alters the risk of 
toxicity. The use of adjusted dose PIs with rifampicin might be better tolerated in 
patients than healthy volunteers. Moreover, patients with TB may have altered 
absorption of antiretroviral drugs. The loss of fat and lean body mass, and 
associated metabolic and endocrine abnormalities have the potential to influence 
the volume of distribution and total body clearance of antiretroviral drugs, 
particularly of lipophilic drugs, such as PIs. Also, it is more likely to cause 
hepatotoxicity in patients than healthy volunteers. Therefore, these approaches 
need to be evaluated in an adequately designed study amongst the relevant 
populations. There is also limited data for children about the outcomes associated 
with these approaches. Frohoff et al. reported that good short-term virologic 
outcomes have been achieved in children co-treated for TB and HIV who received 
super-boosted LPV/r and that treatment limiting toxicity was rare 
9
. Super-boosted 
LPV/r was found to overcome rifampicin-related induction in young children by 
Ren et al. 
127
 Also, intracellular lopinavir could be specifically important for 
potential sanctuary sites of the virus and this concentration might be influenced by 
transporters, including rifampicin, which accordingly affect the drug efficacy. 
Furthermore, factors, such as diet, environment and genetics, influence the activity 
of transporters, metabolizing enzymes and their transcriptional regulators 
66
. 
Therefore, more studies are needed to investigate the pharmacokinetic interactions, 
safety, efficacy and alternative dosage regimens to establish PI-based regimens for 
patients with HIV-associated tuberculosis in high-burden settings for adults and 
children respectively. 
 
Un
ive
rsi
ty 
of 
 C
ap
e T
ow
n
Chapter 1                               Introduction and literature review 
 
29 
 
A more sophisticated analysis of the dynamic interactions between lopinavir, 
ritonavir and rifampicin-based ATT with adjustment for the relevant patients and 
treatment factors may allow the prediction of more suitable dosing approaches in 
patients with TB/HIV. Dosage modifications based on target concentrations 
require accurate knowledge of pharmacokinetic parameters governing drug 
absorption, distribution and elimination, and their variability among different 
individuals and occasions. Individual characteristics as well as simulation of drug 
concentrations are also useful in deciding the dosage regimen in clinics. A more 
thorough understanding of these interactions is required to optimize the dosing 
strategies in order to avoid toxicity and the emergence of drug resistance.  
 
5. Adherence evaluation 
Adherence is directly related to the clinical and virological outcomes of ART. It 
has been demonstrated in adult patients that higher levels of drug adherence are 
associated with improved virological and clinical responses, and that rates 
exceeding 95% are desirable with improved viral suppression of ART 
31,46
. 
Adherence to ART has also been shown to help preventing drug resistance 
128
. A 
full and sustained benefit can only be derived from high levels of adherence to 
ART regimens. Moreover, either in high-income or resource-limited settings, low 
adherence has been associated with higher hospitalization rates, productivity loss, 
disease progression and death 
129
. Therefore, it is critical to ensure optimal 
adherence in order to maximize the benefit of ART, minimize the emergence of 
drug resistance and delay disease progression.  
 
Adherence is complicated by internal and external factors, including the patient, 
the health system, the community and medication barriers. Patient factors could be 
psychosocial (e.g. depression, stigma, alcohol abuse), socioeconomic (e.g. income, 
education, cost of transport), demographics (e.g. gender, age) and clinical (e.g. 
current medical co-morbidity) in nature. Medication factors include pill burden, 
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dose frequency, dietary restrictions and side effects. Although most current 
first-line regimens are one to two pills once or twice daily, second-line regimens 
are more complex. Side effects related to ART are another important issue 
affecting adherence and studies have shown that when patients experience side 
effects, they tend to stop treatment or take medication irregularly 
129
.  
 
Maintaining adherence may be even more challenging in young children, 
especially over long periods, because of factors relating to children, caregivers, 
medications, and the interaction of these factors. The limited number of pediatric 
formulations, poor palatability, high pill burden or liquid volume, frequent dosing 
requirement, dietary restrictions and side effects may hamper the regular intake of 
required medications. Successful adherence to treatment for a child requires the 
commitment and involvement of a responsible caregiver.  
 
Accurate measurement of adherence is challenging. Many approaches, such as 
patient self-reports, pill counts, or pharmacy refill records, can be used to evaluate 
adherence though no standard method exists. Biological markers, including viral 
load and CD4 cell count, can be surrogates for suboptimal adherence. But this 
approach to large extent is influenced by viral resistance, prior treatment failure, or 
poor absorption of the drug. Studies have shown discordance between viral 
suppression and adherence in those contexts 
130
. No approach can produce a 
completely valid and reliable measurement of adherence; hence, a new feasible 
and reliable method would be of utility. 
 
Compared to other antiviral drugs, lamivudine can be used to investigate 
adherence because the concentrations of lamivudine are relatively predictable 
(interindividual variability of clearance is small) 
131
 and it is not affected by 
concurrent rifampicin-based ATT. The drug undergoes relatively rapid absorption 
and peak concentrations are reached in less than 1 h after the dose. 
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Pharmacokinetic studies have demonstrated that lamivudine is well absorbed from 
the gastrointestinal tract with high oral bioavailability of approximately 86% 
131
. 
Based on data derived from a study in healthy volunteers, the mean AUC (CV) 
over a dosing interval of 12 hours is 8.9 µg.h/L (18%) 
132
. Concentrations in 51 
Zambian children aged 1.7 to 18 years, ranged from 0.82-2.28 mg/L at 1 h after 
the dose, while at 12 h the concentrations ranged from 0.06 to 0.11 mg/L 
133
. The 
extent (based on the AUC) of lamivudine absorbed is not influenced by food. The 
likelihood of metabolic interactions of lamivudine with other medicinal products is 
low due to the small extent of hepatic metabolism (5-10%) and low plasma protein 
binding. Also, lamivudine metabolism does not involve CYP3A, making 
interactions with drugs metabolized by this system (e.g. PIs and rifampicin) 
unlikely. Thus the drug has ideal pharmacokinetic properties on which to base 
predictions of the probability of adherence to the previous dose. Therefore, it can 
be used as a marker of recent adherence, to aid interpretation of PI and NNRTI 
concentrations which might be particulary variable during ATT. Patients with 
concentrations below the lower limit of the reference ranges are likely to have 
skipped the previous doses. As part of the results reported in this thesis, we predict 
a normal concentration range for given time points after the dose of lamivudine in 
young children based on a population pharmacokinetic model, which can then be 
used to investigate adherence to ART and to aid interpretation of the therapeutic 
drug monitoring of PIs and NNRTIs. 
 
6. Pharmacometrics 
Pharmacometrics has been described as “the science of developing and applying 
mathematical and statistical methods to characterize, understand, and predict a 
drug’s pharmacokinetic and pharmacodynamic behavior; and quantify uncertainty 
of information about that behavior; and rationalize data-driven decision making in 
the drug development process and pharmacotherapy.” 134 Pharmacometrics 
belongs to the field of pharmacokinetic research and includes a large variety of 
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applications. Pharmacokinetics is referred to as “what the body does to the drugs” 
and pharmacodynamics is “what the drug does to the body”. 135 Pharmacometrics 
was initially developed in order to facilitate more efficient development and use of 
pharmaceuticals through implementing mathematical and statistical models. The 
most commonly used pharmacometric approach is based on mixed-effect models, 
which are especially useful in application to heterogeneous biological data by its 
ability to characterize many sources and levels of variability. The model based 
approach can be used to integrate prior knowledge and pool data across studies 
136
; 
to predict and compare doses and dosage regimens; to extrapolate to other target 
populations; to improve study design by application of optimal design theory and 
clinical trial simulations 
137,138
; and to investigate optimal dosage for population 
and individual treatments 
139
. 
 
6.1. Nonlinear mixed effect modeling  
Traditional pharmacokinetic analysis was performed in two steps (two-stage 
method) 
140–144
. In the first step, individual estimation was performed and in the 
second step the mean and standard deviation of parameters in the population were 
calculated. One weakness of this analysis method is that sufficient observations 
from each individual are required in order to identify the pharmacokinetic 
characteristics. Another weakness of traditional analysis is that it does not capture 
variability well between and within subjects. Furthermore, noncompartmental 
methods cannot be used to simulate alternative dosage regimens which can be 
applied to other situations or populations. 
 
Nonlinear mixed effect modeling (NONMEM) is an alternative to the two-stage 
method. It involves simultaneous estimation of the typical and variance parameters 
based on data from all individuals 
145
 and allows sparse and unbalanced data to be 
used because individuals can utilize information contained in the entire population 
146
. The term “mixed” is used because both fixed and random effects are estimated 
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in the model. Fixed effects relate to the typical parameter estimates and the 
random effect is the estimation of variability, including interindividual variability 
(IIV); interoccasion variability (IOV) 
147
, and intraindividual variability (residual 
error). The general structure of a mixed effects model is expressed as follows: 
                   (1.5) 
where yijk is the j
th
 observed dependent variable at occasion k in individual i. yijk is 
described by a vector of individual parameters Pik and a vector of independent 
variables xijk (usually time and dose). 
  
Compared to the traditional way of analyzing the data, populatio  modeling is a 
powerful tool to summarize large amounts of data and quantify potential 
interactions. The model functions as a repository of knowledge and information 
about the biological system, disease and drug properties are integrated to achieve a 
collated picture. New information can be integrated into the model and thus 
confirm previous knowledge as well as refine the model and new knowledge may 
be obtained.  
 
The individual parameter is a function of the typical value for the population and 
an individual random effect. For parameters that only can take on positive values 
the individual parameters are commonly described using a log-normal distribution 
as follows: 
         
      (1.6) 
where Pik is the individual parameter value at the k
th
 occasion,    is the typical 
parameter estimate, and ηi and ki are the random effects that describe IIV and 
IOV, respectively. The variablesηi and ki are assumed to be normally distributed 
with a mean of zero and a variance of ω2 andπ2. Many biological parameters are 
assumed to be log-normally distributed and IIV and IOV are therefore described 
exponentially. 
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Covariates, such as gender, weight, age, liver or kidney function, etc, can often 
explain a part of the variability between individuals. In such a case the typical 
parameter value will be a function of the individual covariate value, thereby 
explaining a part of the IIV. 
 
The residual variability describes the difference between the individual prediction 
and the observed value. The residual variability may be due to assay error or 
measurement error, model misspecification or incorrect dosing or sampling history 
record. Residual error can be investigated using additive or proportional models. 
The j
th
 observation of individual i can be described using the general expression in 
equation 1.7. 
                          (1.7) 
where yijk is the j
th
 observed dependent variable at occasion k in individual i.  f(…) 
is the individual prediction which is described by independent variables xijk (e.g. 
dose, time) and the individual parameters of the model Pik,  ijk is the residual 
error term describing the difference between the observed value and the individual 
prediction. The values are assumed to be normally distributed with a mean of 
zero and a variance ofδ2.  
 
6.2. Model estimation 
NONMEM 
148
, which was used for analysis throughout this thesis, uses a 
parametric maximum likelihood method for parameter estimation, in which the 
parameters of a model are estimated by maximization of the probability of the data 
under the model. This is performed by minimization of the extended least squared 
objective function. The objective function value (OFV) is approximately 
proportional to -2 times the logarithm of the likelihood of the data and the 
difference in OFV between two nested models is approximatelyχ2 distributed 
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under the assumption that the model is correct and that the errors are normally 
distributed. The likelihood ratio test can be used to compare nested models and a 
difference in OFV of 3.84 corresponds to a significance level of p<0.05 
149–151
. 
 
The likelihood function in most cases cannot be calculated exactly because of the 
non-linearity of the models 
148
. In NONMEM, several alternative methods are 
available including the first-order method (FO), the first-order conditional method 
(FOCE) and Laplacian second-order approximation method (LAPLACE). These 
methods use different types of linearization of the non-linear models which results 
in closed solutions for the likelihood. 
 
6.3. Model validation 
Validation methods are always used throughout the model building process to 
evaluate the adequacy, accuracy and robustness of the model. Graphic and statistic 
diagnostics are most extensively used and enhance the understanding of the data 
and lead to an efficient analysis of the data. Graphic diagnostics are intuitive and 
powerful approaches to interpret the model 
152
. A lot of available graphic 
diagnostic approaches, some of which rely on simulation, evaluate different 
aspects of model adequateness. Each diagnostic approach has its assumptions, 
strengths and weaknesses 
153
.  
 
The plots of population typical model predictions (PRED) and individual model 
predictions (IPRED) versus observations are routinely used as goodness of fit plots 
(GOFs) for diagnostics. These plots interpret how well the observations are 
centered along the line of identity. Residual based diagnostic plots are commonly 
involved in GOFs, including individual weighted residuals (IWRES = 
observations – IPRED) versus IPRED, and conditional weighted residuals 
(CWRES) versus time. It has been demonstrated that CWRES, which are based on 
the FOCE linearization, have better properties compared to WRES. Another new 
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approach based on NONMEM 7 is normalized prediction distribution errors 
(NPDE) 
154–156
. NPDE are not true residuals but based on the rank order of the 
observations in relation to multiple model simulation of the original dataset. The 
general interpretation of residuals-based plots is that they should be normally 
distributed with a mean of 0 across any independent variable. 
  
The most powerful approach is visual predictive check (VPC). VPC is based on 
model simulation to graphically assess whether simulations from a model are able 
to reproduce both the median and certain variability in the observed data. The 
model usually is assessed by comparing the observations to simulations for a 
particular prediction interval, which is a robust approach for model validation. 
 
Bootstrap re-sampling is another approach common used in model validation 
157
. A 
large number of datasets is generated by re-sampling from the original dataset, and 
parameter estimates for each are obtained by estimation with the final model. 
Means, standard errors and 95% confidence intervals (CIs) are compared with the 
estimates calculated from the original dataset. The bootstrap approach provides 
measures of the stability of the final parameter estimates and the robustness of the 
final model. 
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Aims 
 
The primary aim of this thesis was to investigate pharmacokinetics of PI-based 
antiretrovirals, including the complicated drug-drug interactions with rifampicin 
and to compare pharmacokinetic differences between children and adults, using 
population pharmacokinetic models. The secondary aim was to optimize the dose 
regimens of PI-based antiretrovirals in combination with rifampicin, and to 
investigate reference drug concentrations for adherence evaluation. 
  
The specific aims of this thesis were to: 
 To explore the pharmacokinetics of lopinavir and ritonavir, including effect of 
drug intake, bioavailability and mechanisms of metabolic inhibition and 
induction between lopinavir, ritonavir and rifampicin based on developed 
integrated population models in specific patient populations. 
 To evaluate the effect of patient and treatment factors (including age, body 
surface area (BSA), weight, sex, haemoglobin, albumin, alanine transaminase 
(ALT), doses, maturation) on lopinavir and ritonavir pharmacokinetics in the 
respective study populations.  
 To optimize the dose regimen for lopinavir/ritonavir co-administration with 
rifampicin-based ATT for young children and adults to achieve effective 
clinical targets. 
 To investigate the pharmacokinetic difference of lopinavir and ritonavir, as 
well as drug-drug interactions with rifampicin between children and adults 
based on a combined adult-children population pharmacokinetic model. 
 To describe pharmacokinetics of lamivudine in HIV/TB infected young 
children and predict lamivudine reference concentrations for adherence 
evaluation based on developed population pharmacokinetic model.  
 To confirm model-based approach as a powerful tool for characterization of 
the underlying mechanisms and evaluation of potential drug effects
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Material and Methods 
 
1. Data   
The data from three studies (Study I-III) were included in this thesis. Study I, 
Study II, and Study III are named as “children pilot study”, “children double dose 
study” and “adult double dose study”, respectively. Paper I and Paper IV were 
conducted based on pooled data of Study I and Study II; Paper II was conducted 
based on data of Study II; Paper III was conducted based on data of Study I-III 
(described in Figure 2.1). The patient characteristics of three studies are 
summarized in Table 2.1. 
 
 
 
Figure 2.1 Data components of this thesis. 
Mixture effect 
Modeling 
Paper III
Study II
Children  double 
dose study
Study I
Children  pilot 
study
Study III
Adults  double 
dose study
Mixture effect 
Modeling 
Paper I and 
Paper IV
Mixture effect 
Modeling 
Paper II
pool
pool
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Table 2.1 Summary of subjects characteristics involved in the thesis 
 Subgroup Patient 
Lopinavir
:ritonavir 
ratio 
Number 
of subject 
Sampling 
approach 
Children pilot 
study 
(Study I) 
Control group HIV 4:1 15 
intensive Superboosted group 
(during TB treatment) 
HIV/TB 1:1 15 
Children 
double dose 
study 
(Study II) 
Control group HIV 4:1 24 
Intensive 
and sparse 
Double dose group 
(during TB treatment) 
HIV/TB 8:2 20 
After TB treatment HIV/TB 4:1 11 
Adults 
double dose 
study 
(Study III) 
Standard dose, 
no rifampicin 
HIV 4:1 21 
intensive Sequential increase 
dose 
(during rifampicin) 
HIV 
4:1; 
6:1.5; 8:2 
21 
TB treatment: standard first-line regimen including rifampicin dosed at approximately 10 
mg/kg.  
 
2. Study design  
2.1. Children pilot study (Study I) 
This was an open-label, cross-sectional comparative study conducted at multiple 
centers in South Africa. Steady state pharmacokinetic profiles of lopinavir and 
ritonavir were determined in two groups in children: treatment and control groups. 
Patients were recruited at 3 sites: the HIV Clinic at the Red Cross Children’s 
Hospital, Cape Town; the Harriet Shezi Children’s Clinic, Chris Hani Baragwanath 
Hospital, Soweto; and Brooklyn Chest Hospital, Cape Town. Ethical approved of 
this study was sought from the Research Ethics Committees of the University of 
Cape Town and the University of Stellenbosch. No subject was enrolled in the 
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study before they (if old enough) and their legal guardian has been fully informed 
about the study and by means of a subject information document, and had 
provided written informed consent to participate in the study.  
 
Thirty children (aged 6 months to 4.5 years) were enrolled into two groups: 15 
TB-HIV co-infected children receiving lopinavir/ritonavir (ratio of 4:1, LPV/r) 
with additional ritonavir (such that the total ratio of LPV:ritonavir=1:1) as part of 
ART and concomitant rifampicin-based ATT for at least 4 weeks (treatment group) 
and 15 HIV-infected children without TB receiving LPV/r-based ART for at least 4 
weeks (control group).  
 
In the control group, lopinavir at a dose of 230 mg/m
2
 plus ritonavir at a dose of 
57.5 mg/m
2
 (LPV/r, liquid formulation, Kaletra®) were given twice a day in 
combination with twice-daily dual NRTIs to children. In the treatment group, 
besides dose regimens given in the control group, an additional ritonavir at a dose 
of 172.5 mg/m
2
 twice daily (LPV:ritonavir ratio of 1:1) was given to children 
receiving rifampicin-based ATT. The maximum doses were 400 mg lopinavir/100 
mg ritonavir twice daily (not with rifampicin-based ATT) or 400 mg lopinavir/400 
mg ritonavir twice daily (with rifampicin-based ATT). Rifampicin-based ATT 
regimens were administered based on target doses of 10 mg/kg of rifampicin, 5 
mg/kg of isoniazid in fixed dose combinations, as well as pyrazinamide and 
ethambutol, in accordance with the National Tuberculosis Treatment Program. 
Alcohol, caffeine, grapefruit juice, garlic and pepper were avoided during the 
whole study. 
 
Lamivudine was given as a part of ART concurrently with LPV/r during this study. 
The dose of lamivudine was 4 mg/kg twice daily for each patient. The formulation 
used in this study was a suspension. 
 
Un
ive
rsi
ty 
of 
 C
ap
e T
ow
n
Chapter 2                                       Materials and Methods 
 
 
41 
 
An intensive sampling approach was used in this study. Eight blood samples were 
collected for each patient and the exact time of the morning dose of LPV/r, which 
was administered by the study staff, was recorded. From each patient, 1.2 mL 
blood was taken at 0 (pre-dose), 2, 3, 4, 5, 6, 8, and 12 h after drug intake. The 
samples were centrifuged (3000 rpm for 5 minutes) within 30 minutes after 
sampling, and the plasma was stored immediately at -80ºC while awaiting 
quantification of lopinavir, ritonavir and lamivudine concentrations. The following 
potential covariates of pharmacokinetics were measured on the pharmacokinetic 
sampling days: height, weight, haemoglobin, ALT and serum albumin. 
 
2.2. Children double dose study (Study II)  
This was an open-label, cross-sectional comparative study conducted at three 
centers in South Africa. Steady state pharmacokinetic profiles of lopinavir and 
ritonavir were determined on two groups in children: treatment and control group. 
Children were recruited at: the HIV Clinic at the Red Cross Children’s Hospital, 
Cape Town; the Harriet Shezi Children’s Clinic, Chris Hani Baragwanath Hospital, 
Soweto; and HIV Clinic at Tygerberg Hospital, Cape Town. Ethics approval of the 
study was sought from the Medicines Control Council of South Africa, and the 
Research Ethics Committees of the University of Cape Town, Stellenbosch 
University, and the University of the Witwatersrand. No subject was enrolled in 
the study before they (if old enough) and their legal guardian has been fully 
informed about the study and by means of a subject information document, and 
had provided written informed consent to participate in the study.  
 
In total Forty-four children (aged 6 months to 4.5 years) were studied: 20 TB-HIV 
co-infected children receiving double dose of LPV/r as part of ART and 
concomitant rifampicin-based ATT for at least 4 weeks (treatment group) and 24 
HIV-infected children without TB receiving LPV/r-based ART for at least 4 weeks 
(control group). The data safety and monitoring board conducted an interim 
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analysis after pharmacokinetic sampling and terminated this study prematurely 
since most of the subjects could not achieve the effective concentrations. 
 
In the control group, HIV-infected children received a standard dose of Kaletra
®
 
(lopinavir 230 mg/m
2
+ ritonavir 57.5 mg/m
2
,
 
liquid formulation) and 2 NRTIs 
according to the recommended dosing strategy. In the treatment group, patients 
established on rifampicin-based ATT were commenced on an ART regimen 
comprising double the recommended dose of Kaletra
®
 (lopinavir 460 mg/m
2
+ 
ritonavir 115 mg/m
2
) and 2 NRTIs. Eleven children underwent pharmacokinetic 
evaluation, again, at least 4 weeks after completion of ATT, and on standard LPV/r 
doses. These patients were looked as another occasion during modeling building. 
Rifampicin-based ATT regimens were administered based on target doses of 10 
mg/kg of rifampicin, 5 mg/kg of isoniazid in fixed dose combinations, as well as 
pyrazinamide and ethambutol, in accordance with the National Tuberculosis 
Treatment Program. The child received food and beverages according to the 
hospital routine. Alcohol, caffeine, grapefruit juice, garlic and pepper were 
avoided during the whole study. 
 
Lamivudine was given concurrently with LPV/r as a part of ART. The dose of 
lamivudine was 4 mg/kg twice daily for each patient. The formulation of 
lamivudine used in this study was suspension. 
 
Intensive and sparse sampling approaches were used in this study. Intensive 
samples were collected at 0 (pre-dose), 2, 3, 4, 5, 6, 8 and 12 hours after drug 
intake. Sparse samples were collected at 0 (pre-dose), 2, 4 and 8 hours after drug 
intake. The samples were centrifuged (3000 rpm for 5 minutes) within 30 minutes 
after sampling, and the plasma was stored immediately at -80ºC while awaiting 
quantification of lopinavir and ritonavir concentrations. The following potential 
covariates of pharmacokinetics were measured on the pharmacokinetic sampling 
Un
ive
rsi
ty 
of 
 C
ap
e T
ow
n
Chapter 2                                       Materials and Methods 
 
 
43 
 
days: height, weight, haemoglobin, ALT and serum albumin. 
 
2.3. Adult double dose study (Study III) 
The study was an open-label, sequential, four-period, multiple-dose trial in 
HIV-infected adults who were virologically suppressed (viral loads <400 
copies/mL) on LPV/r together with two NRTIs according to the recommended 
dosing strategy. Patients were randomly recruited at antiretroviral clinics in the 
Western Cape and admitted to the pharmacokinetic facility at the Division of 
Clinical Pharmacology, University of Cape Town and Groote Schuur Hospital for 
pharmacokinetic assessment. Ethics approval of the study was obtained from the 
Human Research Ethics Committee of University of Cape To n. No patient was 
enrolled in the study prior to being fully informed about the study and by means of 
a subject information document, and all subjects signed consent had been obtained 
on the study specific consent form.  
 
 
 
Figure 2.2 Description of study design. 
 
The study design is shown in Figure 2.2. The steady state pharmacokinetics of 
lopinavir and ritonavir were evaluated in 21 South African HIV infected 
volunteers under four sequential treatment conditions: LPV/r in standard doses 
(400 /100 mg) 12 hourly together with two NRTIs, which is the standard 2nd-line 
1 7 14 21 28
PK3       PK4PK1 PK2
LPV/r  400/100 mg, bid
Rifampicin 600 mg, qd
600/150 mg, bid 800/200 mg, bid
days
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ART regimen in South Africa, without rifampicin (day 1 to day 7); LPV/r in 
standard doses 12 hourly together with two NRTIs and rifampicin 600 mg daily 
( day 8 to day 14); 1.5 times of the standard dose of LPV/r (600/150 mg) 12 hourly 
together with two NRTIs and rifampicin 600 mg daily (day 15 to day 21); and 2 
times of the standard dose of LPV/r (800/200 mg) 12 hourly together with two 
NRTIs and rifampicin 600 mg daily (day 22 to day 28). The different treatment 
conditions were looked as four different occasions during model building. The 
formulations used in this study were: LPV/r (film-coated tablet): lopinavir 200 mg 
co-formulated with ritonavir 50 mg (Aluvia, Abbott); Rifampicin (tablet 
formulation): rifampicin 600 mg (Rimactane®, Sandoz). Alcohol, caffeine, 
grapefruit juice, garlic and pepper were avoided during the whole study. 
 
Intensive pharmacokinetic sampling was performed one week after each dose 
adjustment (DAY 7, DAY 14, DAY 21 and DAY 28). 4 ml of blood were collected 
in heparinized tubes at 0 (pre-dose), 1.5, 2, 2.5, 3, 4, 5, 6, 8 and 12 h after drug 
administration, centrifuged within one hour from collection to separate the plasma 
(10 minutes at 3000 rpm), and then stored at -80ºC in the laboratory (Department 
of Clinical Pharmacology, University of Cape Town) until drug concentrations 
were determined. The following potential covariates of pharmacokinetics were 
measured on the pharmacokinetic sampling days: height, weight, haemoglobin, 
ALT and serum albumin. 
 
2.4. Summary of study design 
The general summary of study design of studies in this thesis is shown in Table 
2.2. 
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Table 2.2. The summary of study design of studies in this thesis. 
 Study design ATT 
treatment 
Food intake 
Children  
(Study I, II) 
Control and 
treatment groups 
Rifampicin-
based ATT 
not very clear 
 Adults  
(Study III) 
Sequential dosing Rifampicin Fast in the morning dose, but 
took food in the evening dose 
 
3. Laboratory analyses 
Lopinavir and ritonavir plasma concentrations were assayed at the laboratory of 
department of clinical pharmacology of University of Cape Town using validated 
liquid chromatography-tandem mass spectrometry methods 
127
. The lower limits of 
quantification (LLOQ) were 0.05 mg/L for lopinavir and 0.025 mg/L for ritonavir. 
The concentratin of standard curve ranged from 0.12 mg/L to 16 mg/L for 
lopinavir and from 0.075 mg/L to 7 mg/L for ritonavir. Accuracy ranged from 94.3% 
to 103.0 for lopinavir and from 93.6% to 105.3% for ritonavir. The intra-day and 
inter-day precisions of both drugs ranged from 0.14% to 4.72% and from 1.61% to 
4.22%, respectively.  
 
Lamivudine plasma concentrations were assayed in the above mentioned 
laboratory using a validated liquid chromatography-tandem mass spectrometry 
method 
158
. The calibration curve was linear over the range from 20 to 2000 ng/mL. 
Any sample whose lamivudine results were higher than 2000 ng/mL was diluted 
with drug-free plasma and reanalyzed. The LLOQ was 20 ng/mL and accuracy 
ranged from 98.35% to 104.32%. The intra-day and inter-day precisions of 
lamivudine ranged from 4.59% to 6.61% and from 4.23% to 6.62%, respectively.  
 
Routine tests to monitor safety and efficacy of treatment were conducted 
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according to the National Treatment Guidelines which state that patients should 
have monthly monitoring of ALT if antiretroviral and ATT are given concurrently 
and that all patients receiving Kaletra
®
 in conjunction with 2NRTIs should have 
baseline and 6 monthly monitoring of viral load (NASBA EasyQ, Biomerieux, 
Boxtel, The Netherlands), ALT, full blood count, serum cholesterol, glucose, and 
triglycerides as well as CD4+ cell counts at staging and 6 monthly. 
 
4. Model development 
4.1. Software 
The data estimation and simulation were performed using nonlinear mixed effects 
modeling implemented initially in NONMEM 6 (Paper I) and NONMEM 7 (Paper 
II-IV) (GloboMax, Hanover, MD, USA) 
148
. The first order conditional estimation 
method (FOCE) with eta-epsilon INTERACTION was used for the estimation of 
pharmacokinetic parameters. Perl speaks NONMEM (PsN) (updated version from 
from 3.2.4 to 3.4.8) 
159
 was used for executing estimations, covariate modeling 
building, bootstrap procedures, simulations as well as calculations of the VPC. 
Graphical diagnostics of the model fit was performed using Xpose (version 4.1.0) 
implemented in R 
160
. The graphical diagnositics include GOFs, individual plots, 
scatterplots, boxplots, and VPC plots. GOFs and VPC plots have been explained in 
the introduction. GOFs include observed concentrations versus population 
predicted concentration (PRED), observed concentrations versus individual 
predicted concentration (IPRED), IWRES versus IPRED, and conditional 
weighted residuals (CWRES) versus time. The regression lines in these plots 
respresent equal predicted concentrations to observed ones. Therefore, these plots 
could indicate how close the predicted concentrations are close to the observed 
ones; the even and close distribution along the regression line would be a good 
evidence for model predicted profiles. VPC is an approach to diagnose model 
adequacy. The purpose of these plots is to compare if the 5
th
, 50
th
, 95
th
 percentile 
of observed data (solid and dotted lines) are agreement with the 95% confidence 
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interval of each percentile of simulated data (grey shaded areas) based on our 
model. This approach is based on simulation and is a more robust approach for 
model validation. A lot of sctterplots were used for diagonosis during model 
development, for example scatterplots of different candidate covariates versus 
pharmacokinetic parameters could provide strong evidence that which covariate 
would be a significant one. The scatterplots between parameters could indicate 
potential correlations. Boxplots were another useful tool for diagnosis, such as the 
boxplots of demographic characteristics, the individual parameters distribution in 
different subgroups or occasions, the variability distributions, etc. 
 
4.2. Structure and statistic model building 
Different model structures and features were evaluated: one- and 
two-compartment disposition 
38,161–163
; zero- and first-order absorption; an 
absorption with lag time and a series of transit compartments as proposed by Savic 
et al 
164
. The model scheme of transit absorption is shown as Figure 2.3. Mean 
transit time (MTT) was used to describe the drug absorption delay. The transit 
absorption rate (ktr) was used to describe the transit absorption rate between 
different transit compartments. The calculation of ktr is indicated as follows: 
     
   
   
 (2.1) 
where n is the number of transit compartments.  
 
 
Figure 2.3. The model scheme of transit absorption model. 
Dose A1 A2 An Absorption 
compartment
ktr ktr ktr
n transit 
compartments
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The IIV and IOV of the pharmacokinetic parameters of lopinavir and ritonavir 
were modeled using an exponential error model: 
 Pij = Ptvj . e
ηij
 (2.2) 
where Pij is the jth pharmacokinetic parameter for the ith individual; Ptvj is the 
typical value of the jth population parameter, and ηij represents a random variable 
for the ith individual in the jth parameter distributed with a mean of zero and 
variance of ωij. Using a first-order approximation, the variability of the lognormal 
distributions is reported as % coefficient of variation (CV). 
 
Several different error structures were tested for the description of the residual 
unexplained variability (RUV): additive, proportional, combined error models. A 
combined proportional and additive error model (the difference between the 
observed and predicted concentrations) was described as follows:  
 Cij = Cij
’ . (1+ε1) +ε2 (2.3) 
where Cij and Cij
’
 are the jth observed and predicted blood concentrations for the 
ith individual, respectively. ε1 and ε2 are random variables distributed with a mean 
of zero and variances of σ1 and σ2, respectively.  
 
Model development was guided by the OFV, precision in parameter estimates 
(relative standard error, RSE%) obtained by NONMEM output or the bootstrap 
procedure, graphical analysis and scientific plausibility. The difference in OFV 
between two nested models is assumed to be χ2-distrubutions. A decrease in the 
OFV of 3.84, 6.63 or 10.83 was required for addition of one parameter to the 
model to be considered significant, which corresponds to p<0.05, p<0.01 and 
p<0.001, respectively.  
 
4.3. Covariate model building 
Once the basic model (structure and statistic model) was developed, a covariate 
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analysis was performed following a forward inclusion and backward elimination 
stepwise approach similar to Wählby et al 
165
. Firstly, scatter plots of 
pharmacokinetic parameters against each covariate were used to examine the 
effect and regression of covariates. Secondly, each potential covariate was 
incorporated into the basic model to develop the full model. A decrease of 3.84 of 
OFV was considered statistically significant (p=0.05). Covariate selections were 
also guided by a decrease in standard error of the parameters, reduction in IIV, 
IOV and RUV, and goodness-of-fit plots. Available continuous covariates in this 
thesis included age, body weight, height, body surface area, hemoglobin, ALT. The 
categorical covariate includes gender, which was evaluated by stepwise inclusion 
of scaling factor: gender =0 for males and gender =1 for females. Finally, a 
backward elimination process was employed to identify the significant covariates 
for the final model by fixing the significance level α=0.01, χ20.01 =6.63. If removal 
of a covariate resulted in an increase of 6.63 in the OFV, the covariate was retained 
in the final model. The covariate building was conducted manually or through 
programs, such as PSN stepwise covariate modeling (SCM) 
166
 or generalized 
additive models (GAM) 
165
. The case deletions diagnostics (CDD) algorithm 
159
 
was used during model building in order to confirm that there was no significant 
impact from specific individual patient on the overall estimation. This approach is 
a tool primarily used to identify influential components of the dataset, usually 
individuals. Moreover, the difference of OFV by individuals was evaluated during 
covariate building to assess the impact of individual patients. 
 
Remaining physiologically plausible covariate candidates for each parameter were 
tested in NONMEM, using equations similar to those illustrated in Equation 2.4 
(linear relationship) or Equation 2.5 (exponential relationship) for continuous 
covariates and Equation 2.6 for categorical covariates. 
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                (2.6) 
Equation 2.4 and Equation 2.5 are examples describing the influence of body 
weight, a continuous covariate, on oral clearance. (CL/F)typ is the typical apparent 
oral clearance where F is bioavailability, WTmed is the population median body 
weight (kg), and WTi is the body weight of individual i (kg). θWT is the change in 
CL/F per kg change in body weight. (CL/F)’typ is the value of oral clearance when 
body weight is equal to the population median body weight.  
 
In Equation 2.6, the effect of the categorical covariate sex (SEX, 0 for males and 1 
for females) is estimated on oral clearance, (CL/F)typ is the typical apparent oral 
clearance, where F is bioavailability, (CL/F)’typ is the typical value of CL/F in 
male patients, while the typical difference in this value seen in female subjects is 
represented by θSEX. 
 
4.4. Modeling procedure 
4.4.1. Modeling procedure (Paper I and II) 
Modeling procedures are described in Figure 2.4. Firstly, the separate model of 
lopinavir and ritonavir, including basic structure and covariates model, were built 
respectively. Secondly, an integrated model was built involving drug-drug 
interaction as the final model. The covariates tested were body weight, height, 
body surface area, hemoglobin, ALT, gender, and effects of rifampicin 
administration. Since the morning pre-dose concentrations (C0) were on average 
higher than the evening trough concentrations (C12), differences in bioavailability 
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and CL/F after the evening and morning doses were tested in our model to capture 
the diurnal variation. The oral bioavailability of the standard dose of LPV/r 
without rifampicin co-administration was assumed as the reference (100%) to 
which the other conditions were compared.  
 
 
 
 
Figure 2.4. Model procedures of Paper I and Paper II. 
 
4.4.1.1. Lopinavir and ritonavir separate model 
The separate lopinavir and ritonavir models were built following basic model first 
and then covariate model. Model building was guided by OFV, precision of 
parameter estimates, variability (IIV, IOV and RUV) change and graphic 
diagnostics, which was described in the model development. Candidate covariates 
were evaluated by stepwise approach mentioned before. Rifampicin-based ATT 
was investigated as a covariate on the bioavailability and oral clearance. Ritonavir 
dose effect on the bioavailability of lopinavir and ritonavir was also investigated. 
Diurnal variation was tested to decrease the clearance or/and increase 
+ +
Drug-drug interaction
covariates
Rifampicin-based 
antituberculosis
treatment
Rifampicin-based 
antituberculosis
treatment
covariates
Lopinavir 
structure 
model
Lopinavir 
statistic 
model
Ritonavir 
structure 
model
Ritonavir 
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Ritonavir basic 
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model
Ritonavir final 
model
Integrated model
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bioavailability during model building.  
 
4.4.1.2. Lopinavir-ritonavir integrated model 
An integrate lopinavir-ritonavir model was built as the final model. Different 
enzyme inhibition models were tested to describe the drug interaction between 
lopinavir and ritonavir. The drug inhibition models could be chosen as follows: 
(1) Empirical on-off model 
Inhibitor is treated as a covariate and does not involve time 
167
.  
(2) Time-dependent model 
This model includes linear or nonlinear forms to describe time-dependent 
inhibition effects. Considering that the concentration of inhibitor would change 
with time, the clearance of substrate changes with time as well. The models can be 
described as follows: 
Linear inhibition 
162
:      
CL = CLbase - SLP⋅ Cinhibitor                                                 (2.7) 
 
Nonlinear inhibition 
162
:    
          ⋅    
               
                
                           (2.8) 
where CL is the clearance of substrate, CLbase is the baseline clearance, Cinhibitor is 
the concentration of inhibitor, SLP is the slope of the linear relationship between 
clearance of substrate and concentration of inhibitor, Emax is the maximum 
inhibition effect of inhibitor and EC50 is concentration of inhibitor required to 
reach half of Emax,  
(3) Enzyme turnover model 
Inhibition effect can decrease Rin (production rate) or stimulate kout (elimination 
rate
168
. The model describing the inhibitor concentrations decrease Rin is shown as 
follows: 
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                                        (2.9)            
 
This model describes the time course of the inhibition. Time to steady state is 
determined by kout and can be predicted by this model, as well as the enzyme 
turnover half life. The amount of enzyme at steady state (Ess) depends on Rin and 
kout (Ess = 
   
    
). 
 
A sequential approach, in which the ritonavir parameters were fixed in population 
and individual levels, was applied first. Then a simultaneous model was built to 
estimate all parameters simultaneously as the final model.  
 
4.4.2. Modeling procedure (Paper III) 
The modeling procedures are described in Figure 2.5. Firstly, the separate model 
using combined dataset for lopinavir and ritonavir was built respectively. Secondly, 
integrated lopinavir-ritonavir model was developed to estimate all parameters for 
children and adults simultaneously. 
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Figure 2.5. Modeling procedures of Paper III. 
 
The separate model using combined dataset for lopinavir and ritonavir were built 
respectively. The same structure and covariates model was kept to fit combined 
children and adults dataset. Firstly, different parameters were estimated for 
children and adults respectively to build the initial model. Secondly, the model 
was simplified guided by OFV, precision of parameter estimates, variability (IIV, 
IOV and RUV). Finally, the final lopinavir and ritonavir model was obtained 
according to model development methods. 
 
Once the final lopinavir and ritonavir separate model were built, integrated model 
was developed involving drug interactions between lopinavir and ritonavir. 
Correlations between lopinavir and ritonavir were also tested. Rifampicin-based 
ATT effects were tested on children and adults respectively and then compare 
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whether this kind of effect is same for children and adults. All parameters were 
estimated simultaneously. 
 
4.4.3. Modeling procedure (Paper IV) 
The modeling procedure is described in Figure 2.6. Structure and statistic model 
building procedures were similar to previous chapters. A one- and a 
two-compartment disposition were tested, as well as different absorption models: 
zero- and first-order absorption, absorption with lag time and a series of transit 
compartments. The correlations between different parameters were also evaluated. 
Covariate model development was guided by stepwise approach mentioned before 
and the candidate covariates included age, body weight, sex, height, and ALT. 
Rifampicin-based ATT was evaluated as a covariate to investigate whether it 
would influence lamivudine pharmacokinetic parameter. Since the predose 
concentrations were higher than 12 hourly concentrations, diurnal variation was 
also investigated on both clearance and bioavailability in our model.  
 
 
 
Figure 2.6 Modeling procedures of Paper IV. 
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4.5. Model validation 
VPC was used to evaluate the robustness and properties of simulation of the model. 
VPC was based on 1000 datasets simulated with the obtained final parameter 
estimates and the same data structure as the original dataset. Statistics were 
calculated in the same manner for the observed and simulated datasets. For each 
dataset, the median, 5
th
 and 95
th
 percentiles of dependent variable (DV) value was 
calculated in each bin of independent variable (usually time or time after dose). 
 
The nonparametric bootstrap re-sampling method, as implemented in PsN, was 
used to obtain standard errors to evaluate the accuracy and stability of our final 
model parameters. Briefly, from the original data set of N individuals, a fix 
number of bootstrap datasets of N individuals are re-sampled. For each bootstrap 
sample, the population pharmacokinetic parameters are estimated, and then 
parameter statistics are obtained from the whole bootstrap datasets. The 95% 
confidence intervals around the mean of each estimated parameter were assessed 
as their 5th and 95th percentiles and then used to assess precision and robustness 
of the final model parameters. The acceptability of the width of the confidence 
interval depends on the expectation for the particular parameter. This method is 
extremely demanding on time and computer resources.  
 
5. Simulation 
5.1. Simulation for dose optimization (Paper I) 
The final integrated model was used to perform simulations using different dosing 
strategies for patients with different weight bands recommended by the WHO for 
dosing of antiretrovirals in children 
31
. Simulations were performed with model 
variability but without residual error. Simulations using 1000 subjects in each 
weight band (3.0-5.9, 6.0-9.9, 10.0-13.9, and 14.0-19.9 kg) were performed. 
Trough concentrations were predicted using lopinavir/ritonavir ratios of 4:1 and 
1:1 in different mg/kg doses. The target dose in each weight band was expected to 
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achieve lopinavir trough concentrations >1 mg/L in at least 95% of children during 
rifampicin-based ATT.  
 
5.2. Simulation for dose optimization (Paper II) 
The final model was used to simulate concentrations in 2000 in silico subjects 
(with covariates values matching the study population) to evaluate dose regimens 
achieving lopinavir trough concentrations >1 mg/L in patients during rifampicin 
co-treatment. Simulations were performed with model variability but without 
residual error. To explore the possibility that lower doses of LPV/r may be 
sufficient to achieve target concentrations in smaller patients, additional 
simulations using 2000 subjects were performed to predict the proportion of 
subjects with body weight 35-49 kg achieving lopinavir C0>1 mg/L on a 600/150 
mg dose of LPV/r. Simulations were also conducted to evaluate the adequacy of 
doubled doses (800/200 mg twice daily) of LPV/r in patients with weights 111-130 
kg. The body weight used in simulations for each range was distributed evenly. 
The cutoff value of 10
th
 percentile of body weight in our study population was 50 
kg and the highest value in the study population was110 kg. 
 
5.3. Simulation for adherence investigation (Paper IV) 
The final model was used to simulate reference concentrations for adherence 
evaluation in children with different ages. Simulations were performed with model 
variability but without residual error. Simulations using 2000 subjects in 6 months, 
1 year, 2 years and 5 years age were performed. Cutoff concentration reference 
values for the 5
th
, 2.5
th
 and 1
st
 percentiles at 4 h and 12 h after the morning dose 
were calculated. Different non-adherence scenarios were then studied in 2000 
patients: missed last dose; missed last two doses; and missed second last dose. The 
proportions of patients whose concentrations fell below the cutoff reference values 
for the different non-adherence scenarios were estimated using further simulations 
of 2000 patients.  
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Results 
 
1. Results (Paper I) 
1.1. Patients and data description 
The demographic characteristics of study patients are summarized in Table 3.1.1. 
There were no statistically significant differences (t test, p>0.05) in demography 
between the patients included in the ‘super-boosted’ and ‘double dose’ group. A 
total of 216, 120 and 96 concentrations of lopinavir and ritonavir were available 
from children on standard doses of LPV/r without concurrent rifampicin-based 
ATT, children receiving ‘super-boosted’ doses, and children given doubled doses 
of LPV/r, respectively. The data of this study are summarized in Table 3.1.2. 
Figure 3.1.1 illustrates the distribution of relvant demographic and clinical 
variables, in different treatment groups: control group, super-boosted group, and 
double dose group. Plots of concentration of lopinavir and ritonavir against time 
after dose in patients are in Figure 3.1.2 and Figure 3.1.3. The age and body 
weight distribution stratified by gender are shown in Figure 3.1.4.  
 
Table 3.1.1. Demographic characteristics of study patients.  
Characteristic Median Range 
Age  21 month 6 months - 4.5 years 
Body weight (kg) 10.2 5-17 
Gender (M/F) 34/40  
Height (cm) 79 58-103 
BSA (m
2
) 0.48 0.28-0.69 
Haemoglobin (g/L) 10.7 5.7-29.7 
Albumin (g/L) 38 29-47 
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Figure 3.1.1 Demographic characteristics of study population in control, super-boosted, 
and double dose group. 
 
Table 3.1.2. Data descriptions of Paper I. 
 Control group Super-boosted 
group 
Double dose 
group 
Patients status HIV HIV/TB HIV/TB 
Number of patients 39 15 15 
Number of samples 216 120 90 
Lopinavir median dose (mg/kg) 11.6 14.0 23.0 
Ritonavir median dose (mg/kg) 2.9 3.5 5.8 
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Figure 3.1.2. Plots of lopinavir concentration vs. time after dose in pooled patients (a) and 
different groups (b). 
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Figure 3.1.3. Pots of ritonavir concentration vs. time after dose in pooled patients (a) and 
different groups (b). 
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Figure 3.1.4. Covariates: age, body weight, and BSA distribution stratified by gender for 
all data in this study. 
 
1.2. Model description 
1.2.1. Lopinavir separate model 
A one-compartment model with first-order absorption and elimination best 
described the pharmacokinetics of lopinavir. Models with two-compartment 
disposition did not adequately improve the model fit, nor did zero-order absorption 
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and the absorption with lag time. The absorption with transit compartments model 
was also tested for lopinavir, but it did not improve the model fit. The variability 
(IIV and IOV) in oral clearance, volume of distribution, and absorption rate 
constant (ka) were tested in the model according to model development described 
in method. FOCE approach was chosen in the model building. Logarithm 
transforming data were used during the model building, and therefore the residual 
error is implemented as proportional to the observed value. 
 
Rifampicin-based ATT was tested on the bioavailability and oral clearance of 
lopinavir as an on/off relationship since the rifampicin induction was assumed to 
achieve steady state. The additional effect of ATT on lopinavir clearance was not 
significant and was not included in the model. Compared to dosing without ATT 
(assuming 100% as a reference), the relative bioavailability of lopinavir with 
rifampicin was estimated for the different lopinavir/ritonavir dose strategies: 64.2% 
for super-boosted and 16.7% for double dose.  
 
Different covariates, including body weight, age, haemoglobin, gender, BSA, and 
albumin, were analyzed one by one according to model covariates development 
steps as a continuous or discrete factor. Body weight was found to have a 
significant influence on the oral clearance and volume of lopinavir with an 
allometric scaling relationship in the final model. The OFV dropped about 20 
points when this allometric scaling was added. The following formulas were used:  
              
   
  
 
    
 (3.1.1) 
            
   
  
 
 
 (3.1.2) 
where the CL/F is the apparent oral clearance, CL/FSTD is the apparent oral 
clearance of standard patients (with mean body weight),     is each patient’s 
body weight and 10 kg is the median body weight in our population.  
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The oral clearance and volume of distribution were 1.23 L/h and 12.1 L, 
respectively. The IIV of oral clearance and volume were 48.5% and 29.5%, 
respectively. The IOV of relative bioavailability was 53.7%. The proportional 
residual error was 24.7%. The parameter estimates of lopinavir final model are 
shown in Table 3.1.3. The goodness-fit-plots are shown in Figure 3.1.5. VPC of 
lopinavir separate model is shown in Figure 3.1.6. 
 
Table 3.1.3. Population pharmacokinetic parameter estimates of lopinavir model. 
 
Parameter  
Estimate 
(ηshrinkage%) 
RSE (%) 
CL/F (L/h) 1.23 10.2 
V/F (L) 12.1 12.2 
Relative bioavailability 
Super-boosted dose 64.2% 17.3 
Double dose 16.7% 18.3 
ka (h
-1
) 0.55 13.4 
Proportional residual error (%) 24.7 7.98 
IIV on CL/F (%CV) 48.5 (28.9) 26 
IIV on V/F (%CV) 29.5 (34.4) 58.2 
IOV on F (%CV) 53.7 (30.8) 23.1 
IIV on RUV (%CV) 57 (32.1) 22.2 
CL: oral clearance; V: volume of distribution; F: bioavailability; RUV: residual 
unexplained variability; ka: oral absorption rate; IIV: interindividual variability; 
IOV: interoccasional variability. 
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Figure 3.1.5. Goodness-fit-plots of final separate model for lopinavir. 
 
Figure 3.1.6. Visual predictive check (VPC) of the final separate model for lopinavir. The 
solid line is the median of the observed data and the dotted lines are the 5
th
 and 95
th
 
percentiles of the observed data. The shaded areas are the 95% confidence intervals for 
the median, 5
th
 percentile and the 95
th
 percentiles of the simulated data (n=1000). 
Observed concentrations are displayed as circles 
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1.2.2. Ritonavir separate model 
A one compartment model with first-order elimination and a transit compartment 
absorption best described the pharmacokinetics of ritonavir (Figure 3.1.7). Models 
with two compartments disposition and with zero-order absorption did not 
adequately fit the data. Transit compartment model was used to represent a more 
physiological delay in absorption onset and a gradual increase in absorption rate. 
The number of transit compartment was estimated 10.1 for the absorption model 
of ritonavir. Mean transit time (MTT) was used to describe the absorption delay of 
ritonavir. Drug transferred from the final transit compartment to the central 
compartment occurred through an absorption compartment with first-order 
absorption rate ka. The transit absorption rate (ktr) was used to describe the transit 
absorption rate between different transit compartments. The calculation of ktr is 
indicated as follows: 
     
   
   
 (3.1.3) 
where n is the number of transit compartments.  
 
 
Figure 3.1.7 Structure of ritonavir model. 
 
Similar to lopinavir, the variability (IIV and IOV) in oral clearance, volume of 
Dose A1 A2 An Absorption 
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Central 
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distribution, and absorption rate constant was tested according to model 
development described in method. FOCE approach was chosen during the model 
building. Logarithm transforming data were used in the model, and therefore the 
residual error is implemented as proportional to the observed values. 
Rifampicin-based ATT was tested on the bioavailability and oral clearance of 
ritonavir as an on/off relationship. The additional effect of ATT on ritonavir 
bioavailability was not significant and was not included in the model. 
Rifampicin-based ATT induced the ritonavir clearance by about 50%. 
 
Different covariates, as tested for lopinavir before, including body weight, age, 
haemoglobin, gender, BSA, and albumin, were analyzed one by one according to 
model covariates development steps as a continuous or discrete factor. The 
stepwise covariate model (SCM) building tool implemented in PsN was also used. 
Similar to lopinavir, body weight was found having significant influence on the 
oral clearance and volume of ritonavir with an allometric scaling relationship in 
the final model (Equation 3.1.1 and Equation 3.1.2). The OFV was dropped by 
about 15 points when allometric scaling was applied in the model. 
 
The clearance of ritonavir without rifampicin effect was 12.8 L/h, whereas was 
19.1 L/h with rifampicin. The volume was 110 L and MTT was 1.30 h. The IIV of 
oral clearance and volume of distribution were 72% and 81.6%, respectively and a 
strong correlation was found between IIV of clearance and volume (r=0.9). The 
IOV of clearance and MTT were 40.5% and 45.8%, respectively. The proportional 
residual error was 33.9%. The parameter estimates of ritonavir final model are 
shown in Table 3.1.4. The goodness-fit-plots are shown in Figure 3.1.8. VPC of 
ritonavir model is shown in Figure 3.1.9. 
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Figure 3.1.8. Goodness-fit-plots of final separate model for ritonavir. 
 
Figure 3.1.9. Visual predictive check (VPC) of the final separate model for ritonavir. The 
solid line is the median of the observed data and the dotted lines are the 5
th
 and 95
th
 
percentiles of the observed data. The shaded areas are the 95% confidence intervals for 
the median, 5
th
 percentile and the 95
th
 percentiles of the simulated data (n=1000). 
Observed concentrations are displayed as circles. 
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Table 3.1.4. Population pharmacokinetic parameter estimates of ritonavir model. 
Parameter  
Estimate 
(ηshrinkage%) 
RSE (%) 
CL/F (L/h) 
without/after TB treatment 12.8 6.73 
with TB treatment 19.1% 11.6 
V/F (L) 110 10.2 
ka (h
-1
) 3.72 13.8 
NN 10.1 24.5 
MTT (h) 1.30 9.63 
Proportional error (%) 33.9 6.21 
IIV on CL/F (%CV) 72 (26.4) 22 
IIV on V/F (%CV) 81.6 (31.2) 12.3 
IOV on CL/F (%CV) 40.5 (25.3) 37 
IOV on MTT (%CV) 45.8 (19.5) 37.6 
CL: oral clearance; V: volume of distribution; F: bioavailability; RUV: residual 
unexplained variability; ka: oral absorption rate; NN: number of transit 
compartment; MTT: mean transit time; IIV: interindividual variability; IOV: 
interoccasional variability. 
 
1.2.3. Integrated lopinavir-ritonavir model 
After the separate lopinavir and ritonavir model being built, an integrated model 
need to be developed to describe drug-drug interactions between lopinavir and 
ritonavir. Covariates were also tested in order to obtain the final model which 
process described in the methodology. The structure of the final combined model 
is illustrated in Figure 3.1.10. The structural model for lopinavir and ritonavir are 
same as described in the built separate models. A one-compartment model with 
first-order absorption and elimination best described the pharmacokinetics of 
lopinavir. A similar model was used for ritonavir, but the absorption phase 
displayed more complex pharmacokinetics which was described best by a series of 
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10 transit compartments. Since a strong correlation was found between the 
absorption rate constant of lopinavir and ritonavir (r=0.9), the two parameters 
were estimated as proportional to one another. A similar solution was used for IIV 
in oral clearance and volume of distribution of ritonavir. Significant covariate 
relationships were found between body weight and oral clearance and volume of 
distribution of both lopinavir and ritonavir. The OFV dropped more than 50 points 
when allometric scaling was added to the model.  
 
 
Figure 3.1.10 Structure of the final integrated lopinavir-ritonavir pharmacokinetic model. 
(LPV: lopinavir; RTV: ritonavir; MTT: mean transit time; CL/F: apparent oral clearance; 
V/F: apparent volume of distribution; ka: absorption rate constant; kTR: transit absorption 
rate constant; Emax: the maximum inhibition effect on lopinavir oral clearance by ritonavir; 
EC50: the ritonavir concentration needed to reach half of Emax; CRTV: concentration of 
ritonavir). 
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and 77% when the ‘super-boosted’ and ‘double dose’ approaches were used, 
respectively. The additional effect of ATT on lopinavir clearance was not 
significant and was not included in the model. For ritonavir, the effect of ATT was 
significant on oral clearance, then therefore different typical values of clearance 
were estimated for the subjects with and without ATT. The individual parameters 
distribution of clearance of lopinavir and ritonavir were shown in Figure 3.1.11 
and Figure 3.1.12, respectively. 
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Figure 3.1.11. Individual relative oral clearance of lopinavir distribution by 
antituberculosis treatment (TB: rifampicin-based antituberculosis treatment). 
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Figure 3.1.12. Individual relative oral clearance of ritonavir distribution by 
antituberculosis treatment (TB: rifampicin-based ATT). 
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In addition to ATT, the effect of ritonavir dose on the lopinavir bioavailability was 
investigated. In order to investigate both the effect of rifampicin-based ATT and 
the effect of different doses of ritonavir on lopinavir bioavailability (FLPV), the 
following model was used: 
                                      (3.1.4) 
where DoseRTV and DoseRTV-STD denote the individual dose of ritonavir (mg/kg) and 
the median ritonavir dose given in the arm without rifampicin co-administration (3 
mg/kg), respectively. The linear relation between FLPV and ritonavir dose is 
described by the parameter SLP. RIF is the reduction of lopinavir bioavailability 
during ATT compared with reference (no rifampicin, median ritonavir dose).  
 
In order to capture the inhibition effect of ritonavir on the lopinavir clearance, a lot 
of models were tested. Concentrations and exposures of ritonavir were tested 
respectively to investigate this kind of inhibition interaction effect and 
concentration was found better. Various enzyme models were tested, including 
direct inhibition and enzyme turnover models, to describe the relationship between 
ritonavir concentrations and lopinavir clearance. The direct inhibition model of 
ritonavir concentrations on the clearance of lopinavir was chosen and the sigmoid 
relationship used in the final model (see Equation 3.1.5). When this effect was 
introduced, the model fitness was significantly improved (ΔOFV=-95.46) 
compared to without this dynamic effect.  
 
              
         
         
  (3.1.5) 
where CLLPV is the oral clearance of lopinavir, CL0 is the oral clearance of 
lopinavir when no ritonavir is present, Emax is the maximum inhibition effect of 
ritonavir, EC50 is the ritonavir concentration to reach half of Emax, and CRTV is the 
concentration of ritonavir. 
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Addition of a maturation model was test on the clearance of lopinavir and ritonavir 
promoted by Anderson and Holford 
169
, but this model was not supported by the 
data. The model we used as follows: 
            
    
    
    
              
 (3.1.6) 
where CL/F is the apparent oral clearance, TVCL/F is the typical value, PMAi is 
postmenstrual age of each patient, PMA50 is the PMA at which half of the 
maturation is reached, and Hill is a shape parameter that controls steepness of the 
sigmoidal maturation function. 
 
Blow the quantification limit (BQL) data were few in the dataset, 2% of total data 
for both lopinavir and ritonavir, and these data were excluded during model 
building. In order to evaluate the accuracy of predictions for BQL data, the bias 
between predicted and LLOQ values were calculated, in which LLOQ values 0.05 
mg/L for lopinavir and 0.025 mg/L for ritonavir were used. The following equation 
was applied to evaluate the prediction accuracy of BQL data: 
         
        
    
 (3.1.7) 
where BQLA is the accuracy of prediction for BQL data, BQLE is the individual 
estimate of BQL data by the final model, and LLOQ is the lowest limit of 
quantization. Figure 3.1.8 describes the accuracy of prediction for BQL data of 
lopinavir and ritonavir. The low BQLA indicates prediction of BQL data by our 
model are close to LLOQ value, which further proves the minor bias related to 
exclusion BQL data during modeling building. 
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Figure 3.1.13 The accuracy of prediction for BQL data of lopinavir and ritonavir by the 
final model. 
 
The typical volume of distribution of lopinavir was 11.6 L. While the typical oral 
clearance of lopinavir without ritonavir was 4.18 L/h, it should be kept in mind 
that this value is an extrapolation, since lopinavir was never given without 
ritonavir. The number of transit compartments of ritonavir was estimated to be 
10.1 and fixed to 10 in the integrated model. The typical bioavailability of 
lopinavir was 40.5% when ‘super-boosted’ lopinavir was given and 22.6% when 
the dose of LPV/r was doubled during rifampicin-based ATT compared to without 
rifampicin-based ATT. Antituberculosis treatment increased the oral clearance of 
ritonavir by about 50%, from 12.7 L/h to 19 L/h. Figure 3.1.14 shows the 
distribution of lopinavir bioavailability in different dose strategy groups. Due to 
the complexity of the model, numerical instability was experienced when we 
attempted to estimate all of the parameters simultaneously. Consequently the 
maximum effect (Emax) was fixed to 0.9. This value was estimated when ritonavir 
parameters were fixed and only lopinavir parameters estimated. The EC50 was 
estimated 0.0519 mg/L. The population pharmacokinetic parameter estimates for 
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the final combined model are shown in Table 3.1.5. All the parameters were 
estimated simultaneously. The representative individual plots of lopinavir and 
ritonavir are presented in Figure 3.1.15 and Figure 3.1.16. 
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Figure 3.1.14. Individual bioavailability of lopinavir distribution in different doses groups. 
 
 
Figure 3.1.15. Representative individual plots of lopinavir and ritonavir in different regimen 
groups using intensive sampling approach (the solid line is the individual predictive data and the 
dotted line is the population predictive data and observed concentrations are displayed as circles). 
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Figure 3.1.16. Representative individual plots of lopinavir and ritonavir using sparse 
sampling approach (the solid line is the individual predictive data and the dotted line is the 
population predictive data and observed concentrations are displayed as circles). 
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Table 3.1.5. Population pharmacokinetic parameter estimates for both lopinavir 
and ritonavir in final integrated model. 
CL: oral clearance; V: volume of distribution; F: bioavailability; RUV: residual 
unexplained variability; MTT: mean transit time; ka: oral absorption rate; IIV: 
interindividual variability; IOV: interoccasional variability;*CI: confidence 
interval from 250 bootstraps; 
1
slope between ritonavir dose (mg/kg) and 
bioavailability of lopinavir; 
2
the reduction of bioavailability of lopinavir caused by 
rifampicin (                                     ;
 3
median of relative 
Parameters Final model Bootstrap 
Estimates 
(ηshrinkage%) 
Mean  95% CI* 
Lopinavir     
CL/F (L/h)
5
 4.18 4.42 3.41-5.42 
V/F (L)
6
 11.6 11.8 9.20-14.49 
ka  (h
-1
) 0.74 0.771 0.432-1.108 
Slope
1
  0.021   
RIF on F
2
 0.832   
F
3
 
super-boosted dose 40.5% 45.9% 36.3%-55.5% 
double dose 22.6% 22.5% 14.1%-30.9% 
IIV V (% CV) 56.6 (28.3) 54.5 32.1-70.2 
IOV  ka  (% CV) 76.2 (31.2) 78.7 37.5-100.7 
IOV F (% CV) 51.8 (30.6) 50.8 30.9-64.8 
RUV  0.304 0.311 0.252-0.349 
Ritonavir     
CL/F 
(L/h)
5
 
no TB and after TB 12.8 13.0 10.5-15.5 
with TB treatment 19.1 18.5 13.9-23.1 
V/F (L)
6
 105 105 80.7-129.5 
ka (h
-1
) 2.31 2.55 0.54-4.57 
MTT (h) 1.28 1.21 0.80-1.62 
IIV CL (%CV) 72.8 (25.7) 72.7 61.2-81.6 
IOV CL (%CV) 41.6 (24.3) 40.0 21.2-52.6 
IIV V (%CV) 43.3 (31.1) 42.4 30.3-56.2 
IOV MTT (%CV) 31.1 (18.6) 46.9 23.6-65.8 
IOV  ka  (%CV) 98.1 (41.6) 104.3 78.5-120.3 
RUV 0.339 0.342 0.291-0.372 
Lopinavir-Ritonavir 
interaction
4
 
   
Emax 0.9 (fix)   
EC50 (mg/L) 0.0519 0.0492 0.0270-0.0715 
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bioavailability of lopinavir; 
4
               
         
         
 ; 
5 
              
 
   
  
 
    
; 
6
              
   
  
 
 
 
 
 
1.3. Final model evaluation 
Goodness fit plots of final integrated model for lopinavir and ritonavir are shown 
in Figure 3.1.17. Goodness fit plots of final integrated model for lopinavir and 
ritonavir stratified by age are shown in Figure 3.1.18. and Figure 3.1.19. Figure 
3.1.20 shows VPC plots stratified by different lopinavir and ritonavir dose 
strategies. Figure 3.1.21 shows VPC plots stratified by age. The results of 1000 
simulations from the final model demonstrated the adequacy of the model and 
indicated that the model had good properties to investigate alternative dosing 
strategies using simulation. The bootstrap results (Table 3.1.5) confirmed the 
robustness of the final model. 
 
 
Figure 3.1.17. Goodness fit plots of final integrated model for lopinavir (a) and ritonavir (b). 
(a) (b)
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Figure 3.1.18. Goodness fit plots of final integrated model for lopinavir stratified by age 
<= 1 year 1-2 year
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Figure 3.1.19. Goodness fit plots of final integrated model for ritonavir stratified by age 
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Figure 3.1.20. Visual predictive check (VPC) of the final integrated model for lopinavir (LPV; upper 
panel) and ritonavir (RTV; lower panel) stratified for regimens (from left to right; standard, 
‘super-boosted’, and ‘double dose’ approach). The solid line is the median of the observed data and 
the dotted lines are the 5
th
 and 95
th
 percentiles of the observed data. The grey shaded areas are the 95% 
confidence intervals for the median, 5
th
 percentile and the 95
th
 percentiles of the simulated data 
(n=1000). Observed concentrations are displayed as circles. 
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Figure 3.1.21. Visual predictive check (VPC) of the final integrated model for lopinavir (LPV; upper 
panel) and ritonavir (RTV; lower panel) stratified by age. The solid line is the median of the observed 
data and the dotted lines are the 5
th
 and 95
th
 percentiles of the observed data. The grey shaded areas 
are the 95% confidence intervals for the median, 5
th
 percentile and the 95
th
 percentiles of the 
simulated data (n=1000). Observed concentrations are displayed as circles. 
 
1.4. Simulation  
Optimal lopinavir/ritonavir dose recommendations during rifampicin 
co-administration are presented in Table 3.1.6. Simulations predicted that children 
weighing 3-5.9, 6-9.9, 10-13.9 and 14-19.9 kg need respective doses of 52, 40, 35 
and 30 mg/kg LPV/r in 4:1 ratio 12 hourly in order to maintain lopinavir 
concentrations > 1 mg/L in at least 95% of children. An 8 hourly dosing strategy 
would require lower doses of 27, 21, 20 and 18 mg/kg for the respective weight 
bands. When giving lopinavir/ritonavir in ‘super-boosted’ ratio (1:1), the model 
predicted that lopinavir doses of 22, 16, 14 and 12 mg/kg twice daily are needed in 
children weighing 3.0-5.9, 6.0-9.9, 10.0-13.9 and 14.0-19.9 kg, respectively. The 
5
th
 percentiles of simulated lopinavir concentrations using the original and the 
Un
ive
rsi
ty 
of 
 C
ap
e T
ow
n
Chapter 3                                                 Results 
 
 
83 
 
proposed dosage regimens in a typical patient (the patient who has a median age 
and median body weight) when lopinavir/ritonavir was given as standard ratio 4:1 
are presented in Figure 3.1.22.The prediction concentrations of lopinavir using our 
recommended dose strategies are shown in Figure 3.1.23, Figure 3.1.24 and Figure 
3.1.25. 
 
Table 3.1.6 Predicted optimal dosage regimens of lopinavir/ritonavir when 
rifampicin is co-administered based on simulations using the final combined 
model.  
Body weight 
(kg) 
Lopinavir:ritonavir=4:1 Lopinavir:ritonavir=1:1 
12 hourly LPV dose 
(mg/kg) 
8 hourly LPV dose 
(mg/kg) 
12 hourly LPV dose 
(mg/kg) 
3.0-5.9 52 27 22 
6.0-9.9 40 21 16 
10.0-13.9 35 20 14 
14.0-19.9 30 18 12 
 
 
 
Figure 3.1.22.The 5
th
 percentile of simulated lopinavir concentrations obtained for a 
typical patient using different dosage regimens. The dashed line is the target concentration 
of 1 mg/L. 
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Figure 3.1.23. The predicted concentrations of lopinavir using recommended dose in 
Table 3.1.6 as lopinavir:ritonavir= 1:1, 12 hourly strategy stratified by WHO 
recommended body weight bands. The shaded areas, from bottom to top, are the 95% 
confidence intervals for the 5
th
 percentile, median, and the 95
th
 percentiles of the 
simulated data (n=1000).  
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Figure 3.1.24. The predicted concentrations of lopinavir using recommended dose in 
Table 3.1.6 as lopinavir:ritonavir= 4:1, 12 hourly strategy stratified by WHO 
recommended body weight bands. The shaded areas, from bottom to top, are the 95% 
confidence intervals for the 5
th
 percentile, median, and the 95
th
 percentiles of the 
simulated data (n=1000).  
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Figure 3.1.25. The predicted concentrations of lopinavir using recommended dose in 
Table 3.1.6 as lopinavir:ritonavir= 4:1, 8 hourly strategy stratified by WHO recommended 
body weight bands. The shaded areas, from bottom to top, are the 95% confidence 
intervals for the 5
th
 percentile, median, and the 95
th
 percentiles of the simulated data 
(n=1000).  
 
 
2. Results (Paper II) 
2.1. Patients and data description 
The demographic characteristics of patients and trough concentrations observed 
(C0 and C12) are summarized in Table 3.2.1 and Figure 3.2.1 respectively. 
Twenty-one patients, of whom 18 were females, were enrolled in the study, but 3 
patients experiencing adverse events were withdrawn before they completed the 
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study, so only partial data are available for them. Of these three patients, two 
developed grade 3/4 asymptomatic transaminitis (one on standard dose of LPV/r 
with rifampicin and the other on LPV/r 600/150 mg with rifampicin), while 
another patient withdrew consent after developing grade 2 nausea (on LPV/r 
600/150 mg with rifampicin). Other adverse events were mild and resolved 
spontaneously. All participants had 100% adherence according to regular pill 
counts and questioning throughout the study period. Fat free mass was calculated 
using the approach proposed in Janmahasatian et al 
170
. A total of 800 
concentrations were collected for both lopinavir and ritonavir. Data description of 
this study is presented in Table 3.2.2. Figure 3.2.2 illustrates the distribution of 
relvant demographic and clinical variables in this study. Plots of concentrations of 
lopinavir and ritonavir against time after dose in patients are presented in Figure 
3.2.3 and Figure 3.2.4. 
 
Table 3.2.1. Demographic characteristics of patients (n=21). 
Characteristic Median (range) 
Sex (F/M) 18/3 
Age (year) 36 (26 -58) 
Body weight (kg) 64.5 (43.0-110.0) 
Height (cm) 160.5 (148.0 -186.5) 
Body mass index (BMI, kg/m
2
) 26.7 (17.4 -41.4) 
Fat free mass (kg) 39.5 (30.6 -65.9) 
Haemoglobin (g/dL)
1 
11.5 (8.4 -15.0) 
Total bilirubin (umol/L)
2 
7.0 (2.0 -24.0) 
1
 normal range: 11.5-15.0 g/dL  
2
 normal range: 0-21 umol/L 
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Figure 3.2.1.Observed morning and evening trough concentrations of lopinavir (a) and ritonavir (b) 
(PK1-PK4 indicates 4 sequential occasions of this study). 
 
 
 
Figure 3.2.2. The distribution of relvant demographic and clinical variables in the 
study population,: age (a); body weight (b); height (c); ALT (d); haemoglobin (e); 
ritonavir dose per kg (f). 
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Figure 3.2.3. Plots of lopinavir concentrations vs. time after dose in total patients (a) and 
different occasions (b). 
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Figure 3.2.4. Plots of ritonavir concentrations vs. time after dose in total patients (a) and 
different occasions (b). 
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Table 3.2.2. Data descriptions of Paper II. 
Data description Characteristics  
Patients status  HIV infected 
Number of patients 21 
Treatment  4 sequential treatments 
Number of total 
samples 
800 
Dose strategy 
PK1 (day 1 to 7): 400/100 mg lopinavir/ritonavir 
PK2 (day 8 to 14): 400/100 mg lopinavir/ritonavir + 600 
mg rifampicin 
PK3 (day 15 to 21): 600/150 mg lopinavir/ritonavir + 600 
mg rifampicin 
PK4 (day 22 to 28): 800/200 mg lopinavir/ritonavir + 600 
mg rifampicin 
 
2.2. Model description 
2.2.1. Lopinavir separate model 
A one-compartment model with first-order absorption and elimination best 
described the pharmacokinetics of lopinavir. Models with two-compartment 
disposition did not adequately improve the model fit, nor did zero-order absorption 
and the absorption with lag time fit the data. The absorption with transit 
compartments model also did not improve the model fit. The variability (IIV and 
IOV) in oral clearance, volume of distribution, bioavailability and ka were tested in 
the model according to model development as described in the methods. The 
FOCE approach was used in the model building. IIV was found on clearance and 
volume, and IOV was found on ka and bioavailability. The residual error is 
implemented as a combined model: additive and proportional relationship. IIV was 
also found on the residual error in the separate lopinavir model.  
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Rifampicin effect was evaluated on the bioavailability and oral clearance of 
lopinavir as an on/off relationship since the rifampicin induction was assumed to 
achieve steady state. Compared to dosing without rifampicin treatment (assuming 
100% as a reference), the relative bioavailability of lopinavir with rifampicin was 
estimated. Rifampicin was found to increase oral clearance of lopinavir by 61.4% 
and meanwhile, decrease bioavailability by 27.7%. 
 
Table 3.2.3. Population pharmacokinetic parameter estimates of lopinavir separate 
model. 
Parameter  
Estimate  
(ηshrinkage%) 
RSE (%) 
CL/F (L/h) 4.73 9.0 
V/F (L) 45.7 8.9 
RIF on CL + 61.4% 15.2 
Relative bioavailability with RIF 72.3% 7.6 
ka (h
-1
) 0.71 9.8 
Additive error (mg/L) 0.685 8.4 
Proportional error (%) 10.2 7.9 
IIV on CL/F (%CV) 35.2 (28.4) 17.2 
IIV on V/F (%CV) 31.5 (19.3) 21.2 
IOV on F (%CV) 21.7 (10.1) 12.4 
IOV on ka (%CV) 60.5 (37.7) 12.7 
IIV on RUV (%CV) 23.4 (38.9) 23.8 
CL: oral clearance; V: volume of distribution; F: bioavailability; RUV: residual 
unexplained variability; ka: oral absorption rate; RIF: rifampicin administration; 
IIV: interindividual variability; IOV: interoccasional variability. 
 
Different covariates, including body weight, age, gender, haemoglobin, and ALT, 
were analyzed one by one according to the covariates model development 
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methodology as a continuous or discrete factor. Fat free mass was found having 
significant influence on the oral clearance, while total body weight on the volume 
of distribution of lopinavir with an allometric scaling relationship in the final 
model as in Equation 3.2.1 and Equation 3.2.2.  
              
    
  
 
    
 (3.2.1) 
            
   
  
 
 
 (3.2.2) 
where the CL/F is the apparent oral clearance, CL/FSTD is the apparent oral 
clearance of standard patient (with mean body weight or fat free mass),     and 
FFMi are each patient’s body weight and fat free mass, respectively, and 65 kg and 
40 kg are the median body weight and the median fat free mass in our population, 
respectively.  
 
 
Figure 3.2.5. Goodness-fit-plots of final lopinavir separate model. 
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The oral clearance and volume of distribution were 4.73 L/h and 45.7 L, 
respectively. The IIV of clearance and volume were 35.2% and 31.5%, 
respectively. The IOV of relative bioavailability was 21.7%. The additive and 
proportional residual errors were 0.685 mg/L and 10.2%, respectively. The 
parameter estimates of lopinavir separate final model are shown in Table 3.2.3. 
The goodness-fit-plots are shown in Figure 3.2.5. VPC plots of lopinavir separate 
model are shown in Figure 3.2.6. 
 
 
Figure 3.2.6. Visual predictive check (VPC) of the final lopinavir separate model stratified 
by different occasions. The solid line is the median of the observed data and the dotted 
lines are the 5
th
 and 95
th
 percentiles of the observed data. The shaded areas are the 95% 
confidence intervals for the median, 5
th
 percentile and the 95
th
 percentiles of the simulated 
data (n=1000). Observed concentrations are displayed as circles. 
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2.2.2. Ritonavir separate model 
A two-compartment model with first-order elimination and a transit compartment 
absorption best described the pharmacokinetics of ritonavir. The structure of 
ritonavir separate model is shown in Figure 3.2.7. Model with zero-order 
absorption did not adequately fit the data. Transit compartment model was used to 
represent a more physiological delay in absorption onset and a gradual increase in 
absorption rate. The number of transit compartment was estimated 6.33 for the 
absorption model of ritonavir.  
 
 
Figure 3.2.7 Structure of ritonavir separate model. 
 
The variability (IIV and IOV) on oral clearance, volume of distribution, and ka 
were tested according to model development methodology. FOCE approach was 
used in the model building. The residual error was implemented as a combined 
model: additive and proportional relationship. The additive residual error was 
estimated close to zero; therefore only proportional residual error was kept in the 
final model. IIV was found on the oral clearance and volume of distribution in the 
final model. IOV on bioavailability, MTT and clearance were found in the final 
model. 
Dose A1 A2 An Absorption 
compartment
Central 
compartment
ktr ktr
ka
ktr
CL/F
Peripheral 
compartment
Q/F
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Rifampicin induction effect was evaluated on the bioavailability and oral clearance 
of ritonavir as an on/off relationship since the rifampicin induction was assumed to 
achieve steady state. Compared to dosing without rifampicin treatment (assuming 
100% as a reference), the relative bioavailability of ritonavir with rifampicin was 
estimated. Rifampicin administration increased the clearance of ritonavir by about 
22.7% and decreased the bioavailability of ritonavir by about 49.3%. 
 
The bioavailability of ritonavir was found increased with increasing its dose. A 
linear relationship (Equation 3.2.4) was used to evaluate this kind of effect. The 
relative bioavailability of ritonavir was increased by 5.8% for each 10 mg 
increment of its dose. 
                            (3.2.3) 
where F is bioavailability of ritonavir, FSTD is is the bioavailability of ritonavir 
when given 100 mg dose, SLP is the slope of linear relationship between 
bioavailability and dose, DOSERTV is the dose of ritonavir would be given. 
 
Different covariates, including body weight, age, gender, haemoglobin, and ALT, 
were analyzed one by one according to model covariates development steps as a 
continuous or discrete factor. Similar to lopinavir, allometric scaling of fat free 
mass on oral clearance and total body weight on volume of distribution were 
applied into the final separate model of ritonavir (Equation 3.2.2 and Equation 
3.2.3). The OFV dropped about 22 points when this allometric scaling was 
introduced into the model.  
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Figure 3.2.8. Goodness-fit-plots of final ritonavir separate model. 
 
The central oral clearance of ritonavir without rifampicin effect was 18.6 L/h, 
whereas it was 22.9 L/h with rifampicin. The peripheral oral clearance was 33.3 
L/h. The central and peripheral volume of distribution was 22.9 L and 48 L, 
respectively. The number of transit compartment was estimate as 6.33 and MTT 
was 1.43 h. The IIV of oral clearance and volume of distribution were 30.2% and 
52.9%, respectively. The IOV of clearance and MTT were 16.1% and 16.9%, 
respectively. IOV of bioavailability was 37%. The proportional residual error was 
18.1%. The parameter estimates of ritonavir separate final model are shown in 
Table 3.2.4. The goodness-fit-plots are shown in Figure 3.2.8. Visual prediction 
check of ritonavir separate model is shown in Figure 3.2.9. 
 
Un
ive
rsi
ty 
of 
 C
ap
e T
ow
n
Chapter 3                                                 Results 
 
 
98 
 
Table 3.2.4. Population pharmacokinetic parameter estimates for ritonavir separate 
model (RSE% was not available). 
 
Parameter  
Estimate 
(ηshrinkage%) 
CL/F (L/h) 18.6 
Vc/F (L) 22.9 
RIF on CL + 22.9% 
Relative bioavailability with RIF 50.7% 
Q/F (L/h) 33.3 
Vp/F (L) 48 
ka (h
-1
) 8.45 
NN 6.33 
MTT (h) 1.43 
RTV dose on F  + 5.8%/ 10 mg 
Proportional error (%) 18.1 
IIV on CL/F (%CV) 30.2 (12.8) 
IIV on V/F (%CV) 52.9 (38.2) 
IOV on F (%CV) 37 (25.1) 
IOV on MTT (%CV) 16.9 (27.4) 
IOV on CL (%CV) 16.1 (27.5) 
CL: central oral clearance; Vc: central volume of distribution; Q: peripheral oral 
clearance; Vp: peripheral volume of distribution; F: bioavailability; ka: oral 
absorption rate; NN: number of transit compartment; MTT: mean transit time; RIF: 
rifampicin administration; IIV: interindividual variability; IOV: interoccasional 
variability. 
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Figure 3.2.9. Visual predictive check (VPC) of the final ritonavir separate model stratified 
by different occasions. The solid line is the median of the observed data and the dotted 
lines are the 5
th
 and 95
th
 percentiles of the observed data. The shaded areas are the 95% 
confidence intervals for the median, 5
th
 percentile and the 95
th
 percentiles of the simulated 
data (n=1000). Observed concentrations are displayed as circles. 
 
 
2.2.3. Integrated lopinavir-ritonavir model 
The structure of the final integrated pharmacokinetic model is illustrated in Figure 
3.2.10. A one-compartment model with first-order absorption and elimination best 
described the pharmacokinetics of lopinavir. For ritonavir, a two-compartment 
model was appropriate and a series of transit compartments was used to describe 
the complex kinetics in the absorption phase. IIV was supported in CL/F and V/F 
of both drugs, while IOV was characterized in absorption parameters (absorption 
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rate and absorption mean transit time), bioavailability, and to a lesser extent in 
CL/F. 
 
 
 
Figure 3.2.10. Structure of the final integrated lopinavir-ritonavir pharmacokinetic model. 
(LPV: lopinavir; RTV: ritonavir; MTT: mean transit time; CL/F: apparent oral clearance; 
V/F: apparent volume of distribution; ka: absorption rate constant; kTR: transit absorption 
rate constant; Emax: the maximum inhibition effect on lopinavir oral clearance by ritonavir; 
EC50: the ritonavir concentration needed to reach half of Emax; C: concentration) 
 
 
Rifampicin was found to increase the oral clearance of lopinavir and ritonavir by 
71.0% and 36.0%, respectively. Rifampicin treatment also significantly reduced 
the bioavailability of both lopinavir and ritonavir, by 20.2% and 45.0%, 
respectively. The individual bioavailability, oral clearance and elimination rate of 
lopinavir and ritonavir influenced by rifampicin are shown in Figure 3.2.11 and 
Figure 3.2.12 respectively. 
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Figure 3.2.11. Individual bioavailability distributions of lopinavir (a) and ritonavir (b) 
influenced by rifampicin. 
 
 
 
Figure 3.2.12. Individual oral clearance distributions of lopinavir (a) and ritonavir (b) 
influenced by rifampicin. 
 
 
The bioavailability of ritonavir was found increased by its dose. A linear 
relationship (Equation 3.2.3) was used to evaluate this kind of effect. The relative 
bioavailability of ritonavir was increased by 5.8% for each 10 mg increment of its 
dose. 
 
The bioavailability of ritonavir increased with increasing doses: when 
co-administered with rifampicin, the relative bioavailability of ritonavir increased 
by 8.1% for each 10 mg increment of dose. The individual bioavailability of 
ritonavir in different doses of lopinavir/ritonavir is shown in Figure 3.2.13. 
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Figure 3.2.13. Individual bioavailability of ritonavir in different doses of 
lopinavir/ritonavir (RIF: rifampicin). 
 
A different model was used to test the relationship between ritonavir 
concentrations and lopinavir clearance. Besides the direct interaction model, the 
presence of a delay in the onset of inhibition of lopinavir CL/F by ritonavir was 
tested using an indirect model. Finally, in the model, the oral clearance of 
lopinavir is influenced by ritonavir concentration, according to an Emax function 
(Equation 3.2.4). This dynamic interaction between ritonavir and lopinavir 
significantly improved the model fit (ΔOFV=-120, compared to the model no 
drug-drug interaction included). An indirect model describing delay of the 
interaction was not supported by the data. The maximum inhibition effect of 
ritonavir on lopinavir CL/F was 95%, and EC50 was estimated 0.04 mg/L. The 
model estimated oral clearance of lopinavir was 37.9 L/h when no ritonavir is 
present and the oral clearance of ritonavir was estimated 19.2 L/h.  
 
              
         
         
  (3.2.4) 
where CL0 is the CL/F of lopinavir when no ritonavir is present, Emax is the 
maximum inhibition effect of ritonavir by lopinavir, EC50 is the ritonavir 
concentration required to reach half of Emax, and CRTV is the concentration of 
ritonavir.  
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The BQL data were few in the dataset, 1% of total data for lopinavir and 2% for 
ritonavir, and these data were set to LLOQ/2 (0.025 mg/L for lopinavir and 0.0125 
mg/L for ritonavir) values in model building. In order to evaluate the accuracy of 
the prediction of BQL data, the bias between predicted and LLOQ values were 
calculated, in which LLOQ values 0.05 mg/L for lopinavir and 0.025 mg/L for 
ritonavir were used. The following equation was applied to evaluate the prediction 
accuracy of BQL data: 
         
         
    
 (3.2.5) 
where BQLA is the accuracy of prediction for BQL data, BQLE is the individual 
estimate of BQL data by the final model, and LLOQ is the lowest limit of 
quantification. Figure 3.2.14 describes the accuracy of prediction for BQL data of 
lopinavir and ritonavir. The low BQLA indicates prediction of BQL data by our 
model are close to LLOQ value, which further proves minor bias related to 
exclusion BQL data during modeling building. 
 
 
Figure 3.2.14 The prediction precisions of BQL data for lopinavir and ritonavir by the 
final model. 
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The typical clearance of lopinavir without ritonavir was 37.9 L/h, while it should 
be kept in mind that this value is an extrapolation, since lopinavir was never given 
without ritonavir. The number of transit compartment of ritonavir was estimate 
2.03 in the integrated model. The maximum effect (Emax) of ritonavir concentration 
on lopinavir clearance was 95.3%, while EC50 was estimated 0.0351 mg/L. The 
population pharmacokinetic parameter estimates for the final combined model are 
shown in Table 3.2.5. All the parameters were estimated simultaneously. The 
diurnal variation distribution of individual bioavailability and oral clearance for 
lopinavir and ritonavir are presented in Figure 3.2.15 and Figure 3.2.16 
respectively. The representative individual plots of lopinavir and ritonavir are 
presented in Figure 3.2.17. 
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Figure 3.2.15. The diurnal variation distribution in individual bioavailability of lopinavir (a) 
and ritonavir (b). 
 
 
 
Figure 3.2.16. The diurnal variation distribution in individual oral clearance of lopinavir (a) and 
ritonavir (b).  
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Table 3.2.5. Population pharmacokinetic parameter estimates based on the final model of 
both lopinavir and ritonavir. 
 
CL: central oral clearance; Vc: central volume of distribution; Vp: peripheral volume of distribution; 
F: bioavailability; RUV: residual unexplained variability; MTT: mean transit time; ka: oral 
absorption rate; IIV: interindividual variability; IOV: interoccasional variability; RIF: rifampicin; NN: 
number of transit compartment. 
1
 central volume of distribution; 
2
 peripheral volume of distribution; 
Parameters 
Lopinavir Ritonavir 
Estimates 
(ηshrinkage%) 
95% CI* 
Estimates 
(ηshrinkage%) 
95% CI* 
CL/F (L/h) 37.9 28.5-52.1 19.2 18.4 - 22.2 
RIF on CL/F (+)
#
  71.0%  65.7%-75.4% 36.0% 
 35.2% 
-40.0% 
Vc/F (L)
1
 54.7 50.5 - 64.7 22.6 21.9 - 24.6 
ka (h
-1
) 0.991 0.63 - 1.43 3.28 2.90 - 3.38 
Relative bioavailability given 
with RIF 
79.8% 75.7 - 84.7 55.0% 
53.8% - 
58.7% 
Proportional error (%) 12.7 11.6 - 13.6 18.8 17.1 - 20.3 
Evening effect on bioavailability 
(+)
#
 
 42.0% 38.0% - 48.2%  45.0% 
 41.4% - 
53.6% 
Evening effect on CL/F (-)
#
 32.7% 29.6% - 38.4% 32.7% 
29.6% - 
38.4% 
Bioavailability/10 mg 
ritonavir(+)
##
 
   8.1% 
 5.7% - 
11.2% 
Intercompartmental clearance 
(Q/F) (L/h) 
  31.0 25.7 - 34.7 
Vp/F (L)
2
   56.6 50.8 - 66.0 
NN   2.03 1.83 - 2.37 
MTT (h)   1.44 1.39 - 1.53 
IIV CL/F (%CV) 20.2 (28.4) 12.7 - 25.1 21.5 (10.6) 11.5 - 31.7 
IIV V/F (%CV) 27.2 (5.5) 10.3 - 41.4 10.2 (28.7) 9.85 - 10.5 
IOV F (%CV) 21.9 (25.1) 17.1 - 24.0 30.3 (21.8) 24.1 - 40.7 
IOV ka (%CV) 94.2 (41.7) 46.5 - 150.1   
IOV CL/F (%CV) 11.8 (36.4) 4.55 - 16.1 20.4 (27.5) 15.5 - 25.1 
IOV RUV (%CV) 17.1 (38.3) 9.63 - 25.2   
IIV F (%CV)   30.3 (7.3) 17.4 - 49.6 
IOV MTT (%CV)   27.9 (27.4) 19.6 - 38.2 
Lopinavir-ritonavir 
interaction 
Estimates 95% CI*   
Emax 95.3% 94.5% - 96.3%   
EC50 (mg/L) 0.0351 0.0194-0.0438   
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##
 increase in bioavailability per every 10 mg ritonavir dose; 
#
(+)the effect is increased, (-) the effect 
is decreased; *CI: confidence intervals based on mean and SD from 10 bootstrap
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Figure 3.2.17. The representative individual plots of lopinavir (a) and ritonavir (b) (the 
solid line is the individual predictive data and the dotted line is the population predictive 
data and observed concentrations are displayed as circles). 
 
2.3. Final model evaluation 
Goodness of fit plots of final integrated model for lopinavir and ritonavir are 
shown in Figure 3.2.18. Figure 3.2.19 show VPC plots stratified by different 
occasions. The results of 1000 simulations from the final model demonstrated the 
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adequacy of the model and indicated that the model had good properties to 
investigate alternative dosing strategies using simulation. The bootstrap results 
(Table 3.2.5) confirmed the robustness of the final model. 
 
 
Figure 3.2.18. Goodness fit plots of final integrated model for lopinavir (a) and ritonavir (b) (the 
solid line is the individual predictive data and the dotted line is the population predictive data and 
observed concentrations are displayed as circles). 
 
2.4. Simulation 
The simulation predicted that 99.5% of the subjects given 800/200 mg LPV/r 
during rifampicin co-administration can achieve the lopinavir target concentrations 
(>1 mg/L) for C0 (predose concentration), but only 77.9% of subjects for C12 (12 h 
concentration after dose). For patients with body weight <50kg, simulation 
indicated that 600/150 mg doses of LPV/r can achieve target C0  in 95% of 
patients during rifampicin co-administration. An 800/200 mg dose of LPV/r was 
sufficient for patients weighing > 110 kg (95% achieve C0>1 mg/L during 
rifampicin co-administration). 
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Figure 3.2.19. Visual predictive check (VPC) of the final combined model for lopinavir (left 
panel) and ritonavir (right panel) stratified by occasion (PK1-PK4). The solid line is the 
median of the observed data and the dotted lines are the 5
th
 and 95
th
 percentiles of the observed 
data. The grey shaded areas are the 95% confidence intervals for the median, 5
th
 percentile and 
the 95
th
 percentiles of the simulated data (n=1000). Observed concentrations are displayed as 
circles. 
 
3. Results (Paper III) 
3.1. Patients and data description 
Ninety-five patients were involved in this pooled study. A total of 1226 
steady-state concentrations of lopinavir and ritonavir were available in this study. 
As mentioned before, the intensive sampling approach was conducted in the adult 
study, but for children, both intensive and sparse sampling approaches were used. 
The data descriptions are summarized in Table 3.3.1. BQL data were set to 
LLOQ/2 values (0.025 mg/L for lopinavir and 0.0125 mg/L for ritonavir). The 
standard dose of lopinavir and ritonavir without rifampicin for children and adults 
is presented in Figure 3.3.1. The doses of lopinavir and ritonavir actually received 
by children in different dose strategies are presented in Figure 3.3.2. 
Lopinavir Ritonavir
C
o
n
ce
n
tr
at
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n
 (m
g/
L)
Time after dose (h) Time after dose (h)
PK1 PK2
PK3 PK4
PK1 PK2
PK3 PK4
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Table 3.3.1. Data descriptions of the combined dataset in this study. 
 Children Adults 
Patients status HIV or HIV/TB HIV 
Number of patients 74 21 
Number of samples 426 800 
Gender (male/female) 34/40 3/18 
Age (range) 6 months – 4.5 years 26 – 58 years 
Body weight (median, kg) 10.2 (5.0 -17.0) 64.5 (43.0 
-110.0) 
Lopinavir median dose no 
RIF (mg/kg) 
12.0 (9.2 -16.0) 6.0 (3.6 -9.0) 
Ritonavir median dose no 
RIF (mg/kg) 
2.9 (2.3 - 4.0) 1.5 (0.9 – 2.5) 
TB: tuberculosis; RIF: rifampicin-based antituberculosis treatment. 
 
 
 
Figure 3.3.1. The standard doses of lopinavir and ritonavir without rifampicin-based ATT 
for children and adults. 
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Figure 3.3.2. The doses of lopinavir and ritonavir actually received by children in different 
dose strategies (RIF: rifampicin-based antituberculosis treatment). 
 
 
3.2. Model development 
3.2.1. Summary of model characteristics of children and adults 
The structure model of lopinavir is a one-compartment with the first-order 
elimination for both children and adults. For ritonavir, a one-compartment model 
was used for children, but a two-compartment model fitted the adult data, and a 
transit absorption model was used for both children and adults to describe the 
delay characteristics of the drug absorption. Allometric scaling of body size was 
applied on the oral clearance and volume of distribution for both children and 
adults. The dose strategy of lopinavir and ritonavir in children included different 
ratios: 1:1 and 4:1. For adults, lopinavir and ritonavir was given as the same ratio 
of 4:1, but with sequential increased doses. With increase of concentration of 
ritonavir, the oral clearance of lopinavir decreased in a sigmoid relationship for 
both children and adults. In children, rifampicin induction effect was found a 
significant reduction in the bioavailability of lopinavir, and meanwhile it increased 
the oral clearance of ritonavir. While in adults, this effect was found significant on 
the bioavailability and oral clearance for both lopinavir and ritonavir. When 
ritonavir dose increased, the bioavailability was found significant increased for 
lopinavir in children and for ritonavir in adults. The comparisons of population 
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pharmacokinetic differences between the built model of children and adults are 
summarized in Table 3.3.2. 
 
Table 3.3.2. Comparisons of built population pharmacokinetic model between children and 
adults. 
Items Adult model Children model 
Model structure  One-compartment model for 
lopinavir; two-compartment 
model for ritonavir 
One-compartment for 
lopinavir; one-compartment 
model for ritonavir 
Rifampicin induction effect Lopinavir F and CL;  
Ritonavir F and CL 
Lopinavir F; Ritonavir CL 
Ritonavir dose effect Ritonavir F Lopinavir F 
Allometric scaling FFM for CL and WT for V WT for CL and V 
Sampling approach Intensive Some intensive, some sparse 
Doses for lopinavir:ritonavir 4:1; 6:1.5; 8:2 4:1; 4:4; 8:2 
F: bioavailability; CL: clearance; V: volume of distribution; FFM: fat free mass; WT: body 
weight. 
 
 
3.2.2. Integrated lopinavir-ritonavir model using combined dataset for 
children and adults 
The lopinavir and ritonavir model was integrated as the final model using 
combined dataset of children and adults. All pharmacokinetic parameters of 
children and adults were estimated simultaneously. As described before, a sigmoid 
model was used to capture the dynamic effect of ritonavir concentration on the 
oral clearance of lopinavir. The model structure is shown in Figure 3.3.3. A 
one-compartment with the first-order elimination model was used for lopinavir 
and a two-compartment with transit absorption model was used for ritonavir. IIV 
and IOV were kept the same as the separate model of lopinavir and ritonavir using 
the combined dataset of children and adults. 
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Figure 3.3.3. Structure of the final integrated lopinavir-ritonavir pharmacokinetic model. 
(LPV: lopinavir; RTV: ritonavir; MTT: mean transit time; CL/F: apparent oral clearance; 
V/F: apparent volume of distribution; ka: absorption rate constant; kTR: transit absorption 
rate constant; Emax: the maximum inhibition effect on lopinavir oral clearance by ritonavir; 
EC50: the ritonavir concentration needed to reach half of Emax; C: concentration; hill: shape 
factor) 
 
 
Allometric scaling of body weight on the oral clearance and volume of distribution 
in both central and peripheral compartments were applied for lopinavir and 
ritonavir. The follow equations were used in the combined dataset of this study: 
              
   
  
 
    
                                                          (3.3.1) 
            
   
  
 
 
                             (3.3.2) 
where the CL/F and V/F are the apparent oral clearance and the apparent volume 
of distribution respectively; CL/FSTD and V/FSTD are the apparent oral clearance of 
standard patient (with median body weight), respectively;     is each patient’s 
body weight, and 65 kg is the median body weight of adult population.  
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Since no intra-venous dosing data were available, estimating absolute 
bioavailability was not possible. Thus, the relative bioavailability of lopinavir and 
ritonavir was fixed to the reference value of 1 for adults without rifampicin 
co-treatment, and the other values are reported as compared to this reference. In 
children given the median 2.9 mg/kg dose of ritonavir without rifampicin, the 
relative bioavailability of lopinavir was estimated to be 0.787 of that in the adults 
and the relative bioavailability of ritonavir 0.245. Rifampicin decreased the 
bioavailability of lopinavir and ritonavir: for adults and children respectively, the 
bioavailability of lopinavir was reduced to 0.753 and 0.325 of the bioavailability 
in adults without concomitant rifampicin; and the bioavailability of ritonavir was 
reduced to 0.482 in adults and 0.021 in children. Meanwhile, rifampicin increased 
CL/F of lopinavir by 57.7% in adults and 47.6% in children, and the CL/F of 
ritonavir by 33.7% and 22.0% for adults and children respectively. The rifampicin 
effect was also tested to be altered according to body size, but it was not supported 
by our data. Addition of a maturation model was also not supported by the data. 
Diurnal variation was included into the model on the oral clearance and 
bioavailability with a linear relationship to indicate how much diruanal effect to 
decrease oral clearance and increase bioavailability for both children and adults.  
 
In the final integrated model, the relative bioavailability of lopinavir in children 
increased by 0.019 for every 1 mg/kg increment in the dose of ritonavir. However, 
in adults the dose of ritonavir was not found to affect lopinavir’s bioavailability. 
The bioavailability of ritonavir increased by 0.464 and 0.026 in adults and children 
respectively, for every 1 mg/kg increment in the dose of ritonavir. The following 
equations were used for lopinavir and ritonavir: 
                                                       (3.3.3) 
                                           )          (3.3.4) 
where FLPV and FRTV are the typical value of the bioavailability of lopinavir and 
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ritonavir respectively; BIOLPV and BIORTV are the typical value of bioavailability 
for the standard dose of ritonavir (which changes in children and adults); DoseRTV 
and DoseRTV-STD denote the individual dose of ritonavir (mg/kg) and the median 
ritonavir dose given without rifampicin co-administration (1.5 mg/kg for adult and 
2.9 mg/kg for children), respectively. BIOLPV and BIORTV have been fixed to 1 for 
adults without rifampicin co-treatment, while the values for adults with rifampicin 
and for children with and without rifampicin are estimated. The linear relationship 
between F and ritonavir dose is described by the parameter SLPLPV and SLPRTV for 
lopinavir and ritonavir respectively. 
 
Allometric scaling was used to account for size differences, and the typical value 
of the CL and V parameters was thus estimated for an individual of 65 kg, the 
median weight in our adult population. After adjusting for body weight with 
allometric scaling, the typical value for CL/F/ of lopinavir in children was 33.8% 
lower than that in adults. This value refers to lopinavir CL in absence of ritonavir 
and is as such extrapolated from the model. It does not include the inhibitory effect 
of ritonavir, which is captured separately. For ritonavir, the typical value for CL/F 
was about 39% lower in children (13.3 L/h) than in adults (21.7 L/h). Rifampicin 
therapy in administered doses increased CL/F of lopinavir by 57.7% in adults and 
47.6% in children, and the CL/F of ritonavir by 33.7% and 22.0% for adults and 
children respectively. The addition of a maturation model to account for CL 
changes with age was not supported by the data. The correlations between 
lopinavir and ritonavir in IOV of bioavailability and clearance were 87.3% and 
100% respectively the IIV correlation between bioavailabilities for the two drugs 
was 82.4%. 
 
The absorption parameters also differed in children and adults: absorption half-life 
was 0.6 h and 1.8 h in adults and children respectively; and MTT for ritonavir was 
shorter in adults (1.09 h) than in children (2.23 h). Simulation indicated that the 
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maximal concentration occurs much later in children than in adults, of which 3.9 h 
after dosing for children compared to 2.5 h after dosing for adults. All parameters 
were estimated simultaneously. The parameter estimates are presented in Table 
3.3.3. The relative bioavailability of lopinavir and ritonavir predicted by our model 
for children on the different dosing strategies (standard, super-boosted, and double 
dose) with the median doses actually received is shown in Table 3.3.4. The AUC 
of lopinavir and ritonavir predicted by our model for adults and children are shown 
in Figure 3.3.4. In children, compared to adults, the relative bioavailability of 
ritonavir was estimated 0.245 when the standard dose was given without 
rifampicin. Meanwhile, the clearance of ritonavir of children was estimated about 
39% of that of adults. The median of ritonavir concentrations for children and 
adults when standard dose was given without rifampicin were 0.237 mg/L and 
0.527 mg/L respectively. The ritonavir concentrations when standard dose was 
given without rifampicin for adults and children are shown in Figure 3.3.5. 
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Table 3.3.3. Parameter estimates of final integrated lopinavir-ritonavir model using 
combined dataset of children and adults. (The values in parentheses are RSE% obtained 
from 50 samples of bootstrap results; the values in square bracket areηshrinkage) 
Parameters 
Lopinavir Ritonavir 
Adults Children Adults Children 
CL/F (L/h) 23.1(14.5) 15.3 (25.2) 21.7 (6.0) 13.3 (12.3) 
V/F (L) 56.8 (7.0) 38.8 (18.2) 
ka (1/h) 1.12 (14.1) 0.376 (21.4) 2.34 (16.8) 
Bioavailability no RIF 
#
  1 fix 0.787 (15.9) 1 fix 0.245 (16.3) 
Bioavailability with RIF 
#
 0.753 (6.5) 0.325 (27.2) 0.482 (11.1) 0.021 (25.7) 
RIF on CL/F (+)
*
 57.7% (17.9) 47.6% (14.8) 33.7% (19.1) 22.0% (24.3) 
Slope of RTV dose effect 
on bioavailability
**
 
0 0.0188 (30.6) 0.464 (12.7) 0.0259 (25.6) 
Additive error (mg/L) 0.0535 (14.3)  
Proportional error (%) 13.2 (5.9) 21.1 (7.2) 
Evening effect on 
clearance (-)  
51.4% (5.4) 27.3% (6.4) 51.4% (5.4) 27.3% (6.4) 
Evening effect on 
bioavailability (+)  
 19% (3.6)    
MTT (h)  1.09 (14.5) 2.23 (12.9) 
Q/F (L/h)  29.6 (13.3) 
Vp/F (L)     52.7 (11.1) 
IIV CL/F (%CV) 22.2 (39.8) [36]    26.1 (19.9) [25.7] 
IIV V/F (%CV) 22.2 (45.4) [44.4]  
IOV CL/F (%CV) 18.2 (24.8) [24.3]    18.2 (24.8) [25.3] 
IOV ka (%CV) 68.4 (28.2) [47.2]  
IIV F (%CV) 26.3 (27.3) [25.9]    64.5 (15.4) [13.3] 
IOV F (%CV) 28.0 (21.9) [28.8]        42.5 (14.8) [28.9] 
IOV MTT (%CV)        39.0 (16.4) [19.3] 
Lopinavir-ritonavir interaction 
Emax 0.821 (3.7) 
EC50 (mg/L) 0.0983 (17.4) 
Hill 2.76 (19.6) 
Correlation between lopinavir and ritonavir 
IOV F  87.3% (16.7)     IOV CL/F   100% fix   IIV F   82.4% (28.1) 
CL/F: apparent central oral clearance; Vc/F: apparent central volume of distribution; Q/F: apparent 
peripheral oral clearance of ritonavir; Vp/F: apparent peripheral volume of distribution; MTT: mean 
transit time; RIF: rifampicin; IIV: interindividual variability; IOV: interoccasion variability; Emax: 
maximum of ritonavir concentration effect on clearance of lopinavir; EC50: the concentration of 
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ritonavir when half Emax is achieved; Hill: shape factor. 
# 
the median dose of 1.5 mg/kg and 2.9 
mg/kg of ritonavir for adults and children respectively was considered to report these values; 
*
rifampicin increases the apparent clearance of ritonavir. 
**                             ; 
clearance and volume are estimated using allometric scaling for an individual of 65 kg.  
 
Figure 3.3.4. The exposure of lopinavir (upper) and ritonavir (lower) in adults and 
children stratified by dose strategies in integrated lopinavir-ritonavir model using 
combined dataset. 
 
Table 3.3.4. The relative bioavailability of lopinavir and ritonavir adjusted to the 
median doses actually received by children. (The bioavailability without rifampicin of 
adults is assumed as 100% as reference). 
LPV/r dose strategy 
Median dose of 
ritonavir 
Relative 
bioavailability 
Lopinavir Ritonavir 
Standard dose without rifampicin 2.9 mg/kg 0.787 0.245 
Super-boosted dose with rifampicin 14 mg/kg 0.534 0.308 
Double dose with rifampicin 6 mg/kg 0.383 0.101 
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Figure 3.3.5. Ritonavir concentrations in children and adults when standard dose of LPV/r 
was given without rifampicin. 
 
 
3.3. Final model evaluation 
Goodness fit plots of lopinavir and ritonavir in the final integrated model for adults 
and children are shown in Figure 3.3.6 and Figure 3.3.7, respectively. The visual 
predictive check plots of final integrated model for lopinavir and ritonavir are 
shown in Figure 3.3.8. The visual predictive check plots for lopinavir and ritonavir 
in children stratified by different dose strategies are shown in Figure 3.3.9. All 
validation results demonstrated the adequacy and robust of the model. Since the 
model we built was quite complicate, including huge number of parameters, it was 
extreme time consuming. Ten bootstraps were performed and results are presented 
in Table 3.3.3. 
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Figure 3.3.6. Goodness fit plots of lopinavir (left) and ritonavir (right) of final integrated 
model for adults. 
 
 
 
Figure 3.3.7. Goodness fit plots of lopinavir (left) and ritonavir (right) of final integrated 
model for children. 
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Figure 3.3.8. Visual predictive check (VPC) of lopinavir and ritonavir of the final 
integrated model for adults (left panel) and children (right panel). The solid line is the 
median of the observed data and the dotted lines are the 5
th
 and 95
th
 percentiles of the 
observed data. The grey shaded areas are the 95% confidence intervals for the median, 5
th
 
percentile and the 95
th
 percentiles of the simulated data (n=1000). Observed 
concentrations are displayed as circles. 
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Figure 3.3.9. Visual predictive check (VPC) of lopinavir and ritonavir of the final 
integrated model for children stratified by different dose strategies. The solid line is the 
median of the observed data and the dotted lines are the 5
th
 and 95
th
 percentiles of the 
observed data. The grey shaded areas are the 95% confidence intervals for the median, 5
th
 
percentile and the 95
th
 percentiles of the simulated data (n=1000). Observed 
concentrations are displayed as circles. 
 
 
4. Results (Paper IV) 
4.1. Patients and data description 
The patients and data description were presented before. The lamivudine are 
pooled data from Study I and Study II. Briefly, 68 young HIV infected children 
aged 6 months to 4.5 years, of whom 36 were female, were recruited at three 
antiretroviral clinics in South Africa. All children were on antiretroviral treatment 
comprising lamivudine, stavudine or zidovudine and lopinavir/ritonavir and 33 
children with tuberculosis received rifampicin-based ATT. A total of 493 
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concentrations of lamivudine were available from this study. Demographic 
characteristics of study patients are summarized in Table 3.4.1. Figure 3.4.1 
illustrates the distribution of relvant demographic and clinical variables in the 
study population, including age, body weight, BSA, haemoglobin, and ALT. Plots 
of concentration of lamivudine against time after dose in patients are shown in 
Figure 3.4.2 and Figure 3.4.3. The boxplots of pre-dose (C0) and trough 
concentrations (C12) were illustrated in Figure 3.4.4. Only 5 samples were BQL 
data and set to LLOQ/2 value (10 ng/mL) during analysis. 
 
 
 
Figure 3.4.1. The distribution of relvant demographic and clinical variables of this 
study: age (a); body weight (b); BSA (c); haemoglobin (d); ALT (e). 
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Figure 3.4.2. Plots of lamivudine concentration vs time after dose of total patients 
 
Figure 3.4.3. Plots of lamivudine concentration vs time after dose stratified by patients 
with or without antituberculosis. 
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Figure 3.4.4. Boxplots of pre-dose and trough concentrations of this study. 
 
Table 3.4.1. Demographic characteristics of patients. 
Characteristic Median Range 
Age (month) 22 
6 months - 4.5 
years 
Body weight (kg) 10.0 5 - 17 
Gender (M/F) 32/36  
Height (cm) 79 58 - 103 
BSA (m
2
) 0.48 0.28 - 0.69 
Haemoglobin (g/L) 10.7 5.7 - 29.7 
Albumin (g/L) 38 29 - 47 
Weight-for-age z-score (WFA) -0.88 -4.6 – 1.73 
Weight-for-height z-score (WFH) 0.1 -4.8 – 3.75 
Proportion of children with diagnosis of TB 48.5%  
TB: tuberculosis; WFA and WFH are calculated from each child’s weight 
compared to that a normal child (50
th
 percentile) of the same age or height 
according to the WHO maturation chart. 
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Compared to a one-compartment model, a two-compartment model significantly 
improved the fit of data (ΔOFV=-20). Finally, a two-compartment model with 
first-order elimination best described the pharmacokinetics of lamivudine. The 
structure of the final model of lamivudine is illustrated in Figure 3.4.5. Model with 
zero-order absorption did not adequately fit the data. Transit compartment model 
was used to represent a more physiological delay in absorption onset and a gradual 
increase in absorption rate. The number of transit compartment was estimated 2.3 
for the absorption model of lamivudine. Mean transit time was used to describe the 
delay of absorption. Drug transferred from the final transit compartment to the 
central compartment occurred through an absorption compartment with first-order 
absorption rate ka. The ktr was used to describe the transit absorption rate between 
different transit compartments. This model significantly improved model fit by 
about 15 points in OFV value.  
 
 
 
Figure 3.4.5. Structure of lamivudine final pharmacokinetic model. (ka: absorption rate; 
CL: central oral clearance; Q: peripheral oral clearance; F: bioavailability; ktr: transit 
absorption rate) 
 
The variability (IIV and IOV) in oral clearance (central and peripheral), volume of 
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distribution (central and peripheral), and ka were tested in the model according to 
model development described in method. FOCE approach was used in the model 
building. IIV was supported in the clearance, volume of distribution and 
bioavailability in the final model. IOV was characterized in absorption parameters 
(absorption rate and absorption mean transit time), and bioavailability. A 
proportional structure was suitable for the residual error. 
 
Different covariates, including body weight, age, gender, haemoglobin, albumin 
and ALT, were analyzed one by one according to model covariates development 
steps as a continuous or discrete factor. Body weight was found having significant 
influence on both the central and peripheral oral clearance and volume of 
distribution of lamivudine with an allometric scaling relationship in the final 
model (Equation 3.4.1 and Equation 3.4.2). The inclusion of allometric scaling of 
body weight on apparent clearance and volume of distribution had a significant 
impact on the goodness of fit, improving the OFV by approximately 7 points and 
explaining about 2% of IIV in both clearance and volume of distribution.  
              
   
  
 
    
 (3.4.1) 
            
   
  
 
 
 (3.4.2) 
where the CL/F is th  apparent oral clearance, CL/FSTD is the apparent oral 
clearance of standard patient (with mean body weight),     is each patient’s body 
weight, respectively, and 10 kg is the median body weight in our population. 
 
Moreover, age was found have significant influence on oral clearance. Different 
maturation models were compared in our model: linear, exponential and sigmoidal 
relationship. The different maturation equations are shown as follows: 
                               (3.4.3) 
                      
     (3.4.4) 
Un
ive
rsi
ty 
of 
 C
ap
e T
ow
n
Chapter 3                                                 Results 
 
 
129 
 
            
    
    
    
              
 (3.4.5) 
where CL/F is the apparent oral clearance, TVCL/F is the typical value for a 
subject with the median postmenstrual age of 31 months, PMAi is postmenstrual 
age of each patient,     is the coefficient of PMA on TVCL/F, PMA50 is the 
PMA at which half of the maturation is reached, and Hill is a shape parameter that 
controls steepness of the sigmoidal maturation function. 
 
Figure 3.4.6 illustrates the different maturation functions on the clearance. No 
significant differences were found between three maturation relationships. It might 
due to the age range in our dataset was from 6 months to 54 months, and within 
this age range the clearances were almost overlapped in different models (Figure 
3.4.6). However, sigmoidal maturation function indicates more physiological 
meaning than other two relationships. Therefore, sigmoidal maturation was used in 
the final model. The OFV dropped by about 20 points and IIV in CL/F decreased 
from 10.1% to 8.2% when age was introduced into the model with a sigmoidal 
maturation model. The hill coefficient in the sigmoidal model was initially 
estimated to be 0.96, and fixed to 1 in the final model. The effect of maturation on 
CL/F reached 50% by 4 months after birth (Figure 3.4.7). Weight for age or weight 
for height z-score was used to investigate whether wasting patients had the 
different oral clearance or volume of distribution, but neither weight-for-age nor 
weight-for-height z-score improved the model fit. Oral clearance and 
bioavailability were similar in patients with and without tuberculosis. 
Antituberculosis treatment did not influence the pharmacokinetics of lamivudine. 
 
Un
ive
rsi
ty 
of 
 C
ap
e T
ow
n
Chapter 3                                                 Results 
 
 
130 
 
 
Figure 3.4.6. Different maturation function tested using our dataset. 
 
 
Figure 3.4.7. The maturation of lamivudine clearance with age. These values account only 
for the effect of age. 
 
 
Trough concentrations were on average slightly higher in the morning (C0) than in 
the evening (C12) (Figure 3.4.4). To account for this, diurnal variations were tested 
on both bioavailability and clearance in our model, with the latter being found 
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significant. The OFV dropped 26 points when diurnal variations were included in 
the model. The oral clearance was estimated to be 16.7% slower overnight. The 
individual oral clearances of lamivudine during morning and evening are shown in 
Figure 3.4.8. Furthermore, to account for the uncertainty about the time of the 
evening dose, the RUV for the pre-dose concentrations was allowed a larger level 
of error. The proportional error was 12.6% for pre-dose concentrations compared 
to 8.3% for concentrations at later time points. The OFV improved about 17 points 
when different residual errors of pre-dose concentrations were investigated.  
 
 
Figure 3.4.8. Diurnal variation in individual oral clearances.  
 
The population pharmacokinetic parameter estimates are shown in Table 3.4.2. 
The clearance at full maturation was 12.2 L/h/10 kg. The typical value of 
clearance of patients who have median body weight of 10 kg and median age of 22 
months for our dataset is calculated as 8.6 L/h. The variability on bioavailability 
was found to be 28.5% for IIV and 27.0% for IOV with good estimation precision. 
Large variability of absorption parameters, ka and MTT, was found, 71.9% for 
IOV in ka and 70.9% for IOV in MTT. However, variability of clearance was 
limited to 8.2%. The representative individual plots of lamivudine are presented in 
Figure 3.4.9. 
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Table 3.4.2. Population pharmacokinetic parameter estimates of final model for 
lamivudine 
Parameter  
Estimate 
(ηshrinkage%) 
RSE (%) 
CL/F (L/h)* 12.2 16.6 
Vc/F (L)* 20.7 8.4 
Q/F (L/h)* 1.67 12.9 
Vp/F (L)* 37.2 78.8 
ka (h
-1
) 1.65 18.7 
NN 2.3 40.2 
MTT (h) 0.547 24.3 
PMA50 (month) 12.9 37.1 
Proportional error for PRE (%) 
Proportional error (%) 
12.6 70.6 
8.3 8.3 
Evening effect on CL/F (- %) 16.7 5 
IIV on CL/F (%CV) 8.2 (18.9) 34.2 
IIV on V/F (%CV) 25.2 (16.8) 15.8 
IIV on F (%CV) 28.5 (22.2) 17.9 
IOV on F (%CV) 27.0 (23) 16.4 
IOV on ka (%CV) 71.9 (39.2) 20.8 
IOV on MTT (%CV) 70.9 (41.8) 35.3 
CL: central oral clearance; Vc: central volume of distribution; Q: peripheral oral clearance; 
Vp: peripheral volume of distribution; F: bioavailability; ka: oral absorption rate; NN: 
number of transit compartment; MTT: mean transit time; PMA50: half life of maturation 
for postmenstrual age; IIV: interindividual variability; IOV: interoccasional variability; 
PRE: pre-dose concentrations; *For a child of 10 kg (the median weight of the studied 
cohort). 
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Figure 3.4.9. The representative individual plots of lamivudine (the solid line is the individual 
predictive data and the dotted line is the population predictive data and observed concentrations 
are displayed as circles). 
 
4.3. Model validation 
Goodness fit plots of model are shown in Figure 3.4.10. VPC plots are shown in 
Figure 3.4.11 and Figure 3.4.12. The results of 1000 simulations from the final 
model demonstrated the adequacy of the model and indicated that the model had 
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good properties to predict concentration reference using simulation. The bootstrap 
results (Table 3.4.3) confirmed the robustness of the final model. 
 
 
 
Figure 3.4.10 Goodness fit plots of the final model.  
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Table 3.4.3. Bootstrap results from 1000 samples using final model for lamivudine 
Parameter  Median
*
 95% CI
*
 
CL/F (L/h)
**
 12.5 10.6 – 14.4 
Vc/F (L)
**
 20.5 16.4– 24.6 
Q/F (L/h)
**
 1.85 1.48 – 2.22 
Vp/F (L)
**
 38.4 12.1 – 64.7 
ka (h
-1
) 1.67 1.07 – 2.26 
NN 2.31 1.46 – 3.17 
MTT (h) 0.53 0.35 – 0.71 
PMA50 (month) 13.0 9.7 – 16.2 
Proportional error for PRE (%) 
Proportional error (%) 
10.4 3.5 - 17.4 
8.2 7.0 - 9.4 
Evening effect on CL/F (- %)      16.4 13.9 - 18.9 
IIV on CL/F (%CV) 10.7 3.6 – 14.7 
IIV on V/F (%CV) 24.7 19.8 – 25.3 
IIV on F (%CV) 28.7 20.9 – 36.5 
IOV on F (%CV) 26.9 21.5– 32.4 
IOV on ka (%CV) 73.7 53.1 – 93.3 
IOV on MTT (%CV) 73.4 58.7 – 88.1 
CL: central oral clearance; Vc: central volume of distribution; Q: peripheral oral clearance; 
Vp: peripheral volume of distribution; F: bioavailability; ka: oral absorption rate; NN: 
number of transit compartments; MTT: absorption mean transit time; PMA50: 
postmenstrual age at which half of maturation is reached; PRE: pre-dose concentrations; 
IIV: inter-individual variability; IOV: inter-occasional variability. 
*
median and 95% 
confidence interval from 1000 bootstraps. 
**
For a child of 10 kg (the median weight of the 
studied cohort). 
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Figure 3.4.11. Visual predictive check (VPC) of the final model for lamivudine. The 
solid line is the median of the observed data and the dotted lines are the 5
th
 and 95
th
 
percentiles of the observed data. The shaded areas are the 95% confidence intervals for 
the median, 5
th
 percentile and the 95
th
 percentiles of the simulated data (n=1000). 
Observed concentrations are displayed as circles. 
 
 
Figure 3.4.12. Visual predictive check (VPC) of the final model for lamivudine stratified by 
patients with or without antituberculosis. The solid line is the median of the observed data and 
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the dotted lines are the 5
th
 and 95
th
 percentiles of the observed data. The shaded areas are the 95% 
confidence intervals for the median, 5
th
 percentile and the 95
th
 percentiles of the simulated data 
(n=1000). Observed concentrations are displayed as circles. 
 
 
 
Figure 3.4.12. The 5
th
 percentile of lamivudine concentrations in typical patients by 2000 
simulations. 
 
4.4. Simulation  
2000 simulations were used to predict reference concentration of lamivudine. 
Therapeutic drug monitoring results can be used to compare with these reference 
concentrations. The patients whose concentrations are below the cutoff values are 
high likely to have poor adherence. The 5
th
 percentile of lamivudine 
concentrations in typical patients is shown in Figure 3.4.12. Plots of the 5
th
 
percentile for lamivudine concentrations in children of different ages are shown in 
Figure 3.4.13. The cutoff values of 1
st
, 2.5
th
 and 5
th 
concentration percentiles at 4 
and 12 h after the dose were estimated using 2000 simulations. The results are 
shown in Table 3.4.4. For patients who missed the previous one or two doses, the 
simulations indicated that 99% of concentrations at 4 h after dosing were below 
the cutoff values of 1
st
, 2.5
th
 and 5
th
 percentiles. But if patients missed only the 
second last dose, 94% and 87% concentrations at 4 h and 12 h after dosing are 
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above the 5
th
 percentile of reference cut-offs. If we use concentrations at 12 h after 
dosing as an indicator, only about 40% and 85% of concentrations were found to 
be below the 5
th
 percentile of cutoff values for patients who skipped last one dose 
and two doses, respectively. 
 
Table 3.4.4. The cutoff concentration values of lamivudine calculated from 2000 
simulations. 
Age Cutoff value (ng/mL) 
 
1
st
 percentile 2.5
th
 percentile 5
th
 percentile 
4 h 12 h 4 h 12 h 4 h 12 h 
6 months 297.0 44.7 328.9 52.1 372.5 62.0 
1 year 230.1 28.4 262.8 33.5 293.0 39.5 
2 year 200.7 22.4 236.7 26.5 263.6 31.0 
5 year 202.7 20.7 239.1 24.5 265.8 28.6 
 
 
 
Figure 3.4.13. The 5th percentile of concentrations of lamivudine stratified by different 
age by 2000 simulations.   
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Discussion 
 
1. Pharmacokinetics of lopinavir and ritonavir co-administation 
with rifampicin in children  
Despite the complexity of combined antituberculosis and antiretroviral therapies, 
survival of patients presenting with HIV-associated tuberculosis is significantly 
improved when antiretroviral treatment is introduced during anti-tubercular 
therapy
171–173
. However, combined treatment options are limited for young 
children, especially children who have been exposed to nevirapine for prevention 
of mother to child HIV transmission, and those younger than 3 years, in whom 
efavirenz cannot be used. In young children, there is very little data about the 
pharmacokinetics of lopinavir and ritonavir when co-administered with 
rifampicin-based ATT. In Paper I, the pharmacokinetics of lopinavir using an 
integrated population model was described based on two studies evaluating 
lopinavir and ritonavir concentrations in children with and without tuberculosis in 
order to predict the optimal dose of LPV/r (in a 4:1 ratio) in young children treated 
with a rifampicin-based regimen.  
 
Lopinavir target trough concentrations (>1 mg/L) were achieved in the control 
group who received standard doses of LPV/r without rifampicin). In children 
concurrently administered rifampicin-based ATT, ‘super-boosted’ lopinavir almost 
always achieved adequate trough concentrations of lopinavir, but the strategy 
using doubled doses of LPV/r failed. Simulations from this model indicated that, 
using LPV/r oral solution twice daily, lopinavir doses would need to be increased 
dramatically during ATT, especially in children with lower body weights. For 
children weighing 3.0-5.9 kg, the lopinavir dose needed to attain the target would 
be 52 mg/kg 12 hourly, which considerably exceeds the doses used in clinical 
practice and could lead to the appearance of adverse events. High dose of ritonavir 
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is link to toxicity and consequently, an 8 hourly dosage regimen was investigated 
to reduce doses, and indeed this thrice-daily approach would require, in children 
weighing 3.0-5.9 kg, only 27 mg/kg (daily total of 81 mg/kg compared to 104 
mg/kg for twice daily dosing). The total daily doses required to maintain 
therapeutic lopinavir concentrations were lower using the 8 hourly doses. The 5
th
 
percentiles of simulated lopinavir concentrations using the original and the 
proposed dosage regimens in a typical patient (the patient who has a median age 
and median body weight) when lopinavir/ritonavir was given as standard ratio 4:1 
are presented in Figure 4.1. The predicted 95
th
 percentile of lopinavir trough 
concentrations for the 8 hourly approach is 15.8 (5.61-31.5), 12.4 (5.2-24.2), 12.6 
(5.7-25.8), 9.5 (5.1-16.6) mg/L for children weighing 3.0-5.9, 6.0-9.9, 10.0-13.9, 
14.0-19.9 kg respectively. These values are lower than those predicted trough 
concentrations for 12 hourly doses of super-boosted lopinavir: 22.2 (8.3-41.7), 
14.6 (6.2-28.3), 13.3 (5.9-26.3), 10.9 (5.9-23.2) respectively. 
 
 
Figure 4.1 The influence of ritonavir concentrations on the oral clearance of lopinavir 
(The x axis is time after dose, the left y axis is lopinavir clearance, and the right y axis is 
ritonavir concentration). 
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The bioavailability of lopinavir was estimated considering the effects of both 
rifampicin and ritonavir. This model predicts that AUC to lopinavir would drop by 
83.2% if ATT was concomitantly given without any further dose adjustments. On 
the other hand, it increased by 2.1% for each mg/kg of ritonavir added to the dose. 
Even though the relationship between ritonavir dose and bioavailability is 
probably quite complicated, in this model it was described using a linear 
proportionality. This choice was compelled by the limited range of ritonavir doses 
available in the dataset, and should not be used too far outside the tested range. It 
is expected that it to provide reasonable predictions for our purposes. During ATT, 
the relative bioavailability of lopinavir was reduced to 22.6% of the reference in 
children receiving twice the usual dose of LPV/r, while for children given 
‘super-boosted’ lopinavir this value almost doubled reaching 40.5%. IOV in ka of 
lopinavir was significant in the model whereas IIV in lopinavir ka was not 
supported by the data, pointing towards a greater relevance of occasion- rather 
than subject-specific changes during the absorption phase.  
 
The typical oral clearance of ritonavir when concurrently administered with 
rifampicin was 19.1 L/h, an increase of about 50% compared to the value 
estimated without ATT. This model is the first to describe the dynamic effect of 
ritonavir concentrations on the clearance of lopinavir in children using an 
integrated model. The EC50 was estimated to be 0.0519 mg/L, which is a low value 
when compared to normally achieved ritonavir concentrations which supports the 
potency of ritonavir as an inhibitor. In Figure 4.1, the change of lopinavir oral 
clearance due to ritonavir concentrations can be seen for each dosing strategy.  
 
Body weight was introduced as allometric scaling for oral clearance and volume of 
distribution of both lopinavir and ritonavir which is in agreement with previous 
studies in children 
16,138
. Jullien et al 
161
 observed a 39% increase in oral clearance 
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of lopinavir after the age of 12 years for boys. The age range in this dataset (6 
months to 4.5 years) is narrow and could not detect the influence from age and 
gender. This narrow age might explain why age and gender were not significant 
covariates in this model. Development of expression of CYP450 enzymes is 
profoundly affected by age. Distinct patterns of development of isoform-specific 
CYP expression have been found after birth. CYP3A7 is the predominant CYP 
isoform enzyme expressed in fetal hepatocytes and its expression attains a peak 
shortly after birth and then diminishes rapidly to levels that are undetectable in 
most adults. The clearance of carbamzaepine, which is largely dependent on 
CYP3A4, is greater in children than in adults 
84
. Phenytoin metabolism is not 
attatining saturation until approximately 10 days of postnatal age, demonstrating 
the developmental attainment of CYP2C9 activity. A maturation model was not 
supported by this dataset, probably due to lack of data in children below 1 year of 
age 
174
 since most data of this study is above 1 year though the youngest is 6 
mohths. This model could not be used to confidently predict the doses of LPV/r 
achieving the target concentrations beyond the range of the available data. 
Moreover, the pharmacokinetics, efficacy, safety and feasibility of the 8 hourly 
dosing approach needs to be evaluated prospectively in children. 
 
2. Pharmacokinetics of lopinavir and ritonavir when 
co-administered rifampicin in adults 
In Paper II, an integrated population pharmacokinetic model is reported, which 
includes covariate effects and describes the complicated induction and inhibition 
interactions between lopinavir, ritonavir, and rifampicin. The diurnal variation of 
lopinavir and ritonavir concentrations that were observed is explained. Finally, 
previous reported findings have been extended that double dose LPV/r counteracts 
the inducing effect of rifampicin to predict alternative dose regimens of LPV/r for 
low and high weight patients. 
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As shown by La Porte et al. 
12
, either doubling the dose of the capsule form of 
LPV/r or boosting LPV/r with additional ritonavir (such that the ratio of 
lopinavir/ritonavir=1) can sufficiently counteract the effect of rifampicin induction. 
Doubling the dose of LPV/r is more practical to implement, and may be associated 
with less hepatotoxicity than ritonavir boosting. However increased doses of 
LPV/r appear to be poorly tolerated in healthy volunteers given rifampicin 
12, 125
. 
As noncompartment analysis reported by Decloedt et al. 
124
, doubling the dose of 
the tablet form of LPV/r achieved adequate trough concentrations of lopinavir 
during rifampicin coadministraton was found and was better tolerated in HIV 
infected individuals established on a LPV/r antiretroviral regimen.  
 
Previous studies have reported single compartmental elimination kinetics for 
ritonavir 
162,175–177
. However, possibly because of the rich sampling schedule used 
in this study, a two-compartment model was more appropriate to describe the 
kinetics in data of this study. The OFV drop of about 100 points and the 
improvement in the fit of the individual plots supported the inclusion of a 
peripheral compartment. A transit compartment absorption model described the 
delay in absorption better than a model using a lag-time. Dickinson et al. 
178
 
recently reported a sequential population pharmacokinetic model for lopinavir and 
ritonavir in healthy volunteers. Their model did not involve rifampicin-based 
antituberculosis treatment.  
 
Full induction of drug-metabolising enzymes by rifampicin has been thought to be 
reached about one week after starting daily doses of rifampicin 
67
. Hence in this 
study blood samples were taken one week after each dose adjustment. A recent 
report amongst tuberculosis patients started on a rifampicin-containing regimen 
suggests that autoinduction of rifampicin metabolism may be incomplete after 7 
days (the half-life of the induction process was estimated to 6-8 days) 
168,179
. 
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However, as autoinduction approached maximal levels (~85% of total) after 2 
weeks, near full induction should have been achieved when patients in this study 
underwent pharmacokinetic evaluation on 1.5 and 2 times the standard dose of 
LPV/r with rifampicin. Besides the effect of rifampicin, the relative bioavailability 
of ritonavir was found to be influenced by its own dose. When standard doses of 
ritonavir (100 mg) were given with rifampicin, the relative bioavailability of 
ritonavir was 55.0%. This increased to 77.3% and 99.6% when 1.5 times, and 
doubled doses, respectively, were given. Therefore the dose escalation results in a 
more than proportional increase in ritonavir plasma concentrations, which may 
also lead to a stronger inhibition effect. This effect of ritonavir dose on its 
bioavailability might be explained by saturation of first pass metabolism. 
Moreover, as ritonavir is an inhibitor and a substrate of P-gp 
175
, it could inhibit its 
own efflux from enterocytes and hepatocytes. . 
 
The model estimated a value of 37.9 L/h for lopinavir CL/F when no ritonavir 
effect is present, but it should be kept in mind that this value is only an 
extrapolation, since lopinavir was never given without ritonavir. Figure 4.2 depicts 
the dynamic effect between ritonavir concentrations and lopinavir CL/F in a 
typical patient given different dose regimens, and can be used to provide real-life 
values of lopinavir CL/F when the two drugs are administered concomitantly, as is 
always the case during treatment. The sigmoidal inhibition model which was 
finally selected estimates both a very high value of Emax (95%) and a low EC50 
(0.04 mg/L). This points towards the high inhibitory potency of ritonavir at a low 
concentration. Ritonavir is thought to be an irreversible inhibitor 
180
, but Ernest et 
al. reported that reversible mechanisms are also involved 
21
. Like a previous model, 
this model did not support irreversible inhibition 
162,178
.   
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Figure 4.2. The influence of ritonavir concentrations (indicated in black) on the oral 
clearance of lopinavir (grey) in a typical patient. (LPV/r: lopinavir/ritonavir; rif: 
rifampicin) 
 
Body size was the only covariate found to have a significant effect in this model, 
and it was implemented through allometric scaling. For both lopinavir and 
ritonavir, fat free mass was used to scale CL/F, while total body weight was better 
suited for V/F. Since fat tissue normally contributes little to metabolism (fat 
weight fraction estimat d 0.001), fat free mass is expected to be a better predictor 
for CL/F when there are wide variations in body composition 
169
. This was the 
case for the cohort of subjects of this study, in which the BMI ranged from 17.4 to 
41.4 kg/m
2
. On the other hand, fat contributes to V/F for lipophilic drugs like 
lopinavir and ritonavir. Jullien et al.
161
  found CL/F of lopinavir to be related to 
age, sex, body weight, while V/F was related to body weight in children younger 
than 18 years-old. In this study, sex did not explain variability after inclusion of fat 
free mass. However, as few patients were male (3/21), it cannot exclude an 
independent effect of sex. 
 
In this study, median C0 concentrations were higher than C12. Similarly, 
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Heeswijket al. 
181
 reported that some C0 concentrations were higher than C12 
trough concentrations of lopinavir in HIV infected patients, but the effect did not 
reach statistical significance. Robbin et al. 
123
 also found diurnal variation in 
lopinavir pharmacokinetics, with higher concentrations in the morning than in the 
evening. They attributed this phenomenon to reduced hepatic blood flow during 
sleep or to change in plasma lipid concentrations during the overnight fast, which 
may alter the rate of drug absorption or clearance. This pattern of diurnal variation 
has been identified by other investigators for ritonavir and other protease inhibitors 
74,176,182,183
. Since in this study patients received a meal before the evening dose 
was taken, while the morning dose was taken after a 10 hour fast, food could be a 
possible explanation for this kind of variation. It was found in this study that 
lopinavir bioavailability was increased by 42.0% after the evening dose, which is 
in agreement with a study by Awnlet al. 
184
, who found that moderate fat content 
food increased the AUC of lopinavir from 76.5 to 97.1 μg.h/mL (a 26.9% 
increase).The difference between morning and evening trough concentrations in 
subjects of this study was more pronounced than that reported by Awnl et al., 
which indicates the higher C0 concentrations are unlikely to be entirely explained 
by a food effect. Besides the difference detected in lopinavir and ritonavir 
bioavailability, lopinavir and ritonavir oral clearance was found to be slower 
overnight compared to that following the morning dose (a decreased of 32.7% for 
lopinavir). Moreover, one may speculate that other effects play a role, e.g. in this 
study it cannot exclude an absorption interaction between rifampicin (which was 
given with the morning dose) and LPV/r.  
 
Guidelines for therapeutic drug monitoring recommend a lopinavir trough 
concentration >1 mg/L for patients who are naïve to protease inhibitors 
185
. For 
practical reasons, morning trough concentrations are usually used for therapeutic 
drug monitoring studies linking antiviral effect to antiretroviral concentrations 
12124,182,183
. In this study, all patients given 800/200 mg LPV/r with rifampicin 
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co-administration achieved this target. Therefore, 800/200 mg LPV/r is sufficient 
for most patients during rifampicin-based ATT, including patients weighing >110 
kg. For patients with body weight below 50 kg, 600/150 mg LPV/r is sufficient to 
maintain lopinavir C0 concentrations above the target in 95% of subjects during 
rifampicin treatment. In contrast, it has previously been reported that doubling the 
dose of LPV/r oral solution in young children failed to achieve target 
concentrations 
186
. Therefore, further research is necessary to elucidate the reasons 
underlying this difference in the pharmacokinetics between children and adults.  
 
3. Comparison of pharmacokinetics of lopinavir and ritonavir 
co-administration with rifampicin-based antituberculosis 
treatment between children and adults 
A population model was developed to describe the pharmacokinetics of lopinavir 
and ritonavir and the drug-drug interactions between lopinavir, ritonavir and 
rifampicin in children and adults. The model demonstrated important differences 
in the effects of rifampicin, or rifampicin-based antituberculosis treatment, 
between adults and children and provides evidence that drug-drug interaction 
studies in adults should not be used to predict the magnitude of drug-drug 
interactions in children unless there is good mechanistic understanding of the 
processes involved. 
 
The application of allometric scaling for body weight on oral clearance and 
volume of distribution accounted for the different body size of the study 
populations, thus allowing comparison of the pharmacokinetic parameters between 
children and adults. The volume of distribution of lopinavir and ritonavir were 
similar in children and adults after the implementation of allometric scaling. 
However, for both lopinavir and ritonavir, oral clearance was lower in children 
than in adults when size differences have been taken into account. This finding 
Un
ive
rsi
ty 
of 
 C
ap
e T
ow
n
Chapter 4                                                Discussion 
 
 
148 
 
could be explained by incomplete maturation of clearance in the children. The 
number of children aged below 1 year was 12 (16%) and 35 children (52%) were 
between 1 and 2 years old. Holford reported that maturation of hepatic and renal 
clearance of drugs is virtually complete within 2 years of birth, of which the half 
value is nearly achieved during the first year 
187
. Hence, although the maturation 
model was not supported by data of this study, probably due to insufficient data in 
children under 1 year, full maturation of enzymes and transporters may not have 
been achieved in some young children. Moreover, lopinavir and ritonavir are 
metabolized mainly by CYP3A4, which is profoundly induced by postnatal 
environmental factors 
188
; age-related changes in the composition and amount of 
circulating plasma proteins may influence the plasma free drug fractions, thus 
affecting clearance, of highly bound drugs like lopinavir and ritonavir 
83
; and, in 
adults, blood pressure tends to be higher, which may lead to increased hepatic 
blood flow 
189
 and then may result in higher clearance than in children.  
 
The model predicted lower bioavailability of lopinavir and markedly reduced 
bioavailability of ritonavir in children compared to adults. In children, given 
standard doses of LPV/r without rifampicin co-administration, the bioavailability 
of ritonavir was calculated to be 24.5% of that in adults on a 400/100 mg dose of 
LPV/r (Table 3.3.). Meanwhile, the clearance of ritonavir of children was 
estimated about 61% of that of adults after considering size differences. Therefore, 
this model predicted concentrations of ritonavir in children much lower than those 
in adults, which is consistent with the observed concentrations of ritonavir (Figure 
3.3). Slower gastric emptying and reduced intestinal motility in children 
84
, may 
result in reduced bioavailability. Furthermore, differences in the enzymes and 
transporters expressed in enterocytes and hepatocytes resulting in altered affinity 
for the drug substrates may contribute to different bioavailability between adults 
and children. Differences in the disease status between the adult and paediatric 
study cohorts could also play a role: The children had recently been diagnosed 
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with tuberculosis, and tuberculosis could reduce drug absorption 
190
, whereas the 
adults were volunteers established on antiretroviral treatment and generally in a 
good state of health. 
 
Differences in the formulation of LPV/r used in adults and children respectively 
are likely to have contributed to altered bioavailability. In this study, oral solution 
was administered to children and tablet to adults. The mean AUC of lopinavir was 
22% lower for the LPV/r oral solution relative to the capsule formulation under 
fasting conditions 
22
. Compared to capsule, following a single dose of LPV/r 
400/100 mg, the tablet provides similar lopinavir AUC 
184
. Moreover, the LPV/r 
oral solution has poor palatability, and if the children spat out part of their dose, 
lower model predictions of bioavailability would result. However, the morning 
dose of LPV/r on the day of pharmacokinetic evaluation was observed by study 
personnel and no failure to ingest the complete dose was reported. Also, 
bioavailability of ritonavir seems to have been disproportionately affected, 
suggesting that other factors play a role. Compared to adults, smaller ka of 
lopinavir and longer MTT of ritonavir in children were found in this study, which 
is consistent with the possible reasons that described above, such as slower gastric 
emptying and motility in children, as well as formulation factors. 
 
The induction of oral clearance of lopinavir and ritonavir by rifampicin was 
greater in adults than in children (OFV decreased about 10 points). In contrast, the 
effect of antituberculosis treatment on the bioavailability of lopinavir and ritonavir 
was greater in children than was the effect of rifampicin in adults (OFV decreased 
about 30 points). Rifampicin potently induces the expression of CYP3A4 and P-gp 
both in the liver and in the intestine 
67
 
191
. Whether CYP3A4 and p-glycoprotein in 
the intestine and liver, respectively, have altered susceptibility in children to 
induction by PXR-activators such as rifampicin is unknown. The children in this 
study may not have attained full maturation of hepatic CYP3A4 and P-gp and this 
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might account for a smaller effect of rifampicin on clearance than that found in 
adults. Moreover, receptor expression may be different in tuberculosis patients 
192
, 
and therefore autoinduction of rifampicin may display diverse between children 
and adults. However, the potential role of isoniazid which was part of the 
antituberculosis treatment given to the children and is an inhibitor of CYP3A4 and 
CYP2D6 
29,105
, should be considered. It would counteract the rifampicin induction 
effect in some degree. 
 
Higher ritonavir doses were associated with increased bioavailability of ritonavir. 
As ritonavir is an inhibitor and a substrate of Pgp 
175
, it could inhibit its own efflux 
from enterocytes and hepatocytes, thus increasing its bioavailability. Increased 
doses of ritonavir improved the bioavailability of lopinavir in children, but this 
effect was not supported by data in adults in this study. 
 
Potential weaknesses in this study design include bias in the distribution of certain 
characteristics. Different dose strategies were given in adults and children in this 
study and rifampicin was given as part of antituberculosis treatment in children 
and therefore the rifampicin induction effect may be influenced by other 
comedications. Most of the adult patients were females (86%). Sex may affect the 
pharmacokinetics of lopinavir and ritonavir 
193
, and body composition, which 
accounts for sex as well, may be important for adults, especially for some obese 
ones since fat can only contribute to volume but clearance. Food considerably 
affects the bioavailability of lopinavir and ritonavir 
49
, and differences in study 
design with regard to control of food intake could have affected this findings. 
Lastly, although the treatment doses immediately before pharmacokinetic 
evaluation were carefully observed, differences in adherence to prior doses of 
antiretroviral treatment could contribute to the divergent findings between children 
and adults. 
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In conclusion, the lower bioavailability of lopinavir and ritonavir, as well as the 
more potent effect of rifampicin-based antituberculosis treatment on 
bioavailability in children were the main findings of this study, which sought to 
explain the failure of double dose LPV/r to achieve adequate concentrations in 
children on antituberculosis treatment. Ritonavir dose had an important influence 
on the bioavailability of lopinavir and ritonavir. Prospective studies are needed to 
confirm the role formulation factors as well as age and sex related changes in 
enzyme and transporter activity and susceptibility to induction, food and disease 
effects, different dose regimens and the role of concomitant drugs on the 
pharmacokinetics of lopinavir and ritonavir when co-administrated with rifampicin 
in children and adults. 
 
4. Adherence evaluation using lamivudine therapeutic monitoring 
concentrations 
In Paper IV, a population pharmacokinetic model was reported, which includes 
covariate effects and describes the pharmacokinetic variability of lamivudine in 
young children. The diurnal variation of observed lamivudine concentrations was 
explained. Finally, cutoff values for evaluation of adherence to prior doses were 
proposed using lamivudine concentration drug monitoring. 
 
A two-compartment model best described the pharmacokinetics of lamivudine in 
this study. One- or two- or three-compartment pharmacokinetic structure models 
were reported by previous studies. 
59–64, 197
 Most of these studies reported a half 
life of 1-3 hours for lamivudine, while some of studies which measured 
lamivudine concentrations to 48 hours after dosing observed a half life of 
approximately 12 hours. The longer half life may reflect capture of redistribution 
from a slowly equilibrating tissue when an extended sampling period was used. 
56
 
The typical value of the half life in this study was 1.7 h, which approximates that 
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reported from most studies. The delayed onset of absorption was modeled using a 
series of transit compartments, which was also reported by Van der Walt et al. 
196
  
 
Both body weight and age were found to have a significant effect in this model. 
Body weight was accounted for through allometric scaling for both clearance and 
volume.  Bouazza et al. 
131
 also used allometric scaling of body weight for 
clearance and volume in 2-14 year old children, but they did not find any 
additional effect of age on clearance. Moote et al. 
57
 reported that body weight and 
glomerular filtration rate (GFR) influence clearance, but not volume, in adults. 
Tremoulet et al. 
195
 found only age as significant covariate in infants without 
accounting for body weight. In this study, different maturation models were tested 
but there was no statistically significant difference among them. Therefore, a 
sigmoidal model was opted, of which results in physiologically plausible 
predictions when extrapolated outside the observed age range. The age at which 
half of the maturation of clearance process is reached was about 4 months of 
postnatal age, compared to around 2 months described by data of Tremoulet et al 
195
. Both studies indicate that half of the full maturation of lamivudine clearance is 
achieved at a very young age, which may explain why Bouazza et al. 
131
, analyzing 
slightly older children, did not detect such effect. Burger et al. 
133
 reported higher 
CL/F/kg and V/F/kg children under 7 years than in older children. This result was 
not disagreement to the finding because in this model the CL/F was adjusted for 
body weight using allometric scaling, which in part accounted for the effect of 
heavier children having reduced CL/F/kg, hence CL/F/kg decreased with 
increasing size. L’homme et al. 197 investigated the pharmacokinetics of 
lamivudine in African children. They reported mean AUC12h values similar to that 
in the children mean (AUC12h = 5.60 mg.h/L) in children weighing 3-20 kg.  
 
Diurnal variations of lamivudine were investigated in this model, which is the first 
time to be reported. From Figure 1, median C0 concentrations were slightly higher 
Un
ive
rsi
ty 
of 
 C
ap
e T
ow
n
Chapter 4                                                Discussion 
 
 
153 
 
than C12. The clearance of lamivudine was found 16.7% lower overnight. This 
diurnal variation could not be explained by absorption difference because 
bioavailability was not found to change significantly after an evening dose 
compared to a morning dose. Hansen et al. 
198
 reported lower blood pressure 
during evening. Skotnicka et al. 
199
 reviewed diurnal variations of renal activity in 
livestock and indicated most renal activity had maximum values during the day 
and minimum values at night. The slower clearance may be related to decreased 
blood pressure and GFR overnight; but more evidence is needed to support this 
conjecture.  
 
In order to compare this model to others, simulations were performed to compare 
this model to Bouazza et al 
131
 and Tremoulet et al 
195
. This model could describe 
the concentrations in the typical individual for the model reported by Bouazza et al, 
but does not fit for the data used by Tremoulet et al. This may be due to different 
populations or study designs or due to ritonavir inhibition effect on transporters 
200
. 
 
The model built in this thesis has very good prediction property and can be used to 
investigate drug concentrations or exposure for different dose regimens. However, 
there is not enough information to support the lower exposure or concentration is 
related to a reduced virological activity of lamivudine-containing HAART regimen 
in children. Furthermore, lamivudine plasma concentrations can only be 
considered as a limited marker of drug exposure as it is the intracellular 
lamivudine triphosphate metabolite that becomes pharmacologically active 
201
. 
Therefore, it is difficult to investigate optimal dose regimens using plasma 
pharmacokinetic models. On the other hand, adherence has been shown to be 
directly related to clinical and virological outcomes of antiretroviral therapy. 
Higher levels of treatment adherence are associated with improved virological and 
clinical responses. As low variability of lamivudine clearance (only 8.2%) was 
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found, the proposed model has good predictive properties and can be used to 
evaluate adherence to the morning dose prior to a clinic visit. Furthermore, since 
companion antiretroviral drugs are usually administered at the same time, 
lamivudine concentrations can be helpful for interpretation of therapeutic drug 
monitoring results for other drugs in the regimen, like protease inhibitors and 
nonnucleoside reverse transcriptase inhibitors, which have greater 
pharmacokinetic variability. 
 
Lamivudine concentration ranges for children with different ages were predicted 
using this model. As shown in Figure 3.4.13, 6 month-old children are expected to 
have higher concentrations compared to older children. During clinic-based 
therapeutic drug monitoring, pre-dose samples (represented by this 12 h 
concentration), or samples taken at a routine clinic visit (represented by this 
concentration 4 h after the morning dose) are commonly used. The visual 
predictive check plots (Figure 3.4.10), 4 h and 12 h after dosing show narrow 
variability, which is rather predictable. Therefore different percentile of cutoff 
values 4 h and 12 h after dosing of lamivudine are proposed as indicators of 
adherence. For patients ranging 6 months to 5 years, 5
th
 percentile of cutoff values 
for 4 h and 12 h after dosing of 263.6-372.5 and 28.6-62.0 ng/mL respectively. 
The simulations in this study demonstrate that almost all children who skip the 
morning dose on the day of their clinic visit, or the morning dose and the dose of 
the previous evening will have lamivudine concentrations below the proposed 5
th
 
percentile cutoff value at 4 h after the morning dose time. Hence, lamivudine 
concentrations measured in a clinic visit sample can be compared to predicted 5
th
 
percentile reference values, and when lower, they are likely to be related to poor 
adherence to the last dose. This marker of short term adherence is potentially 
useful for interpretation of therapeutic drug monitoring results of PIs and NNRTIs 
and further studies are needed to evaluate how it relates to virological outcome. 
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Ideas about prospective work and limitations 
 
The primary important aim of this thesis was to investigate pharmacokinetics of 
PI-based antiretrovirals (lopinavir, ritonavir and lamivudine), including the 
complicated drug-drug interactions with rifampicin. The secondary important aim 
was to optimize the dose regimens of PI-based antiretrovirals in combination with 
rifampicin. In this thesis, the population pharmacokinetic models of lopinavir, 
ritonavir and lamivudine have been built to describe thoroughly the 
pharmacokinetics of these drugs, as well as the drug-drug interactions between 
rifampicin-based ATT in different populations. The models also investigated the 
effect of patient and treatment factors on the pharmacokinetics of these drugs. 
Different variability, including interindividual, interoccasion and residual 
variability, has been evaluated. The models can be used as a prior to predict drug 
concentrations or exposures and therefore to provide a strong reference for dose 
regimen rationale when PI-based antiretrovirals in combination with rifampicin are 
given. But due to the model being developed based on specific population and 
study design, it need to be cautious when apply the models to other populations. A 
study can be designed in future to investigate whether this models can be 
expanded to other populations. External validation was not applied for the models 
in this thesis due to limit data source. It would be a more powerful evidence to 
confirm the models built in this thesis. 
 
Given this studies were based on a limited number of patients, more prospective 
studies are needed to verify the pharmacokinetic charactercteristics, safety and 
efficacy of antiretroviral treatment in a large number of patients. In silico 
predictions, such as thrice daily dosing approach with LPV/r for children during 
TB treatment, need to be confirmed in clinical studies. Wide age range of children 
can be chosen in futher study to investigate pharmacokinetics and drug-drug 
interactions. 
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Another important aim of this thesis was to compare pharmacokinetic differences 
between children and adults. The first comparison between pharmacokinetics of 
lopinavir and ritonavir with rifampicin-based ATT coadministration in children 
and adults was investigated in this thesis. A further meticulous study can be 
designed to exclude other factors might influence the conclusion, such as dose, 
formulations, companion TB drugs, disease status. Disease progress in patients 
may influence pharmacokinetics of lopinavir and ritonavir, and might affect 
rifampicin induction as well. In future, if possible, the disease progress could be 
considered together with pharmacokinetic model, in which new findings might be 
found. 
 
The last important aim of this thesis was to investigate reference drug 
concentrations for adherence evaluation. Reference lamivudine concentrations 
were investigated for adherence evaluation based on the population 
pharmacokinetic model built in this thesis. However, besides poor adherence, low 
concentrations of patients can be related to other factors, such as give food 
concurrently with drugs. Therefore, in the future, a study can be developed to 
further confirm the reference values proposed by this thesis. 
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Conclusions 
 
In this thesis, pharmacometric models with improved prediction of antiretroviral 
agents with co-administration of rifampicin-based ATT were developed. A 
population pharmacokinetic model was built to simultaneously describe the 
pharmacokinetics of lopinavir and ritonavir, capturing the complicated drug-drug 
interactions between lopinavir, ritonavir and rifampicin in young children and 
adults respectively. The models describe clearly the influence on the lopinavir 
concentrations of induction by rifampicin and inhibition by ritonavir. Considering 
the major concern of administration of ART and ATT concurrently is 
sub-therapeutic drug concentrations due to drug-drug interaction, the model has 
good prediction properties and can be used to investigate optimal dose regimens 
when lopinavir/ritonavir is co-administered with rifampicin-based ATT.   
 
Allometric scaling of body size, including body weight and fat free mass, was used 
to scale oral clearance and volume of distribution of both lopinavir and ritonavir in 
young children and adults. Hence, children or adults with low body weight 
receiving rifampicin-based ATT require higher mg/kg doses of lopinavir/ritonavir 
(no matter in 4:1 or 1:1 ratio) than heavy patients. Oral clearance of lopinavir was 
inhibited dynamically by ritonavir concentrations in a sigmoid relationship. The 
model was used to predict the doses of LPV/r needed to maintain therapeutic 
concentrations of lopinavir during ATT and suggests that an 8 hourly dosing 
regimen should be evaluated in young children. In adults, doubling the dose of 
LPV/r is required for most patients during rifampicin-based ATT, but for patients 
weighing less than 50 kg, 600/150 mg LPV/r can maintain lopinavir trough 
concentrations above the recommended minimum concentration. The higher 
concentrations detected in the morning trough concentrations compared with the 
evening troughs, are explained by both higher bioavailability due to a food effect 
(the evening dose was taken with a meal and the morning dose when fasting) and 
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lower clearance overnight.  
 
Double dose strategy can attain target lopinavir concentration in adults, but it 
failed in most of young children when co-administration of rifampicin-based ATT. 
A more comprehensive population pharmacokinetic model was developed to 
compare the difference of pharmacokinetics of lopinavir and ritonavir in children 
and adults. For both lopinavir and ritonavir, a lower bioavailability of children was 
found compare to adults, and a stronger induction effect of rifampicin on the 
bioavailability was detected in children. The low bioavailability in children might 
be the main reason to explain the different behaviors of double dose strategy in 
children and adults. Ritonavir dose will increase the bioavailability of lopinavir or 
ritonavir, but this effect was also found different in children and adults. The model 
elucidates thoroughly, in children and adults, the pharmacokinetics of lopinavir 
and ritonavir, and accounts for drug-drug interaction with rifampicin. This model 
has extended the available knowledge and would helpful to improve the clinical 
outcome. 
 
Lamivudine was used to develop a population model to predict reference 
concentrations for adherence evaluation. The model has very good prediction 
properties and can also be used to simulate an alternative dose regimen. Compared 
to lopinavir, lamivudine is more predictable due to low variability and less 
drug-drug interactions occurs. The patient whose concentrations are lower than the 
reference values investigated in this theis is high likely to behave poor adherence. 
The model has provided an optional approach to evaluate adherence of patients in 
order to enhance antiretroviral treatment effect and help for interpretation of 
therapeutic drug monitoring results of PIs and NNRTIs. 
 
In conclusion, population pharmacokinetic models for antiretroviral agents 
(lopinavir, ritonavir and lamivudine) co-administration with rifampicin-based ATT 
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were developed. Those models are strong basis for the dose regimen rationale 
when concomitant with ART and ATT in subpopulations or individual, as well as 
in adherence evaluation. The developed models and methods may also 
demonstrate principles in study of treatment improvement in HIV/TB patients and 
could be useful for pharmacometric community. 
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I. Final model control file (Paper I) 
$PROBLEM  final children model,update  ;no problem data|no BQL 
$INPUT ID SDID=DROP DMID=DROP TB RATI STUD=DROP GROU=DROP 
OCC REP=DROP DAT1=DROP TIME AMT DVID ORDV=DROP DV BQL 
MDV EVID CMT SEX=DROP AGE=DROP WT HT=DROP BSA=DROP 
HB=DROP ALB=DROP ALT=DROP SS=DROP II=DROP PROB WRON RDS 
RDSW  
$DATA Dataset_fulldose_RDOSE.csv IGNORE=# 
IGNORE(DVID.EQ.3,PROB.EQ.1,BQL.EQ.1,WRON.EQ.1)  ;no problem 
data,no spurious predose 
$SUBROUTINE ADVAN6 TRANS1 TOL=4  
$MODEL   
COMP(LPVDOSE)   ;1 LPV DOSE 
COMP(LPVOBS)    ;2 LPV CENTRAL 
COMP(RTVDOSE)   ;3 RTV DOSE 
COMP(RTVOBS)    ;4 RTV CENTRAL 
COMP(TRANS)     ;5 
COMP(TRANS)     ;6 
COMP(TRANS)     ;7 
COMP(TRANS)     ;8 
COMP(TRANS)     ;9 
COMP(TRANS)     ;10 
COMP(TRANS)     ;11 
COMP(TRANS)     ;12 
COMP(TRANS)     ;13 
COMP(ABS)       ;14 
 
$PK 
; ------------LPV MODEL------------------ 
  TVCLL= THETA(1)*(WT/10)**0.75 
      TVVL  = THETA(2)*(WT/10) 
      TVKAL = THETA(3) 
 TVKL = TVCLL/TVVL 
 SLP = THETA(4) 
 RIF = 0 
 IF (RATI.NE.0) RIF=THETA(5) 
     TVF1=1+(RDSW-3)*SLP-RIF 
    ;IF (RATI.EQ.1) TVF1=THETA(4) 
    ;IF (RATI.EQ.2) TVF1=THETA(5) 
     
    CLL    = TVCLL*EXP(ETA(1)) 
    VL     = TVVL*EXP(ETA(3)) 
KAL1=0 
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    KAL2=0 
    IF (OCC.EQ.1) KAL1=1 
    IF (OCC.EQ.2) KAL2=1  
 BOVM = KAL1*ETA(4)+ KAL2*ETA(5) 
    KAL    = TVKAL*EXP(BOVM) 
  
OC1L=0 
    OC2L=0 
    IF (OCC.EQ.1) OC1L=1 
    IF (OCC.EQ.2) OC2L=1  
 BOVL = OC1L*ETA(6)+ OC2L*ETA(7) 
 F1 = TVF1*EXP(BOVL) 
 K12 = KAL 
 K20 = CLL/VL 
 S2 = VL 
;----------RTV MODEL-------------------    
 IF (TB.EQ.1) THEN  
 TVCLR = THETA(6)*(WT/10)**0.75 
 ELSE 
 TVCLR = THETA(7)*(WT/10)**0.75 
    ENDIF 
  
     TVVR  = THETA(8)*(WT/10) 
     TVKAR = THETA(9) 
  TVK = TVCLR/TVVR 
  TVMTT = THETA(10) 
  
OC1R=0 
    OC2R=0 
    IF (OCC.EQ.1) OC1R=1 
    IF (OCC.EQ.2) OC2R=1  
    BOVR = OC1R*ETA(8)+ OC2R*ETA(9) 
    CLR    = TVCLR*EXP(ETA(2))*EXP(BOVR)  
    VR     = TVVR*EXP(THETA(11)*ETA(2)) 
    KAR    = (TVK+TVKAR)*EXP(THETA(14)*BOVM)  
 MTTR1=0 
 MTTR2=0 
IF (OCC.EQ.1) MTTR1=1 
    IF (OCC.EQ.2) MTTR2=1  
    BOVT = MTTR1*ETA(10)+ MTTR2*ETA(11) 
MTT = TVMTT*EXP(BOVT) 
KTR=10/MTT 
   K35=KTR 
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    K56=KTR 
    K67=KTR 
    K78=KTR 
K89=KTR 
K910=KTR 
K1011=KTR 
K1112=KTR 
K1213=KTR 
K1314=KTR 
   K14T4=KAR 
   K40 = CLR/VR 
   S4 = VR 
 
;-----------EFFECT MODEL----------------- 
    EMAX = THETA(15)   
EC50 =THETA(16)*EXP(ETA(12))        
           
$DES 
C4 = A(4)/VR 
EFF = EMAX*C4/(EC50 + C4) 
DADT(1) = -KAL*A(1) 
DADT(2) = KAL*A(1)-K20*(1-EFF)*A(2) 
DADT(3) = -KTR*A(3) 
DADT(4) = KAR*A(14)-K40*A(4) 
DADT(5) = KTR*A(3)-KTR*A(5) 
DADT(6) = KTR*A(5)-KTR*A(6) 
DADT(7) = KTR*A(6)-KTR*A(7) 
DADT(8) = KTR*A(7)-KTR*A(8) 
DADT(9) = KTR*A(8)-KTR*A(9) 
DADT(10) = KTR*A(9)-KTR*A(10) 
DADT(11) = KTR*A(10)-KTR*A(11) 
DADT(12) = KTR*A(11)-KTR*A(12) 
DADT(13) = KTR*A(12)-KTR*A(13) 
DADT(14) = KTR*A(13)-KAR*A(14) 
$ERROR ;(OBSERVATIONS ONLY) 
   CP2 = A(2)/VL 
   CP4 = A(4)/VR 
   DEL=1E-6 
   PREDL = (A(2)/VL+DEL) 
   PREDR = (A(4)/VR+DEL) 
   IF(DVID.EQ.1)IPRED = LOG(PREDL) 
   IF(DVID.EQ.2)IPRED = LOG(PREDR) 
   IRES  = DV - IPRED  
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IF (DVID.EQ.1)  W =THETA(12)   ;LPV proportional error 
IF (DVID.EQ.2)  W =THETA(13)   ;RTV proportional error 
   IF (W.EQ.0) W = 1 
   IWRES = IRES/W 
IF (DVID.EQ.1) Y = IPRED + W*EPS(1) 
IF (DVID.EQ.2) Y = IPRED + W*EPS(2) 
AA1=A(1) 
AA3=A(3) 
AA15=A(15) 
ACL = K20*(1-EMAX*A(4)/VR/(EC50 + A(4)/VR))  
$THETA  
 (0,4.18194) ; 1   LPV CL 
 (0,11.6494) ; 2   LPV V 
 (0,0.742656) ; 3   LPV KA 
 0.0209982  ; 4   SLOPE 
 (0,0.832441) ; 5   LPV F1 3.5 RTV 
 (0,19.0592) ; 6   RTV CL ON WITH TB 
 (0,12.7679) ; 7   RTV CL ON CONTROL AND AFTER TB 
 (0,105.047) ; 8   RTV V 
 (0,2.30321) ; 9   RTV KA 
 (0,1.2786) ; 10  RTV MTT 
 (0,1.36432) ; 11  RTV Scale parameter of IIV CL-V 
 (0,0.303897) ; 12  LPV Proportional error 
 (0,0.33894) ; 13  RTV Proportional error 
 (0,1.65796) ; 14  Scale parameter of IOV RTVKA-LPVKA 
 0.9 FIX ; 15   EMAX 
 (0,0.0519067) ; 16   EC50 
$OMEGA  BLOCK(1) FIX 
 0  ; 1  IIV on LPV CL 
$OMEGA  BLOCK(1) 
 0.530957  ; 2  IIV on RTV CL 
$OMEGA  BLOCK(1) 
 0.321054  ; 3  IIV on LPV V 
$OMEGA  BLOCK(1) 
 0.579458  ; 4  IOV on LPV KA 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) 
 0.288538  ; 6  IOV on LPV F1 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) 
 0.172492  ; 8  IOV on RTV CL 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) 
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 0.0951473  ; 10 IOV on RTV MTT 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) FIX 
 0  ; 12  IIV on EC50 
$SIGMA  1.000000  FIX 
$SIGMA  1.000000  FIX 
$ESTIMATION PRINT=1 MAXEVALS=9999 MSFO=run11.msf 
METHOD=1 NOABORT 
$COVARIANCE PRINT=E  MATRIX=S 
$TABLE ID DVID TIME IPRED RES WRES IWRES DV CMT NOPRINT 
ONEHEADER                   FILE=sdtab11 
$TABLE ID TB RATI  OCC NOPRINT ONEHEADER                                         
FILE=catab11 
$TABLE ID WT NOPRINT ONEHEADER                                                  
FILE=cotab11 
$TABLE ID DVID CLL VL KAL F1 CLR VR KAR MTT EMAX EC50 ACL 
ETA1 ETA2 ETA3 ETA4 ETA5 ETA6 ETA7 ETA8 ETA9 ETA10 ETA11 ETA12 
NOPRINT  ONEHEADER FILE=patab11 
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II. Final model control file (Paper II) 
$PROBLEM run5,evening effect on F 
$INPUT ID SDID=DROP TERM WHAT=DROP ODAT=DROP OTIM=DROP 
TIME AMT DVID DV LNDV=DROP MDV EVID CMT SEX AGE WT HT ALT 
HB BQL RDW RTVTOT TB=DROP RATI=DROP RIF EVEN 
$DATA APK_PREDOSE_2.csv    IGNORE=#  ;   ;LPV-RTV data; no bql 
$SUBROUTINES ADVAN13 TRANS1 TOL=8 
$MODEL   
COMP(LPVDOSE)   ;1 LPV DOSE 
COMP(LPVOBS)    ;2 LPV CENTRAL 
COMP(RTVDOSE)   ;3 RTV DOSE 
COMP(RTVOBS)    ;4 RTV CENTRAL 
COMP(LPVPER)    ;5 RTV PERIPHIRAL 
$ABBREVIATED DERIV2=NO 
$PK 
"FIRST 
"     USE PRCOM_INT, ONLY: IMAX 
" IMAX=10000000 
;---TAD variatle; define only for plot 
TAD = TIME - 48   ;dose given at TAD=0 
TADD = TAD+1       ; dose given at TAD=1 
 
;---Code from Anderson & Holford 2009, page 33 [Drug Metab. Pharmacokinet. 
24 (1): 25?6 (2009)] 
IF (SEX.EQ.1) THEN  ; females 
WHSMAX=37.99 
WHS50=35.98 
ELSE        ;males 
WHSMAX=42.92 
WHS50=30.93 
ENDIF 
 
HTM2 = (HT/100)**2 
FFM = (WHSMAX*HTM2*WT)/(WHS50*HTM2+WT) 
 
;----Clearance 
CLFFAT  = THETA(17)                
NFMCL   = FFM + CLFFAT*(WT-FFM)  ;Total weight  
SCL     = (NFMCL/40)**(0.75)     ;CL scaled 
;----volume 
VFFAT  = THETA(18) 
NFMV   = FFM+VFFAT*(WT-FFM)  ;Total weight, 
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SV     = NFMV/65                  ;V scaled 
 
 ;-------IOV CODE-------------------    
IF (TERM.EQ.1) THEN 
 IOVFL = ETA(5) 
 IOVFR = ETA(13) 
 IOVKAL = ETA(21) 
 IOVCLR = ETA(29) 
 IOVCLL = ETA(37) 
 IOVRUV = ETA(45) 
 IOVMTT = ETA(53) 
ENDIF 
IF (TERM.EQ.2) THEN 
 IOVFL = ETA(6) 
 IOVFR = ETA(14) 
 IOVKAL = ETA(22) 
 IOVCLR = ETA(30) 
 IOVCLL = ETA(38) 
 IOVRUV = ETA(46) 
 IOVMTT = ETA(54) 
ENDIF 
IF (TERM.EQ.3) THEN 
 IOVFL = ETA(7) 
 IOVFR = ETA(15) 
 IOVKAL = ETA(23) 
 IOVCLR = ETA(31) 
 IOVCLL = ETA(39) 
 IOVRUV = ETA(47) 
 IOVMTT = ETA(55) 
ENDIF 
IF (TERM.EQ.4) THEN 
 IOVFL = ETA(8) 
 IOVFR = ETA(16) 
 IOVKAL = ETA(24) 
 IOVCLR = ETA(32) 
 IOVCLL = ETA(40) 
 IOVRUV = ETA(48) 
 IOVMTT = ETA(56) 
ENDIF 
IF (TERM.EQ.5) THEN 
 IOVFL = ETA(9) 
 IOVFR = ETA(17) 
 IOVKAL = ETA(25) 
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 IOVCLR = ETA(33) 
 IOVCLL = ETA(41) 
 IOVRUV = ETA(49) 
 IOVMTT = ETA(57) 
ENDIF 
IF (TERM.EQ.6) THEN 
 IOVFL = ETA(10) 
 IOVFR = ETA(18) 
 IOVKAL = ETA(26) 
 IOVCLR = ETA(34) 
 IOVCLL = ETA(42) 
 IOVRUV = ETA(50) 
 IOVMTT = ETA(58) 
ENDIF 
IF (TERM.EQ.7) THEN 
 IOVFL = ETA(11) 
 IOVFR = ETA(19) 
 IOVKAL = ETA(27) 
 IOVCLR = ETA(35) 
 IOVCLL = ETA(43) 
 IOVRUV = ETA(51) 
 IOVMTT = ETA(59) 
ENDIF 
IF (TERM.EQ.8) THEN 
 IOVFL = ETA(12) 
 IOVFR = ETA(20) 
 IOVKAL = ETA(28) 
 IOVCLR = ETA(36) 
 IOVCLL = ETA(44) 
 IOVRUV = ETA(52) 
 IOVMTT = ETA(60) 
ENDIF 
 
; INITIALIZATION 
A_0(1) = 0.0001 
A_0(2) = 0.0001 
A_0(3) = 0.0001 
A_0(4) = 0.0001 
A_0(5) = 0.0001 
; ------------LPV MODEL------------------ 
RIFCLL=1 
RIFBIOL=1 
EVECLL=1 
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EVEBIOL=1 
EVEKAL=1 
 
; Evening effect: FOOD + diunrnal variation 
IF (EVEN.EQ.1) THEN 
 EVECLL=THETA(24) 
 EVEBIOL=THETA(25) 
 EVEKAL=THETA(29) 
ENDIF 
; Rifampicin effect 
IF (RIF.EQ.1) THEN 
 RIFCLL=THETA(2) 
 RIFBIOL=THETA(5) 
ENDIF 
 
; The first theta is the values of morning fasted parameters 
TVCLL = THETA(1)*SCL*RIFCLL*EVECLL 
TVVL  = THETA(3)*SV 
TVKAL = THETA(4)*EVEKAL 
TVF1 = 1*RIFBIOL*EVEBIOL 
 
; BSV 
IIVCLL = ETA(1) 
IIVVL= ETA(2) 
IIVFL = ETA(62) 
 
CLL   = TVCLL*EXP(IIVCLL+IOVCLL) 
VL    = TVVL*EXP(IIVVL) 
KAL   = TVKAL*EXP(IOVKAL) 
F1    = TVF1*EXP(IOVFL+IIVFL) 
 
K20 = CLL/VL 
S2 = VL 
  
;----------RTV MODEL-------------------     
RIFCLR=1 
RIFBIOR=1 
EVECLR=1 
EVEBIOR=1 
EVEMTTR=1 
 
; Evening effect: FOOD + diunrnal variation 
IF (EVEN.EQ.1) THEN 
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 EVECLR=THETA(26) 
 EVEBIOR=THETA(27) 
 EVEMTTR=THETA(28) 
ENDIF 
 
; Rifampicin effect 
IF (RIF.EQ.1) THEN 
 RIFCLR=THETA(7) 
 RIFBIOR=THETA(10) 
ENDIF 
 
; RTV dose on RTV BIO 
SLP = THETA(23) 
RDBIOR=(1+SLP*(RTVTOT-100)/100) 
 
TVCLR = THETA(6)*SCL*EVECLR*RIFCLR 
TVVR  = THETA(8)*SV 
TVKAR = THETA(9) 
TVF3  = 1*RDBIOR*RIFBIOR*EVEBIOR 
TVMTT = THETA(11)*EVEMTTR 
TVQ   = THETA(12)*SCL 
TVV5  = THETA(13)*SV 
TVNN  = THETA(22) 
 
; BSV 
IIVCLR=ETA(3) 
IIVVR=ETA(4) 
IIVBIOR=ETA(61) 
  
; Parameters 
CLR  = TVCLR*EXP(IIVCLR+IOVCLR) 
VR   = TVVR*EXP(IIVVR) 
KAR  = TVKAR 
MTT = TVMTT*EXP(IOVMTT) 
Q   = TVQ 
V5  = TVV5 
NN  = TVNN 
 
BIO  = TVF3*EXP(IOVFR+IIVBIOR) ; This is the actual bioavailability 
  
K40 = CLR/VR 
K45 = Q/VR 
K54 = Q/V5 
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S4 = VR 
 
;-----------EFFECT MODEL----------------- 
EMAXR = THETA(19)   
EC50 =THETA(20)    
HILL = THETA(21)  
 
; Transit  
KTR = (NN+1)/MTT 
F3=0 
 
IF (NEWIND.NE.2.OR.EVID.GE.3.AND.DVID.EQ.2) THEN ; new individual, 
or reset event 
    ; The values read here will be stored in TDOS and PD in this very PK call. 
 TNXD=TIME ; Time of the dose 
 PNXD=AMT ; Amount. If it's zero, the DE is deactivated. 
ENDIF 
 
TDOS=TNXD ; This will either save here the temporary values if it's a new 
individual... 
PD=PNXD ; ...or the values which were read one record ahead during the 
execution of the previous record. 
 
IF(AMT.GT.0.AND.DVID.EQ.2) THEN ; This reads one record ahead and stores 
the data to be used when running the following record 
; IF(AMT.GT.0.AND.ALAG1.EQ.0) THEN ; ; Use this instead if there is ALAG, 
as it will also checks if the ALAG is not 0 
 TNXD=TIME 
 PNXD=AMT 
ENDIF 
 
; Uncomment this if you have ALAG or if you use ADDL 
;IF (DOSTIM.GT.0) THEN ; This will account for the ADDL or lagged doses. It 
will overwrite the time, if it a non-event record 
; TNXD=DOSTIM 
; PNXD=AMT 
;ENDIF 
 
LNGAM = 
NN*LOG(NN)-NN+LOG(NN*(1+4*NN*(1+2*NN)))/6+0.572364942 ; 
approximation of log of gamma(n), 0.572364942 is LOG(PI)/2 
BPK=BIO*PD*KTR 
IF (BPK.LE.0.0001) BPK=0.0001 
Un
ive
rsi
ty 
of 
 C
ap
e T
ow
n
Appendix 
 
 
- 193 - 
 
PIZZA=LOG(BPK)-LNGAM 
$DES 
C4 = A(4)/VR 
IF (C4.LE.0.0001) C4 = 0.0001 
EFF = EMAXR*C4**HILL/(EC50**HILL + C4**HILL) 
 
DADT(1) = -KAL*A(1) 
DADT(2) = KAL*A(1)-K20*A(2)*(1-EFF) 
 
TEMPO=T-TDOS ; this is time after dose, it should always be >= 0 
IF(PD.GT.0.AND.TEMPO.GT.0) THEN 
 KTT=KTR*TEMPO 
 DADT(3)=EXP(PIZZA+NN*LOG(KTT)-KTT)-KAR*A(3) 
ENDIF 
 
DADT(4) = KAR*A(3)-K40*A(4)-K45*A(4)+K54*A(5) 
DADT(5) = K45*A(4)-K54*A(5) 
 
$ERROR ;(ONLY OBSERVATIONS) 
IPREDL = A(2)/VL 
IPREDR = A(4)/VR 
IF(DVID.EQ.1)THEN 
 IPRED = IPREDL 
 W = SQRT(THETA(14)**2 + 
(THETA(15)*IPRED)**2)*EXP(IOVRUV)   ;LPV additive and proportional 
error 
ENDIF 
IF(DVID.EQ.2) THEN 
 IPRED = IPREDR 
 W =THETA(16)*IPRED   ;RTV proportional error 
ENDIF 
 
IRES  = DV - IPRED 
IF (W.EQ.0) W = 1 
IWRES = IRES/W 
Y = IPRED + W*EPS(1) 
 
$THETA  (0,37.4702) ; 1  LPV CL 
 (0,1.59703) ; 2  RIF ON LPV CL 
 (0,54.8) ; 3  LPV V 
 (0,0.968) ; 4  LPV KA 
 (0,0.779,1) ; 5  RIF on LPV BIO 
 (0,19.2) ; 6  RTV CL WITHOUT RIF 
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 (0,1.29) ; 7  RIF on RTV CL 
 (0,21.8) ; 8  RTV V1 
 (0,3.3) ; 9  RTV KA 
 (0,0.559,1) ; 10 RIF on BIO RTV 
 (0,1.44) ; 11  RTV MTT 
 (0,29.3) ; 12 RTV Q 
 (0,53.1) ; 13 RTV V5 
 0 FIX ; 14  LPV Additive error 
 (0,0.13) ; 15  LPV Proportional error 
 (0,0.188) ; 16  RTV Proportional error 
 0 FIX ; 17  CLFFAT 
 1 FIX ; 18  VFFAT 
 (0,0.952,1) ; 19  EMAX ON RTV INHIBITION 
 (0,0.0378) ; 20  EC50 OF RTV 
 1 FIX ; 21  HILL 
 2 FIX ; 22 NN 
 (0,0.599) ; 23 RTV DOSE ON F3 
 (1 FIX)    ; 24 evening LPV CL 
 (0,1.98) ; 25 evening LPV F 
 (1 FIX)    ; 26 evening RTV CL 
 (0,3.65) ; 27 evening RTV F 
 1 FIX ; 28 evening RTV MTT 
 1 FIX ; 29 evening LPV KA 
$OMEGA  DIAGONAL(1) 
 0.0421  ; 1   IIV on LPV CL 
$OMEGA  DIAGONAL(1) 
 0.0791  ; 2   IIV on LPV V 
$OMEGA  DIAGONAL(1) 
 0.0487  ; 3   IIV on RTV CL 
$OMEGA  DIAGONAL(1) 
 0.0103  ; 4   IIV on RTV V 
$OMEGA  BLOCK(1) 
 0.0527  ; 5   IOV on LPV F1 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
 
$OMEGA  BLOCK(1) 
 0.105  ; 13   IOV on RTV F1 
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$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
 
$OMEGA  BLOCK(1) 
 0.713  ; 21   IOV on LPV KA 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
 
$OMEGA  BLOCK(1) 
 0.0434  ; 29   IOV on RTV CL 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
 
$OMEGA  BLOCK(1) 
 0.0159  ; 37   IOV on LPV CL 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
 
$OMEGA  BLOCK(1) 
 0 FIX  ; 45   IOV on LPV RUV 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
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$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
 
$OMEGA  BLOCK(1) 
 0.0863  ; 53   IOV on RTV MTT 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
 
$OMEGA  DIAGONAL(1) 
 0.118  ; 61 IIV on RTV F 
$OMEGA  DIAGONAL(1) 
 0.03  ; 62 IIV on LPV F 
$SIGMA  1.  FIX 
$ESTIMATION PRINT=1 MAXEVALS=9999 SIGL=10 NSIG=2 METHOD 
CONDITIONAL INTERACTION MSFO=run504e.msf  
$COVARIANCE PRINT=E MATRIX=S 
$TABLE ID TIME PRED IPRED RES WRES IWRES DV NPDE CWRES TAD 
TADD NOPRINT  NOAPPEND ONEHEADER FILE=sdtab504e 
$TABLE ID SEX DVID TERM NOPRINT NOAPPEND ONEHEADER 
FILE=catab504e 
$TABLE ID AGE WT FFM HB HT ALT NOPRINT  NOAPPEND 
ONEHEADER FILE=cotab504e 
$TABLE ID CLL CLR VL VR KAL KAR K20 K40 Q V5 F1 BIO MTT IIVCLL 
IIVCLR IIVVL IIVVR IIVBIOR IOVCLL IOVFL IOVFR IOVKAL IOVCLR 
IOVRUV IOVMTT NOPRINT  NOAPPEND ONEHEADER FILE=patab504e 
$TABLE ID TERM TAD TADD CLL CLR VL VR KAL KAR K20 K40 Q V5 F1 
BIO MTT IIVCLL IIVCLR IIVVL IIVVR IIVBIOR IOVCLL IOVFL IOVFR 
IOVKAL IOVCLR IOVRUV IOVMTT AGE SEX WT HT FFM ALT HB RIF 
EVEN RDW DVID NOPRINT  NOAPPEND ONEHEADER 
FILE=mytab504e.tab  
Un
ive
rsi
ty 
of 
 C
ap
e T
ow
n
Appendix 
 
 
- 197 - 
 
III. Final model control file (Paper III) 
$SIZES LVR=64 MAXFCN=10000000 LTH=50 
$PROBLEM **run390, no FIX for EMAX 
$INPUT ID SDID=DROP STUDY TERM WHAT=DROP ODAT=DROP 
OTIM=DROP TIME AMT DVID DV LNDV=DROP MDV EVID CMT  
SEX AGE WT HT ALT HB BQL RDW TB RATI RIF WRON EVEN RTVTOT 
$DATA combined_dataset0502_cheve_RDTOT.csv IGNORE=#  
IGNORE(BQL.EQ.1) IGNORE(WRON.EQ.1);   ; no bql 
$SUBROUTINES ADVAN6 TRANS1 TOL=6 
$MODEL   
COMP(LPVDOSE)   ; 1 LPV DOSE 
COMP(LPVOBS)    ; 2 LPV CENTRAL 
COMP(RTVDOSE)   ; 3 RTV DOSE 
COMP(RTVOBS)    ; 4 RTV CENTRAL 
COMP(RTVOBS)    ; 5 RTV PREPHRAL 
COMP(RTVTR1) ; 6 RTV TRANSIT 1 
COMP(RTVTR2) ; 7 RTV TRANSIT 2 
COMP(RTVTR3) ; 8 RTV TRANSIT 3 
$ABBREVIATED DERIV2=NO 
$PK 
;allometric scaling 
SCLW = (WT/65)**0.75 
SVW = WT/65 
 ;-------IOV CODE-------------------    
 IF (TERM.EQ.1) THEN 
 IOVFL = ETA(3) 
 IOVFR = ETA(4) 
 IOVKAL = ETA(19) 
 IOVRUV = ETA(27) 
 IOVCLL = ETA(35) 
 IOVCLR = ETA(35)*THETA(39) 
 IOVMTT = ETA(43) 
 ENDIF 
 IF (TERM.EQ.2) THEN 
 IOVFL = ETA(5) 
 IOVFR = ETA(6) 
 IOVKAL = ETA(20) 
 IOVRUV = ETA(28) 
 IOVCLL = ETA(36) 
 IOVCLR = ETA(36)*THETA(39) 
 IOVMTT = ETA(44) 
 ENDIF 
 IF (TERM.EQ.3) THEN 
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 IOVFL = ETA(7) 
 IOVFR = ETA(8) 
 IOVKAL = ETA(21) 
 IOVRUV = ETA(29) 
 IOVCLL = ETA(37) 
 IOVCLR = ETA(37)*THETA(39) 
 IOVMTT = ETA(45) 
 ENDIF 
 IF (TERM.EQ.4) THEN 
 IOVFL = ETA(9) 
 IOVFR = ETA(10) 
 IOVKAL = ETA(22) 
 IOVRUV = ETA(30) 
 IOVCLL = ETA(38) 
 IOVCLR = ETA(38)*THETA(39) 
 IOVMTT = ETA(46) 
 ENDIF 
    IF (TERM.EQ.5) THEN 
 IOVFL = ETA(11) 
 IOVFR = ETA(12) 
 IOVKAL = ETA(23) 
 IOVRUV = ETA(31) 
 IOVCLL = ETA(39) 
 IOVCLR = ETA(39)*THETA(39) 
 IOVMTT = ETA(47) 
 ENDIF 
 IF (TERM.EQ.6) THEN 
 IOVFL = ETA(13) 
 IOVFR = ETA(14) 
 IOVKAL = ETA(24) 
 IOVRUV = ETA(32) 
 IOVCLL = ETA(40) 
 IOVCLR = ETA(40)*THETA(39) 
 IOVMTT = ETA(48) 
 ENDIF 
 IF (TERM.EQ.7) THEN 
 IOVFL = ETA(15) 
 IOVFR = ETA(16) 
 IOVKAL = ETA(25) 
 IOVRUV = ETA(33) 
 IOVCLL = ETA(41) 
 IOVCLR = ETA(41)*THETA(39) 
 IOVMTT = ETA(49) 
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 ENDIF 
 IF (TERM.EQ.8) THEN 
 IOVFL = ETA(17) 
 IOVFR = ETA(18) 
 IOVKAL = ETA(26) 
 IOVRUV = ETA(34) 
 IOVCLL = ETA(42) 
 IOVCLR = ETA(42)*THETA(39) 
 IOVMTT = ETA(50) 
 ENDIF 
;Initialization  
A_0(1)=0.000001 
A_0(2)=0.000001 
A_0(3)=0.000001 
A_0(4)=0.000001 
A_0(5)=0.000001  
  
; ------------LPV MODEL------------------ 
 RIFCLL=0 
 EVEBIOL=1 
 EVECL =1 
 ; Rifampicin effect 
  
IF (RIF.EQ.1.AND.STUDY.EQ.1) THEN 
 RIFCLL=THETA(6) 
ENDIF 
IF (RIF.EQ.1.AND.STUDY.EQ.2) THEN 
    RIFCLL=THETA(37) 
ENDIF 
IF (EVEN.EQ.1.AND.STUDY.EQ.1) THEN 
 EVEBIOL= THETA(9) 
 EVECL  = THETA(35) 
ENDIF 
IF (EVEN.EQ.1.AND.STUDY.EQ.2) THEN 
 EVEBIOL= THETA(10) 
 EVECL  = THETA(36) 
ENDIF 
  
TVCLL = THETA(1)*(1+RIFCLL)*SCLW 
TVVL  = THETA(2)*SVW 
TVKAL = THETA(3) 
SLPLF = THETA(4) ; it is fixed to 0 
IF (STUDY.EQ.2) THEN  
Un
ive
rsi
ty 
of 
 C
ap
e T
ow
n
Appendix 
 
 
- 200 - 
 
 TVCLL= THETA(34)*(1+RIFCLL)*SCLW 
    TVKAL = THETA(11) 
    SLPLF = THETA(12) 
ENDIF 
 
BIOL = 1 ; BIO for adults NO RIF 
IF (STUDY.EQ.1.AND.RIF.EQ.1) BIOL=THETA(7) ; BIO for adults WITH RIF 
IF (STUDY.EQ.2.AND.RIF.EQ.0) BIOL=THETA(5) ; BIO for chilren NO RIF 
IF (STUDY.EQ.2.AND.RIF.EQ.1) BIOL=THETA(8) ; BIO for children WITH 
RIF 
 
TVF1 = (BIOL+SLPLF*(RDW-3))*EVEBIOL 
   
; IIV 
IIVCLL = ETA(1) 
IIVVL = ETA(2)   
IIVFL = ETA(51) 
  
    CLL    = TVCLL*EXP(IIVCLL+IOVCLL)*EVECL 
    VL     = TVVL*EXP(IIVVL) 
    KAL    = TVKAL*EXP(IOVKAL) 
 F1    = TVF1*EXP(IOVFL+IIVFL) 
  
    K20 = CLL/VL 
    S2 = VL 
 
;----------RTV MODEL-------------------     
RIFCLR=0 
EVEBIOR=1 
;Rifampicin effect 
;IF (RIF.EQ.1) THEN 
 
;ENDIF 
IF (RIF.EQ.1.AND.STUDY.EQ.1) THEN 
 RIFCLR = THETA(23) 
ENDIF  
IF (RIF.EQ.1.AND.STUDY.EQ.2) THEN 
    RIFCLR = THETA(38) 
ENDIF  
IF (EVEN.EQ.1.AND.STUDY.EQ.1) THEN 
    EVEBIOR= THETA(28) 
ENDIF 
IF (EVEN.EQ.1.AND.STUDY.EQ.2) THEN 
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   EVEBIOR= THETA(29) 
ENDIF 
 
BIOR =1 ; BIO for adults NO RIF 
IF (STUDY.EQ.1.AND.RIF.EQ.1) BIOR=THETA(24) ; BIO for adults WITH RIF 
IF (STUDY.EQ.2.AND.RIF.EQ.0) BIOR=THETA(19) ; BIO for chilren NO RIF 
IF (STUDY.EQ.2.AND.RIF.EQ.1) BIOR=THETA(25) ; BIO for children WITH 
RIF 
 
TVCLR = THETA(15)*(1+RIFCLR)*SCLW 
TVVR  = THETA(16)*SVW 
TVKAR = THETA(17) 
TVMTT =THETA(18) 
SLPRFR = THETA(20) 
IF (STUDY.EQ.2) THEN 
 TVCLR = THETA(26)*(1+RIFCLR)*SCLW 
    TVMTT = THETA(27) 
    SLPRFR = THETA(40) 
ENDIF 
 
TVQ = THETA(21)*SCLW  
TVV5 = THETA(22)*SVW  
 
IF (STUDY.EQ.1) THEN 
TVF3 = (BIOR+SLPRFR*(RTVTOT-100)/100)*EVEBIOR 
ENDIF 
IF (STUDY.EQ.2) THEN 
TVF3 = (BIOR+SLPRFR*(RDW-3))*EVEBIOR 
ENDIF 
    
; IIV 
IIVFR = ETA(52) 
IIVCLR= ETA(53) 
IIVVR = ETA(54) 
  
CLR  = TVCLR*EXP(IIVCLR+IOVCLR)*EVECL 
VR   = TVVR*EXP(IIVVR) 
KAR  = TVKAR 
MTT = TVMTT*EXP(IOVMTT) 
F3  = TVF3*EXP(IOVFR+IIVFR) 
Q   = TVQ 
V5  = TVV5 
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    KTR=3/MTT 
    K36=KTR 
    K67=KTR 
    K78=KTR 
    K8T4=KAR 
    K40 = CLR/VR 
 K45 = Q/VR 
 K54 = Q/V5 
    S4 = VR 
  
;-----------EFFECT MODEL-----------------     
EMAXR = THETA(32)   
EC50 =THETA(33)    
HILL=THETA(41) 
  
$DES 
C4 = A(4)/VR 
IF (C4.LE.0.000001) THEN  
 EFF=0 
ELSE  
 EFF = EMAXR*(C4**HILL)/(EC50**HILL + C4**HILL) 
ENDIF 
 
DADT(1) = -KAL*A(1) 
DADT(2) = KAL*A(1)-K20*A(2)*(1-EFF) 
DADT(3)= -KTR*A(3) 
DADT(4) = KAR*A(8)-K40*A(4)+K54*A(5)-K45*A(4) 
DADT(5) = K45*A(4)-K54*A(5) 
DADT(6)= KTR*A(3)-KTR*A(6) 
DADT(7)= KTR*A(6)-KTR*A(7) 
DADT(8)= KTR*A(7)-KAR*A(8) 
 
$ERROR ;(ONLY OBSERVATIONS) 
   PREDL = A(2)/VL 
   PREDR = A(4)/VR 
   IF(DVID.EQ.1)IPRED = PREDL 
   IF(DVID.EQ.2)IPRED = PREDR  
   IRES  = DV - IPRED     
 IF (DVID.EQ.1)   
W = SQRT(THETA(13)**2 + 
(THETA(14)*IPRED)**2)*EXP(IOVRUV)   ;LPV additive and proportional 
error 
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 IF (DVID.EQ.2)   
W = SQRT(THETA(30)**2 + (THETA(31)*IPRED)**2)   ;RTV additive and 
proportional error 
    IF (W.EQ.0) W = 1 
    IWRES = IRES/W      
 Y = IPRED + W*EPS(1) 
    
$THETA  (0,50)  ; 1 LPV CL for adult 
 (0,60.8) ; 2 LPV V 
 (0,1.13) ; 3 LPV KA for adult 
 0 FIX ; 4 RTV dose on LPV F for adult 
 (0,0.849) ; 5 BIO LPV for children NO RIF 
 (0,0.567) ; 6 RIF ON LPV CL for both 
 (0,0.76,1) ; 7 BIO LPV for adults WITH RIF 
 (0,0.373,1) ; 8 BIO LPV for children WITH RIF 
 (0,1.24) ; 9 EVENING effect on LPV F for adult 
 1 FIX ; 10 EVENING effect on LPV F for children 
 (0,0.386) ; 11  LPV KA for children 
 (0,0.0138) ; 12 RTV dose on LPV F for children 
 (0,0.0729) ; 13  LPV Additive error 
 (0,0.132) ; 14  LPV Proportional error 
 (0,23.6) ; 15  RTV CL for adult 
 (0,42.3) ; 16  RTV V 
 (0,2.34) ; 17  RTV KA 
 (0,1.08) ; 18  RTV MTT for adult 
 (0,0.264,1) ; 19  BIO RTV for children no rif 
 (0,0.742) ; 20 RTV DOSE ON F for adult 
 (0,30.9) ; 21 RTV Q 
 (0,55.9) ; 22 RTV V5 
 (0,0.301) ; 23 RIF ON RTV CL for both 
 (0,0.433,1) ; 24 BIO RTV for adult WITH RIF 
 (0,0.0259,1) ; 25 BIO RTV for children WITH RIF 
 (0,14.3) ; 26  RTV CL for children 
 (0,2.23) ; 27  RTV MTT for children 
 (0,1.05) ; 28 EVEN effect on RTV F for adult 
 1 FIX ; 29 EVEN effect on RTV F for children 
 0 FIX ; 30 RTV additive error 
 (0,0.211) ; 31 RTV proportional error 
 (0,0.918,1) ; 32 EMAX 
 (0,0.0463) ; 33 EC50 
 (0,31.8) ; 34 LPV CL for children 
 (0,0.491) ; 35 EVEN effect on CL adults 
 (0,0.722) ; 36 EVEN effect on CL children 
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 (0,0.444) ; 37 RIF effect on LPV CL for children 
 (0,0.217) ; 38 RIF effect on RTV CL for children 
 (0,0.972) ; 39 IOVCLL-LOVCLR 
 (0,0.0275) ; 40 RTV DOSE ON F for children 
 (0,1.74,30) ; 41 Hill 
$OMEGA  BLOCK(1) 
 0.0426  ; 1   IIV on LPV CL 
$OMEGA  BLOCK(1) 
 0.057  ; 2   IIV on LPV V 
$OMEGA  BLOCK(2) 
 0.0741  ; 3   IOV on LPV F1 
 0.0996 0.185  ; 4   IOV on RTV F1 
$OMEGA  BLOCK(2) SAME 
$OMEGA  BLOCK(2) SAME 
$OMEGA  BLOCK(2) SAME 
$OMEGA  BLOCK(2) SAME 
$OMEGA  BLOCK(2) SAME 
$OMEGA  BLOCK(2) SAME 
$OMEGA  BLOCK(2) SAME 
$OMEGA  BLOCK(1) 
 0.483  ; 19   IOV on LPV KA 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) FIX 
 0  ; 27   IOV on LPV RUV 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) 
 0.0293  ; 35   IOV on LPV CL 
$OMEGA  BLOCK(1) SAME 
 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
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$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) 
 0.154  ; 43   IOV on RTV MTT 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(2) 
 0.0642  ; 51   IIV on LPV F 
 0.107 0.385  ; 52  IIV on RTV F 
$OMEGA  BLOCK(1) 
 0.0689  ; 53   IIV on RTV CL 
$OMEGA  BLOCK(1) FIX 
 0  ; 54   IIV on RTV V 
$SIGMA  1.  FIX 
$ESTIMATION MSFO=msf393 PRINT=1 MAXEVALS=9999  METHOD 
CONDITIONAL INTERACTION   
$COVARIANCE MATRIX=S PRINT=E  
$TABLE FILE=sdtab393 ID TIME PRED IPRED RES WRES CWRES IWRES 
DV NPDE NOPRINT ONEHEADER  
$TABLE FILE=catab393 ID SEX  DVID TERM NOPRINT ONEHEADER  
$TABLE FILE=cotab393 ID AGE WT NOPRINT ONEHEADER  
$TABLE FILE=patab393 ID CLL VL KAL F1 CLR VR F3 Q V5 MTT IIVCLL 
IIVVL IOVCLL IOVKAL IOVRUV IOVFL IIVCLR IIVVR IIVFR IOVFR 
IOVMTT NOPRINT  ONEHEADER  
$TABLE FILE=mytab393 ID STUDY SEX RIF TERM DVID CLL VL KAL F1 
CLR VR Q V5 F3 MTT KAR IIVCLL IIVVL IOVCLL IOVKAL IOVRUV   
IOVFL IIVFL IIVCLR IIVVR IIVFR IOVFR IOVCLR IOVMTT WT RDW 
NOPRINT  ONEHEADER 
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IV. Final model control file (Paper IV) 
$PROBLEM  **run14,maturation,PMA  ;lamivudine pediatric data (pilot+ddk 
study) 
$INPUT ID SDID=DROP OCC TERM ODAT=DROP OTIM=DROP TIME AMT 
DVID DV MDV EVID SEX AGE WT HT ALT HB BQL TB RATI RIF EVEN 
FLAG PRE 
$DATA lamidata_full_halfblq2_pre.csv  IGNORE=#  IGNORE(FLAG.EQ.1) ; 
missing data compared to lpv/rtv; half value for blq 
$SUBROUTINE ADVAN6 TOL=4 
$MODEL   
NCOMP=3 
COMP(DEPOT, DEFDOSE) 
COMP(CENTRAL, DEFOBS) 
COMP(PERI) 
$PK 
TAD = TIME-48 
;allometric scaling 
SCL = (WT/10)**0.75 
SV  = WT/10 
;maturation 
PNA     = AGE+9 
TM50    = THETA(10) 
HILL    = 1             
MFCL    = 1/(1+(PNA/TM50)**(-HILL)) ;maturation 
 ;variability 
   IIVCL = ETA(1) 
   IIVV  = ETA(2) 
   IIVKA = ETA(3) 
   IIVMTT = ETA(4) 
   IIVBIO = ETA(5) 
    
   IF (TERM.EQ.1) THEN 
   IOVBIO = ETA(6) 
   IOVCL= ETA(10) 
   IOVKA= ETA(14) 
   IOVMTT=ETA(18) 
   ENDIF 
   IF (TERM.EQ.2) THEN 
   IOVBIO = ETA(7) 
   IOVCL= ETA(11) 
   IOVKA= ETA(15) 
   IOVMTT=ETA(19) 
   ENDIF    
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   IF (TERM.EQ.3) THEN 
   IOVBIO = ETA(8) 
   IOVCL= ETA(12) 
   IOVKA= ETA(16) 
   IOVMTT=ETA(20) 
   ENDIF 
   IF (TERM.EQ.4) THEN 
   IOVBIO = ETA(9) 
   IOVCL= ETA(13) 
   IOVKA= ETA(17) 
   IOVMTT=ETA(21) 
   ENDIF    
 ;evening effect 
 EVECL=1 
 EVEBIO=1 
 IF (EVEN.EQ.1) THEN 
 EVECL=THETA(11) 
 EVEBIO=THETA(12)  
 ENDIF 
 ;typical parameter  
 TVCL = THETA(1)*MFCL 
    TVV  = THETA(2) 
    TVKA = THETA(3) 
 TVMTT= THETA(4) 
 TVQ  = THETA(5) 
 TVV3 = THETA(6) 
 TVNN = THETA(7) 
     
    CL    = TVCL*EXP(IIVCL+IOVCL)*SCL*EVECL 
    V2    = TVV*EXP(IIVV)*SV 
  Q     = TVQ*SCL 
 V3    = TVV3*SV 
    KA    = TVKA*EXP(IIVKA+IOVKA) 
 MTT   = TVMTT*EXP(IIVMTT+IOVMTT) 
 NN    = TVNN 
   
   K = CL/V2 
   K23 = Q/V2 
   K32 = Q/V3 
   S2 = V2/1000 
    
 IF (NEWIND.NE.2) THEN ; beginning of dataset, or new individual 
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 TDOS=TIME ; TIME will be the time of the first record of that subject even if 
it's not a dose, but... 
 PD=AMT ; ...the amount will be 0 if the first record is not a dose, so no 
problem. 
 ENDIF 
 
 F1=0 ; I need to set bioavailability in compartment 1 to 0 
 BIO=1*EXP(IIVBIO+IOVBIO)*EVEBIO ; This is the actual bioavailability 
 
KTR = (NN+1)/MTT 
L = .9189385+(NN+.5)*LOG(NN)-NN+LOG(1+1/(12*NN)) ; log of gamma 
function approximation. .9189385 is ln(sqrt(2*PI)) 
 
; To speed up the computation, I calculate here all the non-time-varying quantities 
used in $DES 
LBPD=LOG(BIO*PD) 
LKTR=LOG(KTR) 
PIZZA=LBPD+LKTR-L   
 
$DES 
TEMPO=T-TDOS ; this is time after dose, it should always be >= 0 
 
IF(TEMPO.GT.0) THEN 
 KTT=KTR*TEMPO 
 DADT(1)=EXP(PIZZA+NN*LOG(KTT)-KTT)-KA*A(1) 
ELSE 
 DADT(1)=0 ; I believe this is executed only when TEMPO=0, or before the 
first dose is given 
ENDIF 
 
DADT(2)=KA*A(1)-K*A(2)-K23*A(2)+K32*A(3) 
DADT(3)=K23*A(2)-K32*A(3) 
 
$ERROR ;(ONLY OBSERVATIONS) 
    IPRED = F 
    IRES  = DV - IPRED 
    W = SQRT(THETA(8)**2 + (THETA(9)*F)**2) 
 IF (PRE.EQ.1) THEN 
    W = SQRT(THETA(13)**2 + (THETA(14)*F)**2) 
 ENDIF 
    IF (W.EQ.0) W = 1 
    IWRES = IRES/W 
    Y = IPRED + W*EPS(1) 
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IF(AMT.GT.0) THEN ; This reads one record ahead and stores the data to be used 
when running the following record 
TDOS=TIME 
PD=AMT 
ENDIF 
 
$THETA  (0,12.2408) ; 1 CL 
 (0,20.6749) ; 2 V2 
 (0,1.65473) ; 3 KA 
 (0,0.546805) ; 4 MTT 
 (0,1.66709) ; 5 Q 
 (0,37.216) ; 6 V3 
 (0,2.29731) ; 7 NN 
 10 FIX ; 8 Additive error 
 (0,0.0833731) ; 9 Proportional error 
 (0,12.9271) ; 10 maturation TM50 
 (0,0.833404) ; 11 evening effect on CL 
 1 FIX ; 12 evening effect on BIO 
 (0,23.6968) ; 13 additive error for predose 
 (0,0.126263) ; 14 preoportional error for predose 
$OMEGA  BLOCK(1) 
 0.00665976  ; 1 IIV on CL 
$OMEGA  BLOCK(1) 
 0.0636054  ; 2  IIV on V 
$OMEGA  BLOCK(1) FIX 
 0  ; 3  IIV on KA 
$OMEGA  BLOCK(1) FIX 
 0  ; 4 IIV on MTT 
$OMEGA  BLOCK(1) 
 0.0815093  ; 5  IIV on F 
$OMEGA  BLOCK(1) 
 0.0730012  ; 6  IOV on F 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) FIX 
 0  ; 10  IOV on CL 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) 
 0.517322  ; 14  IOV on KA 
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$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) 
 0.50193  ; 18  IOV on MTT 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$OMEGA  BLOCK(1) SAME 
$SIGMA  1.  FIX 
$ESTIMATION PRINT=1 MAXEVALS=9999 MSFO=run17a.msf SIGL=6 
NSIG=3 METHOD CONDITIONAL INTERACTION  
$COVARIANCE MATRIX=S PRINT=E  
$TABLE ID TIME PRED IPRED RES WRES IWRES CWRES NPDE DV  
NOPRINT ONEHEADER FILE=sdtab17a 
$TABLE ID SEX TERM OCC NOPRINT ONEHEADER FILE=catab17a 
$TABLE ID AGE WT HT ALT HB NOPRINT ONEHEADER FILE=cotab17a 
$TABLE ID CL V2 KA K V3 Q F1 MTT NN IIVCL IIVV IIVKA IOVBIO 
IIVBIO IOVCL IIVMTT IOVMTT NOPRINT  ONEHEADER FILE=patab17a 
$TABLE ID OCC TERM CL V2 KA K Q V3 F1 MTT NN SEX AGE WT HT 
ALT HB RIF RATI IIVCL IIVV IIVKA IOVBIO IIVBIO IOVCL IIVMTT 
IOVMTT NOPRINT ONEHEADER FILE=mytab17a.tab 
 
